0001356576-24-000028.txt : 20240508 0001356576-24-000028.hdr.sgml : 20240508 20240508161118 ACCESSION NUMBER: 0001356576-24-000028 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 24926137 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-Q 1 supn-20240331.htm 10-Q supn-20240331
0001356576false12-312024Q1http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharessupn:productsupn:segmentxbrli:puresupn:rightiso4217:EUR00013565762024-01-012024-03-3100013565762024-05-0100013565762024-03-3100013565762023-12-310001356576us-gaap:ProductMember2024-01-012024-03-310001356576us-gaap:ProductMember2023-01-012023-03-310001356576supn:RoyaltyAndLicenseMember2024-01-012024-03-310001356576supn:RoyaltyAndLicenseMember2023-01-012023-03-3100013565762023-01-012023-03-310001356576us-gaap:CommonStockMember2023-12-310001356576us-gaap:AdditionalPaidInCapitalMember2023-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001356576us-gaap:RetainedEarningsMember2023-12-310001356576us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001356576us-gaap:CommonStockMember2024-01-012024-03-310001356576us-gaap:RetainedEarningsMember2024-01-012024-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001356576us-gaap:CommonStockMember2024-03-310001356576us-gaap:AdditionalPaidInCapitalMember2024-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001356576us-gaap:RetainedEarningsMember2024-03-310001356576us-gaap:CommonStockMember2022-12-310001356576us-gaap:AdditionalPaidInCapitalMember2022-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001356576us-gaap:RetainedEarningsMember2022-12-3100013565762022-12-310001356576us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001356576us-gaap:CommonStockMember2023-01-012023-03-310001356576us-gaap:RetainedEarningsMember2023-01-012023-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001356576us-gaap:CommonStockMember2023-03-310001356576us-gaap:AdditionalPaidInCapitalMember2023-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001356576us-gaap:RetainedEarningsMember2023-03-3100013565762023-03-310001356576us-gaap:ConvertibleDebtMember2018-03-310001356576supn:QelbreeMember2024-01-012024-03-310001356576supn:QelbreeMember2023-01-012023-03-310001356576supn:OxtellarXRMember2024-01-012024-03-310001356576supn:OxtellarXRMember2023-01-012023-03-310001356576supn:GOCOVRIMember2024-01-012024-03-310001356576supn:GOCOVRIMember2023-01-012023-03-310001356576supn:APOKYNMember2024-01-012024-03-310001356576supn:APOKYNMember2023-01-012023-03-310001356576supn:TrokendiXrMember2024-01-012024-03-310001356576supn:TrokendiXrMember2023-01-012023-03-310001356576us-gaap:ManufacturedProductOtherMember2024-01-012024-03-310001356576us-gaap:ManufacturedProductOtherMember2023-01-012023-03-310001356576supn:QelbreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576supn:QelbreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:OxtellarXRMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:OxtellarXRMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:GOCOVRIMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:GOCOVRIMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576supn:APOKYNMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576supn:APOKYNMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576supn:TrokendiXrMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576supn:TrokendiXrMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ManufacturedProductOtherMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ManufacturedProductOtherMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberus-gaap:ProductMember2024-01-012024-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberus-gaap:ProductMember2023-01-012023-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMembersupn:AmerisourceBergenDrugCorporationMember2024-01-012024-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMemberus-gaap:ProductMember2024-01-012024-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:McKessonMemberus-gaap:ProductMember2024-01-012024-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMemberus-gaap:ProductMember2023-01-012023-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:McKessonMemberus-gaap:ProductMember2023-01-012023-03-310001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMembersupn:AmerisourceBergenDrugCorporationMember2023-01-012023-03-310001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMember2024-01-012024-03-310001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMember2023-01-012023-03-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-03-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-03-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membersupn:CorporateAndMunicipalDebtSecuritiesMember2024-03-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membersupn:CorporateAndMunicipalDebtSecuritiesMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMember2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001356576supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membersupn:CorporateAndMunicipalDebtSecuritiesMember2023-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membersupn:CorporateAndMunicipalDebtSecuritiesMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMember2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2024-03-310001356576supn:SPN830NDAApprovalMilestoneMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2024-03-310001356576supn:SubsequentCommercialProductLaunchMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2024-03-310001356576supn:AdamasMember2021-11-240001356576supn:Milestone2024Membersupn:AdamasMember2021-11-242021-11-240001356576supn:Milestone2024AndMilestone2025Membersupn:AdamasMember2021-11-242021-11-240001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2023-12-310001356576supn:AdamasMember2023-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2024-01-012024-03-310001356576supn:AdamasMember2024-01-012024-03-310001356576supn:AdamasMember2024-03-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-12-310001356576supn:AdamasMember2022-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2023-01-012023-03-310001356576supn:AdamasMember2023-01-012023-03-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2023-03-310001356576supn:AdamasMember2023-03-310001356576us-gaap:InProcessResearchAndDevelopmentMember2024-03-310001356576us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001356576us-gaap:DevelopedTechnologyRightsMember2024-03-310001356576us-gaap:DevelopedTechnologyRightsMember2023-12-310001356576supn:PatentDefenseCostsMember2024-03-310001356576supn:PatentDefenseCostsMember2023-12-310001356576supn:UncommittedSecuredCreditLineMemberus-gaap:LineOfCreditMember2023-02-080001356576supn:UncommittedSecuredCreditLineMemberus-gaap:LineOfCreditMember2023-03-300001356576us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-04-012023-06-300001356576us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-03-310001356576us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001356576us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001356576supn:StockOptionStockAppreciationRightsMember2023-12-310001356576supn:StockOptionStockAppreciationRightsMember2023-01-012023-12-310001356576supn:StockOptionStockAppreciationRightsMember2024-01-012024-03-310001356576supn:StockOptionStockAppreciationRightsMember2024-03-310001356576us-gaap:RestrictedStockUnitsRSUMember2023-12-310001356576us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001356576us-gaap:RestrictedStockUnitsRSUMember2024-03-310001356576supn:PerformanceBasedUnitsMember2023-12-310001356576supn:MarketBasedUnitsMember2023-12-310001356576us-gaap:PerformanceSharesMember2023-12-310001356576supn:PerformanceBasedUnitsMember2024-01-012024-03-310001356576supn:MarketBasedUnitsMember2024-01-012024-03-310001356576us-gaap:PerformanceSharesMember2024-01-012024-03-310001356576supn:PerformanceBasedUnitsMember2024-03-310001356576supn:MarketBasedUnitsMember2024-03-310001356576us-gaap:PerformanceSharesMember2024-03-310001356576us-gaap:StockCompensationPlanMember2024-01-012024-03-310001356576us-gaap:StockCompensationPlanMember2023-01-012023-03-310001356576supn:LabEquipmentAndFurnitureMember2024-03-310001356576supn:LabEquipmentAndFurnitureMember2023-12-310001356576us-gaap:LeaseholdImprovementsMember2024-03-310001356576us-gaap:LeaseholdImprovementsMember2023-12-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001356576us-gaap:ComputerEquipmentMember2024-03-310001356576us-gaap:ComputerEquipmentMember2023-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2019-04-012019-04-010001356576supn:NAMENDAXRNamzaricQuiTamLitigationMember2019-04-012019-04-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                 to              
Commission File Number: 001-35518
SUPERNUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware20-2590184
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
9715 Key West Avenue
Rockville MD20850
(Address of principal executive offices)(Zip Code)
(301) 838-2500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes  ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒
Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  ☒ No
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classOutstanding at May 1, 2024Trading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per share54,974,254SUPNThe Nasdaq Global Market

1
SUPERNUS PHARMACEUTICALS, INC.
FORM 10-Q — QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED March 31, 2024
Page No.

2
PART I — FINANCIAL INFORMATION

Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
March 31,December 31,
20242023
(unaudited)
Assets
Current assets
Cash and cash equivalents$63,401 $75,054 
Marketable securities234,335 179,820 
Accounts receivable, net147,734 144,155 
Inventories, net75,079 77,408 
Prepaid expenses and other current assets23,772 16,676 
Total current assets544,321 493,113 
Long-term marketable securities11,662 16,617 
Property and equipment, net12,969 13,530 
Intangible assets, net579,752 599,889 
Goodwill117,019 117,019 
Other assets38,367 37,505 
Total assets$1,304,090 $1,277,673 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued liabilities$86,402 $79,569 
Accrued product returns and rebates167,226 154,274 
Contingent consideration, current portion51,379 52,070 
Other current liabilities9,547 4,283 
Total current liabilities314,554 290,196 
Contingent consideration, long-term976 1,380 
Operating lease liabilities, long-term32,994 33,196 
Deferred income tax liabilities, net19,501 24,963 
Other liabilities6,899 6,422 
Total liabilities374,924 356,157 
Commitments and contingencies (Note 15)
Stockholders’ equity
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,965,316 and 54,723,356 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
55 55 
Additional paid-in capital446,960 439,493 
Accumulated other comprehensive loss, net of tax(534)(593)
Retained earnings482,685 482,561 
Total stockholders’ equity929,166 921,516 
Total liabilities and stockholders’ equity$1,304,090 $1,277,673 



See accompanying notes.
3
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
Three Months Ended
March 31,
20242023
(unaudited)
Revenues
Net product sales$138,461 $140,575 
Royalty and licensing revenues5,183 13,189 
Total revenues143,644 153,764 
Costs and expenses
Cost of goods sold(a)
16,309 23,460 
Research and development24,930 21,212 
Selling, general and administrative86,516 85,597 
Amortization of intangible assets20,137 19,966 
Contingent consideration gain(1,095)(1,647)
Total costs and expenses146,797 148,588 
Operating earnings (loss)(3,153)5,176 
Other income (expense)
Interest and other income, net3,396 5,346 
Interest expense— (1,505)
Total other income (expense)3,396 3,841 
Earnings before income taxes243 9,017 
Income tax expense (benefit)119 (7,931)
Net earnings$124 $16,948 
Earnings per share
Basic$0.00 $0.31 
Diluted$0.00 $0.29 
Weighted average shares outstanding
Basic54,801,748 54,380,947 
Diluted55,626,663 62,454,204 
_____________________________
(a) Excludes amortization of acquired intangible assets





See accompanying notes.
4
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Comprehensive Earnings
(in thousands)
Three Months Ended
March 31,
20242023
(unaudited)
Net earnings$124 $16,948 
Other comprehensive gain
Unrealized gain on marketable securities, net of tax59 881 
Other comprehensive gain59 881 
Comprehensive earnings$183 $17,829 







































See accompanying notes.
5
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
Three Months Ended March 31, 2024 and 2023
(unaudited, in thousands, except share data)
jCommon StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202354,723,356 $55 $439,493 $(593)$482,561 $921,516 
Share-based compensation expense related to employee stock purchase plan and share-based awards— — 5,897 — — 5,897 
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld241,960 — 1,570 — — 1,570 
Net earnings— — — — 124 124 
Unrealized gain on marketable securities, net of tax— — — 59 — 59 
Balance, March 31, 202454,965,316 $55 $446,960 $(534)$482,685 $929,166 
Common StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202254,253,796 $54 $408,115 $(3,210)$481,245 $886,204 
Share-based compensation expense related to employee stock purchase plan and share-based awards— — 6,306 — — 6,306 
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld216,826 — 1,811 — — 1,811 
Net earnings— — — — 16,948 16,948 
Unrealized gain on marketable securities, net of tax— — — 881 — 881 
Balance, March 31, 202354,470,622 $54 $416,232 $(2,329)$498,193 $912,150 










See accompanying notes.
6
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
Three Months Ended March 31,
20242023
(unaudited)
Cash flows from operating activities
Net earnings$124 $16,948 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization20,749 20,601 
Amortization of deferred financing costs and debt discount— 532 
Amortization of premium/discount on marketable securities1,894 (1,056)
Change in fair value of contingent consideration(1,095)(1,647)
Other noncash adjustments, net2,449 2,459 
Share-based compensation expense5,897 6,306 
Deferred income tax benefit(5,482)(435)
Changes in operating assets and liabilities:
Accounts receivable(3,579)21,971 
Inventories1,990 (1,851)
Prepaid expenses and other assets(7,517)(341)
Accrued product returns and rebates12,952 (3,813)
Accounts payable and other liabilities10,019 (10,548)
Net cash provided by operating activities38,401 49,126 
Cash flows from investing activities
Purchases of marketable securities(193,700)— 
Sales and maturities of marketable securities142,324 240,058 
Purchases of property and equipment(248)(278)
Net cash provided by (used in) investing activities(51,624)239,780 
Cash flows from financing activities
Proceeds from Credit Line
— 93,000 
Payments on Credit Line— (14,637)
Proceeds from issuance of common stock2,910 2,256 
Employee taxes paid related to net share settlement of equity awards(1,340)(445)
Net cash provided by financing activities1,570 80,174 
Net change in cash, cash equivalents, and restricted cash(11,653)369,080 
Cash and cash equivalents at beginning of year75,054 93,120 
Cash, cash equivalents, and restricted cash at end of period
$63,401 $462,200 
Supplemental cash flow information
Cash paid for income taxes$336 $203 
Cash paid for operating leases4,002 3,457 
Noncash operating and investing activities
Lease assets obtained for new operating leases$2,604 $2,601 




See accompanying notes.
7
Supernus Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1.    Business Organization
Supernus Pharmaceuticals, Inc. (the "Company", see Note 2, Consolidation) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
The Company has eight commercial products that it markets: Qelbree®, GOCOVRI®, Oxtellar XR®, Trokendi XR®, APOKYN®, XADAGO®, MYOBLOC®, and Osmolex ER®. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("OFF" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.
In December 2023, the Company submitted to the U.S. Food and Drug Administration (FDA) a notification of discontinuance to withdraw Osmolex ER from distribution, stating that manufacturing has been discontinued and distribution of the product will cease by April 1, 2024.
2.    Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC.
In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Reclassifications
The prior year amount related to the caption Employee taxes paid related to net share settlement of equity awards in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.
Consolidation
The Company's unaudited condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation.
The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including
8
the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred.
The Company incurred approximately $24.3 million and $25.9 million in advertising expense for the three months ended March 31, 2024 and 2023, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the unaudited condensed consolidated statements of earnings.
Restricted Cash
The Company had a restricted cash balance of $403.8 million as of March 31, 2023 which was held in an escrow account with Wilmington Trust, Trustee, in connection with the payoff of the 0.625% Convertible Senior Notes Due 2023 (2023 Notes) which occurred on April 1, 2023.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
Three Months Ended
March 31, 2023
End of periodBeginning of period
(unaudited)
Cash and cash equivalents$58,442 $93,120 
Restricted cash403,758—
Total cash, cash equivalents, and restricted cash per statements of cash flows$462,200 $93,120 
Recently Issued Accounting Pronouncements and Disclosure Rules
New Accounting Pronouncements Not Yet Adopted
Accounting Standards Update (ASU) 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) - The new standard, issued in November 2023, improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also clarifies that entities with a single reportable segment are subject to both new and existing reporting requirements under Topic 280. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2024. We expect ASU 2023-07 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) - The new standard, issued in December 2023, requires entities to disclose additional information with respect to the effective tax rate reconciliation and to disclose the disaggregation by jurisdiction of income tax expense and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31,
9
2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
SEC Final Climate Rule
In March 2024, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (Final Rule). This rule will require registrants to disclose certain climate-related information in registration statements and annual reports with staggered compliance dates for large accelerated filers for the fiscal year beginning 2025 through 2033 for the various aspects of the Final Rule. On April 4, 2024, the SEC issued an order staying the Final Rule. The SEC’s administrative stay is expected to remain in place until the completion of litigation filed in various federal courts challenging, among other things, the agency’s authority to adopt the Final Rule. The Company is currently evaluating the final rule to determine its impact on the Company's disclosures.
3. Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Net product sales
Qelbree$45,104 $25,782 
Oxtellar XR26,943 28,915 
GOCOVRI26,562 26,010 
APOKYN16,649 17,209 
Trokendi XR15,989 34,790 
Other(1)
7,214 7,869 
Total net product sales$138,461 $140,575 
Royalty and licensing revenues5,183 13,189 
Total revenues$143,644 $153,764 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
The Company recognized noncash royalty revenue of $2.3 million for the three months ended March 31, 2023. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023.
The following table shows the percentage of net product sales to total net product sales:

Percentage of Net Product Sales
Three Months Ended March 31,
20242023
(unaudited)
Qelbree33%18%
Oxtellar XR19%21%
GOCOVRI19%18%
APOKYN12%12%
Trokendi XR12%25%
Other(1)
5%6%
Total100%100%
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
10
Each of our three major customers, Cencora, Inc., Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total gross product sales and collectively accounted for more than 70% of our total gross product sales for the three months ended March 31, 2024 and 2023.
4. Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2024December 31, 2023
(unaudited)
Corporate, U.S. government agency and municipal debt securities
Amortized cost$246,635 $197,153 
Gross unrealized gains1 5 
Gross unrealized losses(639)(721)
Total fair value$245,997 $196,437 
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2024
(unaudited)
Less than 1 year$234,335 
1 year to 2 years11,662 
Total$245,997 
As of March 31, 2024, there was no impairment due to credit loss on any available-for-sale marketable securities.
5.    Fair Value of Financial Measurements
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
11
Financial Assets and Liabilities Recorded at Fair Value
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2024 (unaudited)
Total Fair Value as of March 31, 2024
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$14,272 $14,272 $— $— 
Money market funds49,129 49,129 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities234,335 3,950 230,385 — 
Long-term marketable securities
Corporate and municipal debt securities11,662 — 11,662 — 
Other noncurrent assets
Marketable securities - restricted (SERP)612 17 595 — 
Total assets at fair value$310,010 $67,368 $242,642 $— 
Liabilities:
Contingent consideration$52,355 $— $— $52,355 
Total liabilities at fair value$52,355 $— $— $52,355 
Fair Value Measurements as of December 31, 2023
Total Fair Value as of December 31, 2023
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$35,957 $35,957 $— $— 
Money market funds39,097 39,097 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities179,820 — 179,820 — 
Long-term marketable securities
Corporate and municipal debt securities16,617 — 16,617 — 
Other noncurrent assets
Marketable securities - restricted (SERP)568 16 552 — 
Total assets at fair value$272,059 $75,070 $196,989 $— 
Liabilities:
Contingent consideration$53,450 $— $— $53,450 
Total liabilities at fair value$53,450 $— $— $53,450 
The fair value of restricted marketable securities is recorded in Other assets on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, accrued expenses, and line of credit approximate fair value due to their short-term maturities.

12
6. Contingent Consideration
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):
March 31,
2024		December 31,
2023
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$51,379 $52,070 
Contingent consideration, long-term976 1,380 
Total$52,355 $53,450 
The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020 and the Adamas Acquisition in 2021. The contingent consideration liabilities are measured at fair value using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration (gain) expense.
USWM Contingent Consideration
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments for regulatory and development milestones and sales-based milestones. As of March 31, 2024, the remaining potential contingent consideration payments are up to $55 million in regulatory and development milestones comprised of (1) $25 million related to the FDA's approval of the SPN-830 NDA and (2) $30 million related to the subsequent commercial product launch.
The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, timing of projected revenues, and the discount rate.
Adamas Contingent Consideration
On November 24, 2021 (the Adamas Closing Date), the Company completed its acquisition of all the outstanding equity of Adamas (Adamas Acquisition). The Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, as further defined in the CVR agreement. One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated revenue projections, volatility, estimated discount rates and risk-free interest rate.


13
Change in the Fair Value of Contingent Consideration
The following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2023$46,400 $7,050 $53,450 
Change in fair value recognized in earnings680 (1,775)(1,095)
Balance at March 31, 2024 (unaudited)$47,080 $5,275 $52,355 
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2022$46,270 $8,697 $54,967 
Change in fair value recognized in earnings(1,710)63 (1,647)
Balance at March 31, 2023 (unaudited)$44,560 $8,760 $53,320 
The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:
•The Company recorded a $0.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2024. The change in fair value of contingent consideration for the USWM milestones was primarily due to passage of time.
•The Company recorded a $1.7 million gain due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2023. The change in the fair value of contingent consideration for the USWM milestones was primarily due to the change in timing of the regulatory and developmental milestone achievement and estimated discount rates.
The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:
•The Company recorded a $1.8 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2024. The change in fair value of contingent consideration was primarily due to passage of time.
•The Company recorded a $0.1 million expense due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2023. The change in fair value was primarily due to the passage of time and estimated discount rates.
7.    Intangibles Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2024		December 31,
2023
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights6.61661,311 (208,667)452,644 661,311 (190,395)470,916 
Capitalized patent defense costs0.4243,820 (40,712)3,108 43,820 (38,847)4,973 
Total intangible assets6.57$829,131 $(249,379)$579,752 $829,131 $(229,242)$599,889 
14
Amortization expense for intangible assets was $20.1 million and $20.0 million, for the three month periods ended March 31, 2024 and 2023, respectively.
U.S. patents covering Trokendi XR and Oxtellar XR will expire no earlier than 2027. The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market on January 1, 2023. The Company entered into settlement and license agreements that allows a third party to enter the Oxtellar XR market in September 2024, or sooner under certain conditions.
8.    Debt
Uncommitted Demand Secured Line of Credit
On February 8, 2023, the Company entered into a credit line agreement with UBS (the "Credit Line"). The Credit Line provides for a revolving line of credit of up to $150 million, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of (i) the UBS Fixed Funding Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of (i) the UBS Variable Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line.
The Credit Line is secured by a first priority lien and security interest in certain of the Company’s assets, including each account of the Company at UBS Financial Services Inc. (the “Collateral Account”), and other such collateral (collectively, the Collateral), as further defined in the Credit Line. The Company may be required to post additional collateral if the value of the Collateral declines below the required collateral maintenance requirements.
Upon certain customary events of default, all amounts due under the Credit Line will become immediately due and payable without demand, and UBS has the right, in its discretion, to liquidate, transfer, withdraw or sell all or any part of the Collateral and apply the proceeds to repay any borrowings pursuant to the Credit Line.
The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.
On March 30, 2023, the Company borrowed $93.0 million under the Credit Line, which bore a variable interest rate. The funds from this borrowing were used to repay outstanding indebtedness under the 2023 Notes. In the second quarter of 2023, the Company repaid the total principal balance of $93.0 million under the Credit Line and the interest incurred on the Credit Line of $0.7 million. As of March 31, 2024, there was no outstanding debt under the Credit Line.
9.    Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Research and development$1,365 $958 
Selling, general and administrative4,532 5,348 
Total$5,897 $6,306 






15
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20236,583,822 $29.20 5.90
Granted 1,107,662 $27.94 
Exercised (154,567)$18.83 
Forfeited (71,499)$25.31 
Outstanding, March 31, 2024 (unaudited)7,465,418 $29.26 6.37
As of March 31, 2024 (unaudited):
Vested and expected to vest7,465,418 $29.26 6.37
Exercisable 4,715,920 $27.82 4.84
As of December 31, 2023:
Vested and expected to vest6,583,822 $29.20 5.90
Exercisable4,110,537 $26.58 4.43
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023300,141 $36.90 
Granted193,914 $27.94 
Vested(95,397)$36.87 
Forfeited(1,750)$35.86 
Nonvested, March 31, 2024396,908 $32.54 
Performance Share Units
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023251,630 $32.22 20,000 $28.63 271,630 $31.96 
Vested(39,080)$33.47 — $— (39,080)$33.47 
Forfeited(52,000)$28.93 — $— (52,000)$28.93 
Nonvested, March 31, 2024160,550$32.98 20,000$28.63 180,550$32.51 




16
10.    Earnings per Share

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2024 and 2023 (dollars in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
(unaudited)
Numerator:
Net earnings $124 $16,948 
After-tax interest expense for 2023 Notes— 892 
Numerator for dilutive earnings per share$124 $17,840 
Denominator:
Weighted average shares outstanding, basic54,801,748 54,380,947 
Effect of dilutive securities:
Stock options, RSUs and SARs824,915 1,289,321 
Convertible notes— 6,783,936 
Weighted average shares outstanding, diluted55,626,663 62,454,204 
Earnings per share, basic$0.00 $0.31 
Earnings per share, diluted$0.00 $0.29 
The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted EPS because their inclusion would be anti-dilutive:
Three Months Ended
March 31,
20242023
(unaudited)
Stock options, RSUs, PSUs520,152 240,398 
11.    Income Tax Expense (Benefit)
The following table provides information regarding the Company’s income tax expense (benefit) for the three months ended March 31, 2024 and 2023 (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Income tax expense (benefit)
$119 $(7,931)
Effective tax rate49.0 %(88.0)%

Income tax expense was $0.1 million for the three months ended March 31, 2024, as compared to an income tax benefit of $7.9 million for the three months ended March 31, 2023. The change was primarily due to almost break-even pre-tax income for the three months ended March 31, 2024 and greater full year 2024 forecasted losses as compared to the same period in 2023. The effective tax rate for the three months ended March 31, 2024 was higher compared to the same period in 2023 primarily due to near break-even pre-tax losses forecasted for the full year 2023. The annual forecasted earnings represent the Company's best estimate as of March 31, 2024 and 2023, are subject to change and could have a material impact on the effective tax rate in subsequent periods. Accounting Standard Codification (ASC) 740, Income Taxes (ASC 740), requires the Company to estimate the annual effective income tax rate for the full year and apply it to pre-tax income (loss) for each interim period, taking into account year-to-date amounts and projected results for the full year.
17
12.    Leases
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2024December 31, 2023
(unaudited)
Assets
Operating lease assetsOther assets$29,748 $28,994 
Total lease assets$29,748 $28,994 
Liabilities
Operating lease liabilities, current portionAccounts payable and accrued liabilities$9,133 $8,331 
Operating lease liabilities, long-termOperating lease liabilities, long-term32,994 33,196 
Total lease liabilities$42,127 $41,527 

13.    Composition of Other Balance Sheet Items
The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of March 31, 2024 and December 31, 2023, the Company has reduced accounts receivable by approximately $12.0 million and $10.7 million, respectively for prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues and represent estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
Inventories, Net
March 31,
2024		December 31,
2023
(unaudited)
Raw materials$18,803 $16,274 
Work in process23,246 31,212 
Finished goods33,030 29,922 
Total$75,079 $77,408 
Property and Equipment, Net
March 31,
2024		December 31,
2023
(unaudited)
Lab equipment and furniture$13,120 $13,069 
Leasehold improvements14,023 14,023 
Software883 883 
Computer equipment960 960 
28,986 28,935 
Less accumulated depreciation and amortization(16,017)(15,405)
Property and equipment, net$12,969 $13,530 
Depreciation and amortization expense on property and equipment was approximately $0.6 million and $0.6 million for the three months ended March 31, 2024, and 2023, respectively.
18
Accounts Payable and Accrued Liabilities
March 31,
2024		December 31,
2023
(unaudited)
Accounts payable$14,397 $1,964 
Accrued compensation, benefits, & related accruals16,444 20,722 
Accrued sales & marketing13,263 11,666 
Accrued manufacturing expenses9,118 11,652 
Accrued R&D expenses9,092 10,530 
Operating lease liabilities, current portion (2)
9,133 8,331 
Accrued royalties (1)
6,963 7,918 
Other accrued expenses7,992 6,786 
Total$86,402 $79,569 
_______________________________
(1) Refer to Note 15, Commitments and Contingencies.
(2) Refer to Note 12, Leases.
Accrued Product Returns and Rebates
March 31,
2024		December 31,
2023
(unaudited)
Accrued product rebates$107,681 $96,984 
Accrued product returns59,545 57,290 
Total$167,226 $154,274 
14.    Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Interest expense$— $(656)
Interest expense on nonrecourse liability related to sale of future royalties— (317)
Noncash interest expense on debt— (532)
Total$— $(1,505)

Noncash interest expense on debt is related to amortization of deferred financing costs on the 2023 Notes. The Company fully amortized the deferred financing costs on the 2023 Notes in the first quarter of 2023.
15.    Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
19
USWM Enterprise Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply.
MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services which was effective in April 2019. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit which was denied on November 3, 2022. On December 23, 2022, the defendants filed renewed motions to dismiss directed to the remaining unresolved issue. On March 20, 2023, the District Court entered an order and final judgement dismissing with prejudice the FCA claim while declining to exercise supplemental jurisdiction over the state false claims act claims which were dismissed without prejudice. On April 19, 2023, the plaintiff appealed the District Court's dismissal of the Federal False Claims Act claim. On February 20, 2024, the plaintiff filed a motion for an indicative ruling and to set aside the judgment in the District Court, based on the same arguments raised in his appeal. That motion was fully briefed and the District Court determined that the motion for an indicative ruling was suitable for determination without a hearing. On May 7, 2024, the District Court denied the plaintiff’s motion for an indicative ruling. The plaintiff’s appeal remains pending in the United States Court of Appeals for the Ninth Circuit.

20
APOKYN Litigation
On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No.22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. On January 10, 2023, the Company filed motions to dismiss all claims and the lawsuit in its entirety. As of April 12, 2023, briefing on those motions is now complete. Those motions remain pending. On April 10, 2023, the Court issued a scheduling order that provides for a Pretrial Conference on March 7, 2025, and a jury trial beginning on March 24, 2025. Pretrial discovery is ongoing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
16.    Subsequent Events
SPN-830 Regulatory Development
In April 2024, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for SPN-830. The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA. The first area relates to product quality. Prior to the issuance of the CRL, the Company submitted additional product quality data to the FDA, which it had not yet reviewed at the time of the CRL's issuance. The second relates to the master file for the infusion device, which is proprietary to the device manufacturer. No clinical safety or efficacy issues were identified as a requirement for approval.
The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we may identify indicators of impairment for the related IPR&D asset, which represents an estimate of the fair value of SPN-830, resulting from the receipt of the CRL. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration liabilities related to the milestone payments due upon the achievement of certain FDA regulatory approvals and the commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, any potential adjustments would be recognized and reported within the second quarter of 2024. Any material adjustments to the fair value of the IPR&D asset or the fair value of contingent consideration liabilities could impact the Company’s results of operations and financial condition.
21
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help the reader understand the results of operations and the financial condition of Supernus Pharmaceuticals, Inc. The interim condensed consolidated financial statements included in this report and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 27, 2024.
In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. These forward-looking statements may include declarations regarding the Company’s belief or current expectations of management, such as statements including the words “budgeted,” “anticipate,” “project,” “forecast,” “estimate,” “expect,” “may,” “believe,” “potential,” and similar statements or expressions, which are intended to be among the statements that are forward-looking statements, as such statements reflect the reality of risk and uncertainty that is inherent in our business. Actual results may differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date this report was filed with the Securities and Exchange Commission. Our actual results and the timing of events could differ materially from those discussed in our forward-looking statements because of many factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K and elsewhere in this report as well as in other reports and documents we file with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q.
Unless the content requires otherwise, the words "Supernus," "we," "our" and "the Company" refer to Supernus Pharmaceuticals, Inc. and/or one or more of its subsidiaries, as the case may be. These terms are used solely for the convenience of the reader. Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. For example, MDD US Operations, LLC, a wholly-owned indirect subsidiary of Supernus Pharmaceuticals, Inc., is the exclusive licensee and distributor of APOKYN in the United States and its territories. Adamas Operations, LLC, a wholly-owned indirect subsidiary of Supernus Pharmaceuticals, Inc., wholly owns the patents and patent applications related to GOCOVRI and Osmolex ER and has a license agreement with Supernus Pharmaceuticals, Inc., granting Supernus Pharmaceuticals, Inc. rights to market and sell GOCOVRI and Osmolex ER.
Solely for convenience, in this Quarterly Report on Form 10-Q, the trade names are referred to without the TM symbols and the trademark registrations are referred to without the circled R, but such references should not be construed as any indicator that the Company will not assert, to the fullest extent under applicable law, our rights thereto.

22
Overview
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
We have a portfolio of commercial products and product candidates.
Commercial Products
•Qelbree® (viloxazine) extended-release capsules is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. The United States Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age in April 2021, and in adult patients in April 2022. The Company launched Qelbree for pediatric patients in May 2021 and for adult patients in May 2022 in the United States (U.S.).
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "OFF" episodes.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S. market.
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the U.S. market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "OFF" episodes ("end-of-dose wearing off" and unpredictable "ON/OFF" episodes) in patients with advanced PD.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "OFF" episodes.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
•Osmolex ER® (amantadine) extended-release tablets is for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution, stating that manufacturing has been discontinued and distribution of the product will cease by April 1, 2024.
23
Research and Development
We are committed to the development of innovative product candidates in neurology and psychiatry, including the following:
Product Candidates Table.jpg
SPN-830 (apomorphine infusion device)
SPN-830 is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("OFF" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. If approved, it would be the only continuous infusion of apomorphine available in the U.S. and an important step for PD patients that would have otherwise been candidates for potentially invasive surgical procedures, such as deep brain stimulation. Continuous slow infusion may also limit some of the side effects of a bolus injection of apomorphine.
In October 2023, we resubmitted the New Drug Application (NDA) for SPN-830 to the FDA. In November 2, 2023, the Company announced that the FDA had acknowledged the resubmission of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) date of April 5, 2024. In April 2024, the FDA issued a Complete Response Letter regarding the NDA for SPN-830. For further discussion, see Operational Highlights section below.
SPN-820 (NV-5138)
SPN-820 is a first-in-class, orally active small molecule that increases the brain mechanistic target of rapamycin complex 1 (mTORC1) mediated synaptic function intracellularly. SPN-820 does not bind to or modulate any cell surface receptors and therefore is unlikely to have abuse potential given lack of binding to targets implicated in drug abuse. In addition, unlike leucine, it is not incorporated into proteins during protein synthesis, and therefore, it is more available at the target site in the brain than leucine.
SPN-817 (huperzine A)
SPN-817 represents a novel mechanism of action (MOA) for an anticonvulsant. SPN-817 is a novel synthetic form of
huperzine A, whose MOA includes potent acetylcholinesterase inhibition, with pharmacological activities in CNS conditions such as epilepsy. The development will initially focus on the drug's anticonvulsant activity, which has been shown in preclinical models to be effective for the treatment of partial seizures and Dravet Syndrome. SPN-817 is in clinical development and has received Orphan Drug designation for several epilepsy indications from the FDA.
Operational Highlights
Qelbree Update
•Total IQVIA prescriptions were 176,503 for first quarter 2024, an increase of 31% compared to the prior year period.
•Patient enrollment is ongoing in the Phase IV open-label study to assess the efficacy of Qelbree over the course of 14 weeks of treatment in approximately 500 adults with attention deficit hyperactivity disorder (ADHD) and mood
24
symptoms. The primary outcome measure is change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS).
Product Pipeline Update
SPN-830 (apomorphine infusion device) for treatment of Parkinson's disease (PD)
•In April 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) in response to the Company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete, but that the application is not ready for approval in its present form.
•The Company will announce the timing for its resubmission after further discussion with the FDA, which is expected to take place in May 2024.
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression
•More than half the number of planned patients have been enrolled in the ongoing Phase IIb multi-center randomized double-blind placebo-controlled parallel design study of SPN-820 in adults with treatment-resistant depression. The study is examining efficacy and safety of SPN-820 over a course of five weeks of treatment in approximately 268 patients in up to 50 clinical sites. The primary outcome measure is the change from baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. Topline data from the Phase IIb trial is expected in the first half of 2025.
•The Company has initiated a Phase II open-label study in approximately 40 subjects with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, as well as onset of efficacy.
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
•The Company will hold a conference call on Thursday, May 23, 2024 to report on interim data from approximately 40 patients from the open-label Phase IIa clinical study of SPN-817 for treatment-resistant seizures (webcast details forthcoming). The study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as assessing efficacy. Topline results for the full study are expected in the second half of 2024.
SPN-443 – Novel stimulant for ADHD/CNS
•The Company plans to initiate a Phase I single dose study in healthy adults in 2024 following submission of an Investigational New Drug application. The primary objective of the study is to assess safety and tolerability.
Critical Accounting Policies and the Use of Estimates
A summary of our significant accounting policies is included in Note 2, Summary of Significant Accounting Policies of our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023. There were no significant changes to the disclosures with respect to our critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2023.
25
Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023
Revenues
Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty and licensing revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three months ended March 31, 2024 (dollars in thousands):
Three Months Ended March 31,Change
20242023AmountPercent
Net product sales
Qelbree$45,104 $25,782 $19,322 75 %
Oxtellar XR26,943 28,915 (1,972)(7)%
GOCOVRI26,562 26,010 552 2 %
APOKYN16,649 17,209 (560)(3)%
Trokendi XR15,989 34,790 (18,801)(54)%
Other(1)
7,214 7,869 (655)(8)%
Total net product sales$138,461 $140,575 $(2,114)(2)%
Royalty and licensing revenues
5,183 13,189 (8,006)(61)%
Total revenues$143,644 $153,764 $(10,120)(7)%
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Net Product Sales
The $2.1 million and 2% decrease in net product sales for the three months ended March 31, 2024, as compared to the same period in 2023, was primarily due to the $18.8 million decline in net product sales of Trokendi XR due to generic erosion, and a decline in net product sales of Oxtellar XR, partially offset by the $19.3 million increase in net product sales from Qelbree.
Sales Deductions and Related Accruals
We record accrued product returns and accrued product rebates as current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the unaudited condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.
The following table provides a summary of activity with respect to accrued product returns and rebates during the periods indicated (dollars in thousands):
Accrued Product Returns and Rebates
Product
Returns		Product
Rebates		Allowance for
Sales Discounts		Total
Balance at December 31, 2023$57,290 $96,984 $10,719 $164,993 
Provision
Provision for current year sales5,640 100,301 15,812 121,753 
Adjustments relating to prior year sales(1,403)668 38 (697)
Total provision$4,237 $100,969 $15,850 $121,056 
Less: Actual payments/credits(1,982)(90,272)(14,531)(106,785)
Balance at March 31, 2024$59,545 $107,681 $12,038 $179,264 
26
Accrued Product Returns and Rebates
Product
Returns		Product
Rebates		Allowance for
Sales Discounts		Total
Balance at December 31, 2022$45,008 $106,657 $12,995 $164,660 
Provision
Provision for current year sales6,203 102,181 15,661 124,045 
Adjustments relating to prior year sales(400)2,457 31 2,088 
Total provision$5,803 $104,638 $15,692 $126,133 
Less: Actual payments/credits(1,771)(112,483)(16,498)(130,752)
Balance at March 31, 2023$49,040 $98,812 $12,189 $160,041 
Accrued Product Returns and Rebates
The accrued product returns balance increased from $57.3 million as of December 31, 2023 to $59.5 million as of March 31, 2024 principally due to the timing of related return activity and an increase in provision for product returns primarily related to Qelbree.
The accrued product rebates balance increased from $97.0 million as of December 31, 2023 to $107.7 million as of March 31, 2024 due to timing of Medicaid billing from states.
Provision for Product Returns and Rebates
The provision for product returns decreased from $5.8 million for the three months ended March 31, 2023 to $4.2 million for the three months ended March 31, 2024. The decrease was primarily attributable to lower sales of Trokendi XR.
The provision for product rebates decreased from $104.6 million for the three months ended March 31, 2023 to $101.0 million for three months ended March 31, 2024. The decrease was primarily attributable to lower Trokendi XR sales partially offset by higher Qelbree sales.
Royalty and Licensing Revenues
Royalty and licensing revenues were $5.2 million and $13.2 million for the three months ended March 31, 2024 and 2023, respectively. The decrease was primarily due to lower royalties on generic Trokendi XR for the three months ended March 31, 2024 due to the increased number of generic entrants.
Cost of Goods Sold
Cost of goods sold was $16.3 million and $23.5 million for the three months ended March 31, 2024 and 2023, respectively. The $7.2 million decrease was primarily driven by manufacturing efficiencies, mainly related to Qelbree.
Research and Development Expenses
R&D expenses were $24.9 million and $21.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was primarily due to increased clinical program costs on SPN-820 and increased manufacturing costs of our product candidates.
Selling, General and Administrative Expenses
The following table provides information regarding our selling, general and administrative (SG&A) expenses during the periods indicated (dollars in thousands):
Three Months Ended March 31,Change
20242023AmountPercent
 Selling and marketing $59,567 $57,230 $2,337 4%
 General and administrative 26,949 28,367 (1,418)(5)%
 Total $86,516 $85,597 $919 1%
27
Selling, general and administrative expenses increased by 1% to $86.5 million for the three months ended March 31, 2024.
Amortization of Intangible Assets
Amortization of intangible assets was $20.1 million and $20.0 million for the three months ended March 31, 2024 and 2023, respectively.
Contingent Consideration (Gain) Expense
Contingent consideration was a gain of $1.1 million and a gain of $1.6 million for the three months ended March 31, 2024 and 2023, respectively. The contingent consideration gain was primarily driven by the passage of time.
Other Income (Expense)
Other income (expense) was income of $3.4 million and $3.8 million for the three months ended March 31, 2024 and 2023, respectively. The $0.4 million decrease was due to lower interest income on marketable securities largely driven by an overall lower investment balance, partially offset by the interest expense recognized in three months ended March 31, 2023 related to the 2023 Notes, which were paid off in April 2023.
Income Tax Expense (Benefit)
Income tax expense of $0.1 million for the three months ended March 31, 2024, as compared to an income tax (benefit) of $7.9 million for the three months ended March 31, 2023. The change was primarily due to almost break-even pre-tax income for the three months ended March 31, 2024 and greater full year 2024 forecasted losses as compared to the same period in 2023. The effective tax rate was 49.0% for the three months ended March 31, 2024, as compared to (88.0)% for the three months ended March 31, 2023. The effective tax rate for the three months ended March 31, 2024 was higher compared to the same period in 2023 primarily due to near break-even pretax losses forecasted for the full year 2023. The annual forecasted earnings represent the Company's best estimate as of March 31, 2024 and 2023, are subject to change and could have a material impact on the effective tax rate in subsequent periods. ASC 740, Income Taxes (ASC 740), requires an estimate of the annual effective income tax rate for the full year and apply it to pre-tax income (loss) for each interim period, taking into account year-to-date amounts and projected results for the full year.
Financial Condition, Liquidity and Capital Resources
Cash and Cash Equivalents and Marketable Securities

Cash and cash equivalents, marketable securities, and long-term marketable securities are comprised of the following (dollars in thousands):
March 31December 31Change
20242023AmountPercent
Cash and cash equivalents$63,401 $75,054 $(11,653)(16)%
Marketable securities234,335 179,820 54,515 30%
Long-term marketable securities11,662 16,617 (4,955)(30)%
Total$309,398 $271,491 $37,907 14%
We have financed our operations primarily with cash generated from product sales, supplemented by revenues from royalty and licensing arrangements, as well as proceeds from the sale of equity and debt securities. Continued cash generation is highly dependent on the success of our commercial products, as well as the success of our product candidates if approved by the FDA. While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to the following: continued market and payor pressures for our commercial products; the unfavorable impact of the loss of patent exclusivity for Trokendi XR in January 2023; the potential unfavorable impact of the forthcoming loss of exclusivity of Oxtellar XR and XADAGO; funding for research and development of our product candidates; and the additional funding to launch SPN-830, if approved by the FDA.
The Company believes its balances of cash, cash equivalents, restricted cash, and unrestricted marketable securities, which totaled $309.4 million as of March 31, 2024, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next 12 months and beyond.
28
We may, from time to time, consider raising additional capital through: new collaborative arrangements; strategic alliances; additional equity and/or financings from debt or other sources, especially in conjunction with opportunistic business development initiatives. We will continue to actively manage our capital structure and to consider all financing opportunities that could strengthen our long-term financial profile. Any such capital raises may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
Cash Flows
Cash flows are comprised of the following (dollars in thousands):
Three Months Ended March 31,Change
20242023Amount
 Net cash provided by (used in):
 Operating activities $38,401 $49,126 $(10,725)
 Investing activities (51,624)239,780 (291,404)
 Financing activities 1,570 80,174 (78,604)
 Net change in cash, cash equivalents, and restricted cash$(11,653)$369,080 $(380,733)
Cash and cash equivalents at beginning of year75,054 93,120 (18,066)
Cash, cash equivalents, and restricted cash at end of period$63,401 $462,200 $(398,799)
Operating Activities
Net cash provided by operating activities was $38.4 million and $49.1 million for the three months ended March 31, 2024, and 2023, respectively. The decrease in cash flows provided by operating activities is primarily due to lower net income for the three months ended March 31, 2024 compared to the same period in prior year and changes in working capital which reflects the timing impacts of cash collections on receivables and settlement of payables.
Investing Activities
Net cash used in investing activities was $51.6 million for the three months ended March 31, 2024 compared to $239.8 million cash provided by investing activities during the same period in 2023. The change was primarily due to higher cash flows from the sales and maturities of marketable securities in 2023. Proceeds from the sales and maturities of marketable securities in 2023 were used to repay the 2023 Notes at maturity date of April 1, 2023.
Financing Activities
Net cash provided by financing activities were $1.6 million for the three months ended March 31, 2024 compared to $80.2 million used during the same period in 2023. The change was primarily due to the net proceeds from the draw on the line of credit in the first quarter of 2023 which was used to repay the 2023 Notes in April 2023.
Material Cash Requirements
Refer to “Part II, Item 7 — Management’s Discussion and Analysis of Liquidity and Capital Resources”, of our Annual Report on Form 10-K for the year ended December 31, 2023, and Note 15, Commitments and Contingencies, in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this Quarterly Report on Form 10-Q for the discussion of our contractual obligations.
Recently Issued Accounting Pronouncements
For a discussion of new accounting pronouncements, see Note 2 in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this Quarterly Report on Form 10-Q.




29
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
The primary objective of our investment activities is to preserve our capital to fund operations and to facilitate business development activities. We also seek to maximize income from our investments without assuming significant interest rate risk, liquidity risk, or risk of default by investing in investment grade securities with maturities of four years or less. Our exposure to market risk is confined to investments in cash and cash equivalents, marketable securities, and long-term marketable securities. As of March 31, 2024, we had cash and cash equivalents, marketable securities, and long-term marketable securities of $309.4 million.
The Company has a credit line agreement with UBS (the "Credit Line") which provides a revolving line of credit of up to $150 million and can be drawn at any time. As of March 31, 2024, there was no outstanding debt under the Credit Line. In the future, we may borrow funds under the Credit Line. Variable rate borrowing, which may occur under the Credit Line, exposes us to interest rate risk as increases in interest rates would increase our borrowing costs.
Any borrowed funds pursuant to our Credit Line are subject to a collateral maintenance requirement. The Credit Line is secured primarily by our portfolio of marketable securities, which is primarily comprised of corporate and U.S. government agency and municipal debt securities and may fluctuate in value. The fluctuations may be driven by, among other things, changes in interest rates, economic conditions, and other financial conditions as well as idiosyncratic factors related to a security’s issuer. To the extent a fluctuation in value results in the value of the collateral decreasing below the required collateral maintenance requirements we may be required to promptly post additional collateral. Additionally, our Credit Line is an uncommitted facility that may be terminated by the lender at any time. During periods of rapidly changing interest rates, economic conditions or other financial conditions, the Credit Line may be terminated by the lender and/or the lender may declare that all borrowings thereunder are immediately due.
Our cash and cash equivalents consist primarily of cash held at banks and investments in highly liquid financial instruments with an original maturity of three months or less. Our marketable securities, which are reported at fair value, consist of investments in U.S. Treasury bills and notes; bank certificates of deposit; various U.S. governmental agency debt securities; and corporate and municipal debt securities. We place all investments with governmental, industrial, or financial institutions whose debt is rated as investment grade. We generally hold these securities to maturities of one to four years. Because of the relatively short period that we hold our investments and because we generally hold these securities to maturity, we do not believe that an increase in interest rates would have any significant impact on the realizable value of our investments.
We do not have any currency or derivative financial instruments.
We may contract with clinical research organizations (CROs) and investigational sites globally. Currently, we have ongoing clinical trials being conducted outside the U.S. We do not hedge our foreign currency exchange rate risk. Transactions denominated in currencies other than the U.S. dollar are recorded based on exchange rates at the time such transactions arise. As of March 31, 2024 and December 31, 2023, substantially all of our liabilities were denominated in the U.S. dollar.
Inflation generally affects us by increasing our cost of labor and the cost of services provided by our vendors. We do not believe that inflation and changing prices over the year ended December 31, 2023, and the three months ended March 31, 2024 had a significant impact on our consolidated results of operations.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures required by Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act has been appropriately recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure. We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024, the end of the period covered by this report. Based on that evaluation, under the supervision and with the participation of our management, including our CEO and CFO, we concluded that our disclosure controls and procedures are effective as of March 31, 2024.


30
Changes in Internal Control over Financial Reporting
Our management, including our CEO and CFO, evaluated changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024.
During the three months ended March 31, 2024, no changes occurred in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1.    Legal Proceedings
From time to time and in the ordinary course of business, Supernus Pharmaceuticals, Inc. (the "Company") and any of its subsidiaries may be subject to various claims, charges and litigation. The Company and any of its subsidiaries may be required to file infringement claims against third parties for the infringement of our patents.
Oxtellar XR®
I. Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, C.A. No. 22-cv-1431 (GBW) (D. Del.)
The Company received a Paragraph IV Notice Letter from generic drug maker Ajanta Pharma Limited (“Ajanta”) dated September 19, 2022, directed to ten of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; 10,220,042; and 11,166,960 generally cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists all ten of the Company’s Oxtellar XR® patents as expiring on April 13, 2027. On October 28, 2022, the Company filed a lawsuit against Ajanta alleging infringement of the Company’s ten Oxtellar XR® patents. The Complaint—filed in the U.S. District Court for the District of Delaware—alleges, inter alia, that Ajanta infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its October 28, 2022, Complaint within 45 days of receiving Ajanta’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ajanta’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On January 3, 2023, Ajanta answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ajanta also asserted Counterclaims seeking declaratory judgments of non-infringement and invalidity. On January 24, 2023, the Company filed its Reply, denying the substantive allegations of Ajanta’s Counterclaims. The Court issued a Scheduling Order on July 13, 2023, that sets a trial date of February 10, 2025. The Company entered into a settlement agreement with Ajanta, and on January 18, 2024, a stipulation of dismissal without prejudice was entered by the U.S. District Court for the District of Delaware. The agreement has been submitted to the applicable governmental agencies.
Trokendi XR®
II. Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, et al., C.A. No. 21-cv-6964 (GC)(DEA) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Ajanta Pharma Limited dated February 10, 2021, directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028, and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On March 26, 2021, the Company filed a lawsuit against Ajanta Pharma Limited and Ajanta Pharma USA Inc. (collectively “Ajanta”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ajanta infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its March 26, 2021, Complaint within 45 days of receiving Ajanta’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ajanta’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On June 7, 2021, Ajanta answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ajanta also asserted Counterclaims seeking declaratory judgments of non‑infringement and invalidity for the Trokendi XR® Orange Book patents. On June 28, 2021, the Company filed its reply, denying the substantive allegations of Ajanta’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit with the lawsuit against Torrent, discussed
31
in Section III, below. The consolidation order extended the 30‑month stay preventing the FDA from approving Ajanta’s ANDA to December 16, 2023. The Company entered into a settlement agreement with Ajanta, and on April 4, 2023, a stipulation of dismissal without prejudice was entered by the U.S. District Court for the District of New Jersey. The agreement has been submitted to the applicable governmental agencies.
III. Supernus Pharmaceuticals, Inc. v. Torrent Pharmaceuticals Ltd., et al., C.A. No. 21-cv-14268 (GC)(DEA) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Torrent Pharmaceuticals Ltd. dated June 15, 2021, directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028, and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 28, 2021, the Company filed a lawsuit against Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. (collectively, “Torrent”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Torrent infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 28, 2021, Complaint within 45 days of receiving Torrent’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Torrent’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 29, 2021, Torrent answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Torrent also asserted Counterclaims seeking declaratory judgments of non‑infringement for the Trokendi XR® Orange Book patents. On November 3, 2021, the Company filed its reply, denying the substantive allegations of Torrent’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit with the lawsuit against Ajanta, discussed in Section II, above. The Court held a bench trial between July 31, 2023, and August 3, 2023. Closing arguments for the trial were held on October 4, 2023. On December 12, 2023, the Court issued an Order enjoining Torrent from launching its generic drug product through January 31, 2024, or until the Court’s trial decision issues, whichever is sooner. On January 30, 2024, the Court issued a Trial Opinion and Order, deciding in Supernus’s favor that the patent claims that Supernus asserted at trial against Torrent are both valid and infringed. The District Court entered a Final Judgment in Supernus’s favor on February 22, 2024.
On March 4, 2024, Torrent filed a Notice of Appeal of the Final Judgment with the U.S. Court of Appeals for the Federal Circuit. The Federal Circuit docketed the appeal as Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited because the lawsuit against Torrent was consolidated with the lawsuit against Ajanta (see Section II above). Torrent’s opening brief for the appeal is due by May 28, 2024.
IV. Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc., et al., C.A. No. 23-cv-4015 (GC)(DEA) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Ascent Pharmaceuticals Inc. dated June 15, 2023, directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028, and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 26, 2023, the Company filed a lawsuit against Ascent Pharmaceuticals Inc., Camber Pharmaceuticals, Inc., and Hetero Labs Ltd. (collectively, “Ascent”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ascent infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 26, 2023, Complaint within 45 days of receiving Ascent’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ascent’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 28, 2023, the Court entered a stipulation of dismissal without prejudice as to only defendants Camber and Hetero, which included stipulations that, among other things: (i) Ascent Pharma will not contest personal jurisdiction or venue in this District for this Action; (ii) Camber and Hetero will be bound by any injunction in this Action to the extent it concerns the Ascent ANDA; and (iii) Ascent Pharma will collect and produce any relevant discovery that is in the possession, custody, or control of Camber and Hetero. On October 11, 2023, Ascent Pharma answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. On November 21, 2023, the Court issued a scheduling order that provides for a Pretrial Conference in July 2025 and a bench trial in July/August 2025. The Company entered into a settlement agreement with Ascent Pharmaceuticals Inc., and on May 2, 2024, a stipulation of dismissal without
32
prejudice was entered by the U.S. District Court for the District of New Jersey. The agreement will be submitted to the applicable governmental agencies.
APOKYN®
V. Sage Chemical, Inc., et al. v. Supernus Pharmaceuticals, Inc., et al., C.A. No. 22-cv-1302 (CJB) (D. Del.)
On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited (“Britannia”), and US WorldMeds Partners, LLC (“US WorldMeds”) violated state and federal antitrust law in connection with APOKYN® (apomorphine HCl). On October 16, 2022, Plaintiffs amended their complaint to add additional defendants MDD US Enterprises, LLC, MDD US Operations, LLC (each a subsidiary of Supernus Pharmaceuticals, Inc.), USWM, LLC (“USWM”), Paul Breckinridge Jones, Sr., Herbert Lee Warren, Jr., Henry Van Den Berg, and Kristin L. Gullo. On January 10, 2023, Defendants filed an Omnibus Motion to Dismiss the Amended Complaint seeking dismissal of each of Plaintiffs’ claims and the lawsuit in its entirety and US WorldMeds with USWM, Britannia, and the group of individual defendants each filed separate motions to dismiss. As of April 12, 2023, briefing on those motions is now complete. Those motions remain pending. On April 10, 2023, the Court issued a scheduling order that provides for a Pretrial Conference on March 7, 2025, and a jury trial beginning on March 24, 2025. Pretrial discovery is ongoing as of the date of this filing.
Adamas Litigation
In November 2012, Adamas Pharmaceuticals, Inc. (Adamas) granted Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc (Forest), an exclusive license to certain of Adamas's intellectual property rights relating to human therapeutics containing memantine in the United States. Under the terms of that license agreement, Forest has the right to enforce such intellectual property rights which are related to its right to market and sell Namzaric and NAMENDA XR for the treatment of moderate to severe dementia related to Alzheimer's disease. Adamas has a right to participate in, but not control, such enforcement actions by Forest.
Since 2018 multiple generic companies have launched generic versions of NAMENDA XR. A number of companies have submitted ANDAs including one or more certifications to the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(iv), requesting approval to manufacture and market generic versions of Namzaric, on which Adamas became entitled to receive royalties from Forest beginning in May 2020.
Adamas and Forest have settled with all such Namzaric ANDA filers, including all first filers on all the available dosage forms of Namzaric. Subject to those agreements, the earliest date on which any of these agreements grant a license to market a Namzaric ANDA filer's generic version of Namzaric is January 1, 2025 (or earlier in certain circumstances). Alternatively, the Namzaric ANDA filers with the earliest date have the option to launch an authorized generic version of Namzaric beginning on January 1, 2026 instead of launching their own generic version of Namzaric on January 1, 2025. Adamas and Forest intend to continue to enforce the patents associated with Namzaric.
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (Case No. 3:18-cv-03018-JCS) against it and several Forest and Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by a named individual, Zachary Silbersher, asserting rights of the Federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high prices being charged to government payors.
Adamas's patents in question were licensed exclusively to Forest. The complaint includes a claim for damages of “potentially more than $2.5 billion dollars,” treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motions to dismiss the complaint. The appeal was heard by the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit, which was denied. On December 23, 2022, defendants filed renewed motions to dismiss directed to the remaining unresolved issue. On March 20, 2023, the District Court entered an order and final judgment dismissing with prejudice the FCA claim while declining to exercise supplemental jurisdiction over the state false claims act
33
claims which were dismissed without prejudice. On April 19, 2023, the plaintiff appealed the District Court's dismissal of the Federal False Claims Act claim. On February 20, 2024, the plaintiff filed a motion for an indicative ruling and to set aside the judgment in the District Court, based on the same arguments raised in his appeal. That motion was fully briefed and the District Court determined that the motion for an indicative ruling was suitable for determination without a hearing. On May 7, 2024, the District Court denied the plaintiff’s motion for an indicative ruling. The plaintiff’s appeal remains pending in the United States Court of Appeals for the Ninth Circuit.
On December 10, 2019, a putative class action lawsuit alleging violations of the federal securities laws was filed by Ali Zaidi against Adamas and certain of Adamas's former directors and officers in federal court in the Northern District of California (Case No. 4:19-cv-08051). This lawsuit alleges violations of the Securities Exchange Act of 1934 by Adamas and certain of Adamas's former directors and officers. On October 8, 2021, the presiding judge dismissed the litigation, and granted Plaintiffs leave to amend their complaint. On November 5, 2021, Plaintiffs filed their second amended class action complaint. On December 10, 2021, Adamas filed a motion to dismiss the Second Amended Complaint. Plaintiffs opposed the motion to dismiss. On January 13, 2023, the Court granted in part and denied in part Defendants’ Motion to Dismiss. All claims against Adamas have been dismissed with prejudice, but claims against one of the individual defendants, who may have certain rights to indemnification, remain. On February 27, 2023, plaintiffs advised the Court that plaintiffs would proceed only on the remaining claim against one of the individual defendants. The individual defendant filed an answer denying the claim on April 28, 2023. On September 21, 2023, the parties reached an agreement in principle to settle the Zaidi litigation, subject to court approval. On October 31, 2023, the Court granted the parties' stipulation staying all proceedings and vacating all existing deadlines. On April 2, 2024, the Court preliminary approved the settlement of the case, including a $4.7 million payment from insurers, subject to further consideration at a settlement hearing to be held on August 30, 2024.
Adamas believes it has strong factual and legal defenses to all actions and intends to defend itself vigorously.
Item 1A. Risk Factors
Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes; the additional information in the other reports we file with the Securities and Exchange Commission; and the risks described in our Annual Report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the period ended March 31, 2024. These risks may result in material harm to our business and our financial condition and results of operations. If a material, adverse event was to occur, the market price of our common stock may decline, and you could lose part or all of your investment.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
(a)    Sales of Unregistered Securities.

During the three months ended March 31, 2024, all of the Company's grants of equity awards occurred pursuant to its 2021 Equity Incentive Plan (the "2021 Plan"). Securities issued under the 2021 Plan are registered on the Company's Form S-8 filed on June 25, 2021.
Item 3.    Defaults Upon Senior Securities
None.
Item 4.    Mine Safety Disclosures
None.
Item 5.    Other Information
(a)     None.
(b)    None.
(c)    Insider Trading Arrangements and Policies.
There were no insider trading arrangements adopted or terminated during the quarter.

34


Item 6.    Exhibits
The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:
Exhibit
Number
Description
31.1
31.2
32.1
32.2
101
The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL: (i) Cover Page, (ii) Condensed Consolidated Statements of Earnings, (iii) Condensed Consolidated Statements of Comprehensive Earnings, (iv) Condensed Consolidated Balance Sheets, (v) Condensed Consolidated Statements of Changes in Stockholders' Equity, (vi) Condensed Consolidated Statements of Cash Flows, and (vii) the Notes to Condensed Consolidated Financial Statements, tagged in summary and detail.
104
The cover page of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL (included with the Exhibit 101 attachments).

35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC.
DATED: May 8, 2024By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer
DATED: May 8, 2024By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice-President and Chief Financial Officer

36
 EX-31.1 2 supn-20240331x10qxex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION
I, Jack A. Khattar, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 8, 2024By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-31.2 3 supn-20240331x10qxex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION
I, Timothy C. Dec, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 8, 2024By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer



 EX-32.1 4 supn-20240331x10qxex321.htm EX-32.1 Document

EXHIBIT 32.1
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack A. Khattar, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 8, 2024By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-32.2 5 supn-20240331x10qxex322.htm EX-32.2 Document

EXHIBIT 32.2
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy C. Dec, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 8, 2024By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer


 EX-101.SCH 6 supn-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Business Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Disaggregated Revenues link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value of Financial Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Contingent Consideration link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Tax Expense (Benefit) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Composition of Other Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Interest Expense link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Disaggregated Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Fair Value of Financial Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Contingent Consideration (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Income Tax Expense (Benefit) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Composition of Other Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Interest Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Business Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Disaggregated Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Investments - Unrestricted Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value of Financial Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Contingent Consideration - Current and Long-Term Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Contingent Consideration - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Share-Based Payments - SAR Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Share-Based Payments - Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 supn-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 supn-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 supn-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair value gain (loss) recognized in earnings Change in fair value recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Pay vs Performance Disclosure [Line Items] Total Accrued Liabilities, Current Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Accrued royalties Accrued Royalties, Current Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Nonvested, beginning balance (in shares) Nonvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Payments on Credit Line Repayments of Short-Term Debt Debt Debt Disclosure [Text Block] Amortization of premium/discount on marketable securities Investment Income, Net, Amortization of Discount and Premium Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Schedule of unrestricted available-for-sale marketable securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Royalty and licensing revenues Royalty And License [Member] Royalty And License Deferred income tax liabilities, net Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total PSUs Performance Shares [Member] Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Total other income (expense) Nonoperating Income (Expense) Commitments and contingencies (Note 15) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Income Tax Expense (Benefit) Income Tax Disclosure [Text Block] Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Raw materials Inventory, Work in Process and Raw Materials, Net of Reserves Diluted (in dollars per share) Earnings per share, diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Other income (expense) Other Nonoperating Income (Expense) [Abstract] Total fair value Total Debt Securities, Available-for-Sale, Excluding Accrued Interest Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Net earnings Net earnings Net Income (Loss) NAMENDA XR/Namzaric Qui Tam Litigation NAMENDA XR/Namzaric Qui Tam Litigation [Member] NAMENDA XR/Namzaric Qui Tam Litigation Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Leases Lessee, Operating Leases [Text Block] Schedule of cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Total intangible assets, carrying amount, gross Intangible Assets, Gross (Excluding Goodwill) Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Additional cash payments upon milestone achievements minimum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of goods sold Cost of Goods and Services Sold Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Executive Category: Executive Category [Axis] Number of RSUs Number of PSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Accrued product returns Accrued Product Returns Represents the amount of accrued product returns. Name Forgone Recovery, Individual Name Goodwill Goodwill Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Unrealized gain on marketable securities, net of tax Unrealized gain on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, long-term Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held Investments Classified by Contractual Maturity Date [Table Text Block] RSUs Restricted Stock Units (RSUs) [Member] Summary of restricted stock units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Long-term marketable securities Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent Income Statement Location [Axis] Income Statement Location [Axis] Other noncurrent assets Other Assets, Noncurrent [Abstract] Milestone 2024 Milestone 2024 [Member] Milestone 2024 Schedule of common stock equivalents excluded in the calculation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Interest expense Interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount APOKYN APOKYN [Member] APOKYN Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock equivalents excluded in the calculation of diluted income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Noncash operating and investing activities Noncash Investing and Financing Items [Abstract] Interest expense Interest Expense Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Property and equipment, gross Property, Plant and Equipment, Gross Outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Lease assets obtained for new operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Schedule of interest expense Interest Income and Interest Expense Disclosure [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount After-tax interest expense for 2023 Notes Interest on Convertible Debt, Net of Tax Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities, current portion Operating Lease, Liability, Current Software Computer Software, Intangible Asset [Member] Marketable securities Debt Securities, Current [Abstract] Sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property and equipment Property, Plant and Equipment [Line Items] Carrying Amount, Net Finite-Lived Intangible Assets, Net Recently Issued Accounting Pronouncements and Disclosure Rules New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of year Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash per statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Accrued product rebates Accrued Rebates Represents the amount of accrued rebates. SPN-830 NDA Approval Milestone SPN-830 NDA Approval Milestone [Member] SPN-830 NDA Approval Milestone Impairment due to credit losses Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Security Exchange Name Security Exchange Name Total assets at fair value Assets, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss, net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax USWM Acquisition MDD US Enterprises LLC (Formerly USWM Enterprises) [Member] MDD US Enterprises LLC (Formerly USWM Enterprises) Employee Stock Option Employee Stock Option [Member] 1 year to 2 years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Total costs and expenses Costs and Expenses Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Total Other Nonoperating Expense Market-Based Units Market Based Units [Member] Market Based Units Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accrued product returns and rebates Total Accrued Product Returns and Rebates. Carrying value as of the balance sheet date of accrued product returns and rebates. Share-Based Payments Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other noncash adjustments, net Other Noncash Income (Expense) Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Contingent consideration arrangements, value (in dollars per share) Business Combination, Contingent Consideration Arrangements, Value, Price Per Share Business Combination, Contingent Consideration Arrangements, Value, Price Per Share Business Acquisition [Axis] Business Acquisition [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Other current liabilities Other Liabilities, Current Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Cash Cash [Member] Income Statement [Abstract] Income Statement [Abstract] Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld (in shares) Stock Issued During Period, Shares, New Issues Costs and expenses Costs and Expenses [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash, Restricted Cash and Money market funds Cash and Cash Equivalents, Fair Value Disclosure Accrued product returns and rebates Increase (Decrease) In Accrued Product Returns And Rebates Amount of increase (decrease) in product returns and rebates. Acquired in-process research and development Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Nonvested, beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Marketable securities - restricted (SERP) Assets for Plan Benefits, Defined Benefit Plan Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories, net Total inventories Inventory, Net Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Advertising Expense Advertising Cost [Policy Text Block] Total Shareholder Return Amount Total Shareholder Return Amount Net product sales Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-Based Payments Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Debt instrument, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Advertising costs Advertising Expense Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Income per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Cash paid for operating leases Operating Lease, Payments Common stock shares outstanding (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Capitalized patent defense costs Patent Defense Costs [Member] Represents information concerning the capitalized patent defense costs related to the Watson litigation. Accrued R&D expenses Accrued Research and Development Expenses, Current Represents the amount of clinical trial and clinical supply costs accrued. Proceeds from Credit Line Proceeds from Short-Term Debt Cardinal Health Cardinal Health [Member] Cardinal Health Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Numerator for dilutive earnings per share Net Income (Loss) Available to Common Stockholders, Basic Schedule of inventories Schedule of Inventory, Current [Table Text Block] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Contingent Consideration Contingent Consideration Disclosure [Text Block] Contingent Consideration Disclosure Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Total lease liabilities Operating Lease, Liability Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based payments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Earnings (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Schedule of balance sheet information related to leases Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block] Lessee, Operating and Finance Lease, Balance Sheet Disclosure Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Corporate and municipal debt securities Corporate And Municipal Debt Securities [Member] Corporate And Municipal Debt Securities Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, $0.001 par value; 130,000,000 shares authorized; 54,965,316 and 54,723,356 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Accrued sales & marketing Accrued Professional Fees, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Trokendi XR Trokendi Xr [Member] Represents information pertaining to Trokendi XR patent litigation. Total current assets Assets, Current Contingent consideration Contingent consideration Business Combination, Contingent Consideration, Liability Restricted cash Restricted Cash All Individuals All Individuals [Member] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Litigation Case [Domain] Litigation Case [Domain] Interest and other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Statement [Table] Statement [Table] Contingent consideration, long-term Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] PEO Name PEO Name Concentration risk percentage Concentration Risk, Percentage Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Weighted Average Remaining Contractual Term (in years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Interest Expense Other Nonoperating Income and Expense [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Contingent consideration, current portion Business Combination, Contingent Consideration, Liability, Current Interest expense on nonrecourse liability related to sale of future royalties Interest Expense, Other Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Corporate, U.S. government agency and municipal debt securities Debt Securities, Available-for-Sale, Current Other accrued expenses Other Accrued Liabilities, Current Convertible notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Product Concentration Risk Product Concentration Risk [Member] Business Organization Nature of Operations [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Litigation settlement Litigation Settlement, Amount Awarded to Other Party Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Three Major Customers Three Major Customers [Member] Three Major Customers Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total stockholders’ equity Balance Balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Subsequent Events [Abstract] Earnings before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Lab equipment and furniture Lab Equipment And Furniture [Member] Represents information pertaining to lab equipment and furniture. Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Contingent consideration arrangements, excess acquisition date fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Entity Emerging Growth Company Entity Emerging Growth Company Earnings per share EPS Basic And Diluted [Abstract] EPS Basic And Diluted Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) McKesson McKesson [Member] McKesson Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Marketable securities Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stock options, RSUs, PSUs Share-Based Payment Arrangement [Member] Title Trading Arrangement, Individual Title Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Allowance for expected sales discounts and allowances Allowance for Expected Sales deductions Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors. Corporate and municipal debt securities Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] Contingents value rights Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Earnings per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Reconciliation of the beginning and ending balances related to the contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Summary of stock options and SAR activities Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Additional cash payments upon milestone achievements maximum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Other Manufactured Product, Other [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Schedule of accrued product returns and rebates Schedule of Accrued Product Returns and Rebates [Table Text Block] Tabular disclosure of the accrued product returns and rebates. Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total liabilities at fair value Liabilities, Fair Value Disclosure Employee taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Cash paid for income taxes Income Taxes Paid, Net Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Acquired developed technology and product rights Developed Technology Rights [Member] Retained Earnings Retained Earnings [Member] Schedule of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease assets Operating Lease, Right-of-Use Asset Remaining Weighted Average Life (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Basic (in dollars per share) Earnings per share, basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Arrangement Duration Trading Arrangement Duration Acquired in-process research and development In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Restrictions on cash and cash equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Consolidation Consolidation, Policy [Policy Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Composition of Other Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Schedule of business acquisitions by acquisition, contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Termination Date Trading Arrangement Termination Date Common stock shares authorized (in shares) Common Stock, Shares Authorized Short-term debt Short-Term Debt Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Annual minimum purchase quantity requirement amount Purchase Commitment, Annual Minimum Amount Committed Purchase Commitment, Annual Minimum Amount Committed Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Number of commercial products Number Of Commercial Products Number Of Commercial Products All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Other comprehensive gain Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income tax benefit Deferred Income Tax Expense (Benefit) Subsequent Commercial Product Launch Subsequent Commercial Product Launch [Member] Subsequent Commercial Product Launch Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] AmerisourceBergen Drug Corporation AmerisourceBergen Drug Corporation [Member] AmerisourceBergen Drug Corporation Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Convertible Debt Convertible Debt [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock option and Stock Appreciation Rights Stock Option Stock Appreciation Rights [Member] Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights. Insider Trading Arrangements [Line Items] Schedule of fair value of the financial assets and liabilities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Entity Registrant Name Entity Registrant Name Corporate, U.S. government agency and municipal debt securities Corporate And U.S. Government Agency And Municipal Debt Securities [Member] Corporate And U.S. Government Agency And Municipal Debt Securities Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Stock options, RSUs and SARs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Contingent consideration gain Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Amortization of deferred financing costs and debt discount Noncash interest expense on debt Amortization of Debt Issuance Costs and Discounts Liabilities: Liabilities, Fair Value Disclosure [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Accrued compensation, benefits, & related accruals Employee-related Liabilities, Current Fair Value of Financial Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalents [Abstract] Other comprehensive gain Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Summary of disaggregation of revenues by nature Disaggregation of Revenue [Table Text Block] Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld Stock Issued During Period, Value, New Issues Performance-Based Units Performance Based Units [Member] Performance Based Units Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Summary of performance stock unit Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets: Assets, Fair Value Disclosure [Abstract] Less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Adamas Acquisition Adamas [Member] Adamas Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Oxtellar XR Oxtellar X R [Member] Represents information pertaining to Oxtellar XR product. Long-term marketable securities Debt Securities, Noncurrent [Abstract] Disaggregated Revenues Revenue from Contract with Customer [Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional  Paid-in Capital Additional Paid-in Capital [Member] Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] GOCOVRI GOCOVRI [Member] GOCOVRI Contingent consideration arrangements, excess acquisition date fair value, term Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value, Term Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value, Term Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover page. Cover [Abstract] The Milestones Milestone 2024 and Milestone 2025 [Member] Milestone 2024 and Milestone 2025 Qelbree Qelbree [Member] Qelbree Subsequent Events Subsequent Events [Text Block] Share-based compensation expense related to employee stock purchase plan and share-based awards APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Fair Value, Recurring [Member] Other liabilities Other Liabilities, Noncurrent Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Uncommitted Secured Credit Line Uncommitted Secured Credit Line [Member] Uncommitted Secured Credit Line Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Net change in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Notes payable Debt Instrument [Line Items] Basic (in shares) Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Operating earnings (loss) Operating Income (Loss) Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Revenues Revenues [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement Statement [Line Items] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accrued manufacturing expenses Accrued manufacturing expenses Accrued manufacturing expenses Non-cash royalty revenue Revenue From Royalty Agreement Represents revenue from the sale of certain royalty and milestone rights. EX-101.PRE 10 supn-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 supn-20240331_g1.jpg begin 644 supn-20240331_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1#N17AI9@ 34T *@ @ ! $[ ( M , (2H=I 0 ! (5IR= $ 8 0SNH< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@ M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB M:'1T<#HO+W=W=RYW,RYO&UL;G,Z&UP M;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG M=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL> M)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H< M&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*O_ !$( A<%? ,!(@ "$0$#$0'_Q ? !!0$! 0$! 0 M 0(#! 4&!P@)"@O_Q "U$ " 0,# @0#!04$! 7T! @, !!$%$B$Q M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C MY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! 0$! 0$! 0(#! 4& M!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< 0(#$00%(3$&$D%1!V%Q$R(R M@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JB MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR M\_3U]O?X^?K_V@ , P$ A$#$0 _ /I&BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ K@_C9_R1W6_^V'_ *41UWE<'\;/^2.ZW_VP_P#2 MB.MJ'\6/JOS)ELSY*HHHKZDY HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "N\_YMU_[FK_VTK@Z[S_FW7_N:O\ VTK&K]GU12.#HHHK8D**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *[SXV?\EBUO_MA_P"D\=<'7>?&S_DL6M_]L/\ TGCK%_Q8 M^C_-%=#@Z***V)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@#O/A9_P SE_V*M]_[)7!UWGPL_P"9R_[%6^_]DK@ZQA_$E\BGL@HH MHK8D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#O/A9_S.7_ &*M M]_[)7!UWGPL_YG+_ +%6^_\ 9*X.L8?Q)?(I[(****V)"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@#O/@G_R6+1/^V__ *3R5P==Y\$_^2Q:)_VW_P#2 M>2N#K%?Q9>B_-E= HHHK8D**** "BBB@ HHHH **** "BBB@ HHHH *[S_FW M7_N:O_;2N#KO/^;=?^YJ_P#;2L:OV?5%(X.BBBMB0HHHH **** "BBB@ HHH MH **** "BBB@ KO/%O\ R1WX??\ <2_]*%K@Z[SQ;_R1WX??]Q+_ -*%K&I\ M4/7]&4MF<'1116Q(4444 %%%% !1110!WGP3_P"2Q:)_VW_])Y*X.N\^"?\ MR6+1/^V__I/)7!UBOXLO1?FRN@4445L2%%%% !1110 4444 %%%% !1110 5 M]:_!/_DCNB?]M_\ THDKY*KZU^"?_)'=$_[;_P#I1)7FYC_"7K^C-:6YWE%% M%>$= 5P?QL_Y([K?_;#_ -*(Z[RN#^-G_)'=;_[8?^E$=;4/XL?5?F3+9GR5 M1117U)R!17KW[/VBZ7K6MZPFL:;9Z@D=NC(MU LH4[CR P.*ZN#QS\)[CQ$- M%?P;!!,UP;;S7TBWV!]VWJI+8)[XKDJ8AQFX1BVRDKIMGSM17JGQB^'EGH'C M#2XO#%OY::SE([0/PLNX#"DG@'<.IP.>U8*_!WQXUU+;KH#^9$H=_P#28=H! MSCYM^">.@.:N&(IS@IWM?N.4&G8XFBMG1?".O>(M1EL=$TR:\GA;;+Y>-L9S MCER=HZ=S5SQ#\//%7A:T%UKNC36UN2 9E=)44GIDH2!^-:NI!.S:N*S.:HK4 MT'PWK'BC4/L6@V$M[.!N94P H]2QP /J:WS\(_'(U-=/.@2"X:,RKF>+85! M.'W;<_,.,YHE4A%VDTA)-['&45T.C^!/$>OZK?:;I.G?:+O3V*W,?GQKY9#% M3RS 'D'H34FI_#SQ3HOA\:WJFDM;:>VW$KS1Y^;I\F[<,_2E[6G>W,O^''RO MLL:9KR:+J%A+;:A M(ZHD$F!N+'"X/0@GOG%-5(-\J:N*SM/E?8Y6BMCQ'X3USPE=1V_B'3I+*25=T99E97'?#*2#CZ\5CU<9*2O%W0FFM MPKO/^;=?^YJ_]M*X.N\_YMU_[FK_ -M*SJ_9]4-'!T445L2%%%% !1110 44 M5[=!H.CG]EY]5.E6)U'8Q^V&V3SO^/G;]_&[IQUZ5C6JJE%-]6E]Y4(\TE$\ M1HKI[;X<^++S1K/5;/1I;BSO6"V[Q2(QC2V]KD RK(D@7/3=L8[?QQ5>UIWMS*_J))O8Y>BM?P]X6UOQ5>-:^']/ MEO94&Y]I"J@]V8@#\37L'PA^&]SIGB/5+7QSX;@?-JCP"\ACG3.[G:WS+GIG M!S4U:T*2;;U[ DWL>$45ZI\/K6;_ (2WQ+%8>!K'Q2DE>?P:/J.M^(I;#2=.DENWE?%K -VSGD9'&!Z]*(U5)V\K[E.-K^3L9 M=%=CJ?PG\;Z1I\E[?:!,((QN=HI8Y2H]2J,3C\*P] \,ZSXHOC::!I\M[,HW M,$P @]2QP!^)JE4A)-IK0EIKF>"/#&M^'/']UIFI^";7Q!>K8F0Z?=7, 6-2RXDW-N7/;'7F MN,UBQO+[QI?V=II#6]W)>2*NG6H$GE-N/[M=@P<=.!CBKC54I67:^Z#ELFV8 MU%=I<_"'QW:6+7C:%J/B#68M)TFV,]],6"0 MEU3)4$GEB . >IJHU(2O9IV$TUJS/HKL[;X1^.;NYN((/#\I>W?9(6FB5'I0CKN DGBC;'NK.&'T(KE-4TF_T34)+'5K26TNH_O12K@C MW]Q[T1J0D[1:;%9VN4Z***T$%%%% !1110 5WGQL_P"2Q:W_ -L/_2>.N#KO M/C9_R6+6_P#MA_Z3QUB_XL?1_FBNAP=%%%;$A16_X$MH+SX@:';W<,<\$M]$ MLD4J!E=2PR"#P17O7C/Q#\,_ VMII>K>"[::=X5F#6VE6S+M)(ZL0<_*>UA7)JK;,\THK=\.>"O$7BTR?\ "/:7+>+$%[+[9K>BS6]L" TR.DJKGIDH3C\:W=2"ERMJY"3>QS%%:WA_P +ZUXI MO&MM TZ6]E0 OLP%0'IEB0!^)K1U_P"'/BSPO8_;-;T6:WM@0&E1TE5<]-Q1 MCC\:;J03Y6]02;V.8HK6\/\ A;6_%-TUOH&FS7LB8WE J9Z;F. /Q-7_$/P M\\5>%K076NZ--;6Y(!F5TE12>F2A('XT.I!/E;U!)O8YJBM^'P1XAN/";^)8 M-.,FD1@EKA9HSMPVTY3=NX/M[]*B\->$-=\7W,UOX=L#>20('D'FH@4$X'+D M#\*.>.NNVX>9BT5O:1X)\1:]JUSINCZ9)=W-HY2?RW79&0<8,F=O4''/..*7 MQ'X'\2>$EC;Q!I4UI'(<+)N5T)]-RDC/MG-'M(7M=7'9F!173:7\.O%>M:)! MJ^EZ0]S97$GEQ2)-'EFW;?NEMW4=<8[]*T/^%/\ CHWDEJ-$'GQQB5H_MD&0 MI) /W^>5/Y5+K4XNSDOO"S>QQ-%7-.TJ]U75X=+L(#+>SR>5'%D*2WIDX _& MK/B'PUJWA34AI^O6HM;HQB3RQ*DGRG.#E"1V-7S1O:^HK,RJ***H1WGPL_YG M+_L5;[_V2N#KO/A9_P SE_V*M]_[)7!UC#^)+Y%/9!17TCHT7@OPS\&-&\0^ M(?#%C?;H(UE=-/ADE=F)&27QG\34_AZ+X9?%73[^QTKPW'82P*"Q%E';RH#T M96C)'4="?J,5SRQEN9\K:3LV5&-TFWN?,]%=/9?#[7]8UK5]/T&S^W'29FCG M82I'@!F /SL,YVGI3-8^'WBCP_H<>KZSI36EE(5"R/-'G+= 5#;@?J*Z?:T] MKK_A]B>5IV.;HKL-.^%'C?5=-2_LM F:WD7P_$/2;/2_CMI-IHGAVRN8S% PTN-(X8KABS?*$JWWCOW+M0$@'KZ5E3Q"FHNV_F6XV;78\_HKL MX/A'XYN;ZXM(O#\IEMB!(6FB5,D X#EMK<$="<5A7FAZGX?\1Q:=K&G/%=I( MA-M+@"0$\#/((/3/(K:-2$G:+3)DFDW8R:*]%^+L-S#>Z7]J\$V?A(F.3;': MSPR"XY')\I1C'OZUCZ-\+O&>OZA2R6T@RDDDL<6\>H#L"1[BHA6BX*< MM/FOS&XV=CDJ*T-:T'5/#NHFPUNQFL[D '9(/O#U!'!'N*Z6R^$'CN_LTN;? MP_*(I &7S9XHFQU^ZS C\JIU()XSA0!G@< MU+K14XQ7VBE%N_D9GPL_YG+_ +%6^_\ 9*X.N\^%G_,Y?]BK??\ LE<'1#^) M+Y">R"BBO=O@II7A^3X<:UJVOZ)9:C]BN9'+3VD)_A5XUUE-#L_"$%K<7*MY9FTN"/=@$D!HR2#@'TK MG-$\":3H?[1!T*2TAO=,:V>>*"[02A04R 0PYP(M8\?:V_A3P\!IL4X2/RO+@B'R+D(&*@\YZ=\UYOJ&EWVE M:E)I^HVDMM=Q-M>&1<,#VX[Y[>M;4JT*B33U:O8)1<6_(J45VUM\'?'MW:K< M1>'I1&Z[@))XHVQ_NLX(_*N7N]%U*QUAM)NK&XCU!7$?V8QDN6/0 =\]L=:N M-2$G:+39-G:Y1HKN%^#/CYK?SAX>DV[=V#5LW[3)&),?]<] MV_/MC-<=)&\,K1S(T">O' &5?$0H+WM^Q4(NRM=1^*&CVFH6T-W;2/('AG MC#HV(V/*G@\BO8?%/BSX7^$?$DVBZGX+MWN(0A>2#2;9DPRAAR2#T/I45:[I MS4%&[:N.,;W?8^;:*]Q^,'@KPV?!-EXP\*VL=DDS1EDA3RTECD&5.SHI!QTQ MP3[5-XP\$PZA\'O"G_"->'[9]6NQ;;Y+6V199,P,6+. #C/))-0L7%Q4K=;> M@^36U^ESPBBNC\1> /%'A.V2XU_2);6!SM$H=)$!]"4) /UJ+PYX(\1^+5D; MP]I4MXD1VO)N5$!QG&YB!GVS72JD''F35B&FMS!HKH_$7@#Q1X3MTN-?TB6U M@<[1*'21,^A9"0#]:7P]\/?%7BJT-UH6CRW-N"1YS.D:$CJ 7(!_"E[2'+S7 M5@LUH)/":1OX@TF:TCD.U9=RNA/7&Y21GVS2^'/ WB7Q:DDGA_ M29;N.(X>7+N#36X45]!Z1H/@7X;_#?3M<\6:7'JUWJ"H6W0)< M$LPW;$5CM 49R>.GT%9GQ5\(^%;[X>6OC7PG:QV"NR9CAC\M)48XY3HK ^GO MUXKE^MQY^6SM>U_,N,+J_E?Y'A]=Y_S;K_W-7_MI7!UWG_-NO_N>&O _P 0/A??>(?"VE1:;-:1221M M%;K;L&C7<4=5^4Y'?GV-87@GPYIFI?L^ZS>-HUI=ZH#<+!.;57F#87:%;&[. M3QBLOK:Y6VFFNGJ5R:QL]SQ&BNMU+X6^--(TE]3O]!GCM8UWNRR([(/4JK%@ M/7(XK$T/P]JWB74/L.A6,M[<;=Q6,<*/4D\ >Y-=2J0DFTUH0TUN9M%=?JWP MJ\:Z'ITE_J6A2I;1#=(\, N5PJI MGIEF( _$TE4@U=-6!IK]]JNAS16T8R\DIV,<#W M-8V@^'-7\3ZA]BT&PEO9\9*Q@ */5F. H]R1352$E=-6!IKP+(2!^-+N#36X45ZS\+;3P#IGAJ^\0> M,[BQO+R-B(M.F97<(/2(GYV8^N< =LFNG\8>&_!?C+X3W'B[POID>DR6J-(G MEP+!NVG#(Z+\I]B.^.>HKFJ8I0GRM.W]T_2K*UNIS!YL\%NB229@).Y@,G) MYYKJH/\ A"/"7PD\/ZYXA\+65[]HMH$=XM.@DD=VCSN)?&>AYSFLWBDHW2ZV M'&+E;S5SYKHKZ2T>#X7?%:RN=.TG18M,O8XRX5+5+:9!TWCR_E8 D<$GKR*^ M?=?T:X\/>(+W2;S!FLYFB8CHV.A'L1@_C5TL0JDG!JS!QLN9&?17U#X"\#>& M=%\%Z':^)=(TZXU75,N#=VLZ=-KFBZ?>WM_ON0UU:I(P3("@%@ M3C&T_P# J\4\8:#->?%;5]'\.Z=O*1L?[JL6/X"L+PYX3UOQ9?RV7A^R^U MW$,?F2(94CVKD#.7('4BME5IM-J2T)::W,>BNNF^&WBK2].CUC5-',&G+(@> M22:/H6 'R[LX)]N:[[X]^&]-TZ;P[!X?T>TM)KII4*65LL9E;Y HPH&3SQ]: MS>(ASQC'6]_P5RE%N]^BN>)T5T'B3P/XA\(Q02>(K%+,7!(B4W,3LV.ORJQ. M/?&*O:5\+/&FMZ8FH:=H,SVTB[D>26.(N/4*[ D>AQS6GM:?+S>V<>U1/$0A*,6_B_K\>A48N5TNAXQ7UK\$_\ MDCNB?]M__2B2ODJOK7X)_P#)'=$_[;_^E$E$= 5P? MQL_Y([K?_;#_ -*(Z[RN#^-G_)'=;_[8?^E$=;4/XL?5?F3+9GR51117U)R' MM?[-?_(?US_KUC_]"-;=Q\6?AKH^M7$D'A"1-1MIG'VB+3;96+@D$AP^>3GG MK7GGPC\?Z7X!U/4;C6+>\F2ZA6-!:HK$$-GG?/#^TKMRVL:1=HOU_0[_5?']S\0/BQX?NY(/LMI;7T$=M;[MQ4& M526)[D\?D![UV7[0/BS6-*UC2]+TC4[JQB:W::46TK1F0EBHR1@D8!X]Z\4T M"_BTKQ)INH7"NT5I=Q3.J %BJN"<9QS@5UGQ9\<:;X\\1VFH:1!=0Q06HA9; MI%5BVYCQM9N.:J6'2J4U%>ZKE1G?F;WLOS_R/1K2]F\$?LT6^I>'&6*]O-KR MW*J"RM(^"?J HSTIOP,\1:KXLM==T3Q-=3:K9"!2#=N9& ?<&4L>2".Q/&. M*XSP#\6+?0/#LGAGQ5I9U71),[53!>,,E85*,_P!Y'ENY/1_UM84'I'6UOZO\ MSJ? 2)X2^#'B?5=$*M>1SW6R; 8CR_E3/J /F_$U5^ ?C'7]*MIK^IB_!S_DK'CC_KO)_P"CVKR_Q9XI\1^(_'EU M;"^NKQ5U,BSL2Q>(,KE4 B/RY[ZI#=W$5[(6TWQPOB&QCW&*^-U''+QN&\M@XZ<<5T4*;]HIM? M90ZCLII=SVR\E\:+X@T>?QGXWTKP[)$49=-LI'+W +\AXP<-G[HY(XX[FH_C M6BCXE>"9 H#M. 6QR0)DP/U/YUF:U\8/ >JWEMKL_A*ZNM?M$ @:^UM4PDUR22>Z.Q^/7B_7/#^JZ';:+J,]C&RM/)Y#E3(P8 !B.H MZ\=#GFKGQW\5ZQH6@:-'HM[-8M?.S2RP.4\A2UA9'%TBJ22P/&UFJQ\5_B-I'CNPT>'2+>]A:QW^:;I$4'<% QM8 M_P!T^E%+#R4:5X[-W_0MR7.]=+?H=M\:I7U'X-^&]0NSON9)('9\8R7@8M^9 MKY^KT_QS\2M'\3?#31O#UA;7T=W8&'S7FC01G9$4."&)ZGN!7F%=F%@X1DFK M:LQD[QCZ!7>?\VZ_]S5_[:5P==Y_S;K_ -S5_P"VE:U?L^J$C@Z***V)"BBB M@ HHHH *]]M_^31W_P!QO_2JO J].B^).CI\#&\&&VOO[1*D>:(T\GF;S.N[ M=T_V>M37!ZE\2-(O/@C:^#HK: M]&H0A-TK1IY)VR;C@[L]/:D\%_$?2/#GPNUSPW>V][)>:@9O*DA1#&N^((-Q M+ ]1V!KDG0DX5'RZN6GII_P2J4DG3OTW.W\#W,GA?]F[4-;T8!-0D,LC2A02 MK;_+!_!1FI/@!XMUS79M8L=:O[C4(H$26.6X<'T[8K@_AK\4X/" M>E76@^(M/;4=%NBS%$"LR%AAAM8@,I],C]:ZSP[\8_ 7A2>6U\/^&;^QT^4% MY)%"O-))D8!W2'Y0-W\1]@.:*U*=ZBY;\VS%%KE2VLRU\"_^1Y\9_P#77_VK M)4WP=ABL/#_C/6[>-6OX[J9%8C)"HI<#Z$G]*XGX;?$O1_!WB3Q!J&IVU]+% MJ;[H5MXT9E^=F^;+#'##IFL[P'\4)?!7B#4)3:F\TK492TUN2%8,]'>[;^TS?FZ.3]NS*(CGJ@SA?IT]J MW?A9/X[DT[6KGPT^EV=A,S/=W^H*(TB?:B^*M':YT^^FDFV6 M4:@#S/O1["0-OI@\5K)2E"7)2MMOU_X8G9J[ZGJ7P^5W\%ZS:WGBU/%94-OE M!:18@T?*;V)W#K]*Y7]GB_NY?#NOV\MU.\-KY?D1M(2L60Y.T=%R>>*IZ#\9 MO!'A^VN])TGPU?:?I,B'8T.V2:1SD,7W/Z8Q\S?A7)?"KXCZ?X!O=4AU&UNK MO3[X+@PJOF*5W8RI8#D-S\W'O7.Z-24*JMNE;;IZ#NER^3-WX"ZE?:M\3KZY MU2]N+V?^S'7S;F5I&P)(\#+$G%=1\+-/MF^)GCW5619+NUO)(X@1RH:1R?6-$T?4;32)-.^S+ H5Y#*7#%CND/&!C[QK%T/XGW'AG MXC:MK^EV[3V.I7$CRVDQV%T9RR\C(##/7GJ:VJ4IU'+E5KQM^(72B[ZZI_@: MW@CXF>+-1^*]B;S4[F:"_NQ#+9%B8E1CC"IT7;UR.>.3UKL;W3;33OVJ],:R M14^UV[7$RKT\PQ2 G\=H/XUD)\5?AQINJS>(-'\'W:Z[("V^0*L8,.6T6O73 M84GI+6]['<^.O'?B"S^.]GIECJ5Q;V-M'OB]X6UF[MO/BMHA)*J@;F42'\R,Y%>;>*?&%AK?Q8'B>TAN4LOM-O+ MY Q&?E..:V?B)\2-$\6>,M'U>TTF:ZM+&/;-::@!&)OF)Q\C'C_ M "01Q2A0E%TGR[)W^[_,J[N=*\>:G!J7A#XE76F7NQ1'9).#'D' MJ;9MI8^N+-O=CA60'IMP-I!/(]ZZI?'7P@ MENK>_G\$7L-Y %*I;JHC!7ID"55;ZE:XWXE?$";X@:]%=?9OLEI:H8[>$MN; M!.2S'U/'';'XT4*?&S_DL M6M_]L/\ TGCK@Z[SXV?\EBUO_MA_Z3QUB_XL?1_FBNAP=%%%;$G2?#O_ )*3 MX?\ ^PA#_P"A"NQ_:'_Y*3!_V#H__0WK@/"NJP:'XNTO5+M9'@L[I)I%B +% M5.3@$@9_&O;=1^-'PSU>Y%QJWA.YOIPH02W.FVTC!1VRSDXY-<5?G56$XQO: MY3:KL@/W J\*.F>3Z50\%_$?2/#GPNUSPW> MV][)>:@9O*DA1#&N^((-Q+ ]1V!KFE2J3A4FXVAK!QC*"OL[_>=3\+/& MGAM_AU)X3U769O#U[O#O%[^!KN3P]X]F\ M0:,L;2202N&DDCQE@)@29/7!(&./KP/@OQ=X&T_0'TOQAX0%Z[9S>VX#2N"< M_P 3*5(X&58<=O7=U'XL^&-&\'7FA?#G0+G3Q>AEEENV!V[A@D?.Y8XX&2,4 MZM*:J-TXN[?6S7_ )IR5DI;'0^'[F7PI^S%-J^A,(;^?<[SH/F#--Y>?J%X' MI7FD'Q;\6Q^%[K0KB^6^@N0ZO->J9I@K#!7_%2W\-Z#<>'/$ M^FMJFASECL3!>/=]Y<' 8'KUM?_%+P7I/A*[T7P-X4>(788.VHJK*I((W M'Y],ENQB2YNB-R=>1\[EB,\9.!GI45*,_WD>6[D]'_6U@@](ZVM_7XFK\%= M0M9KKQ+X$NY/-LY_-:W#-GGQ6 MGP#M/LNOP^');X&2;5)@ORLTA!Y++R0 H.:6ZB$BD+E5YD8L0PR#G/.*\U\!_%+3]&\+3^%O&.E/JNBR$E!%@NF3DK@D M9&>0<@@_HWQ/XR^'DOAA]+\(^"_*F<$+=WO$D63DD,'9F/' +8'IC@YU*$W4 MDK/5WTM_PZL.G))1OT_K\3O_ GK%QH/[+\FHV,IAN8HYQ%(!RC-,5!'OS7G M_P */'.H6GQ0LY=;U*YO$U!?L4LMU,TC#)^3EB3PV/S-.MOB/I$/P-E\&-;7 MIU%]V)1&GD\S;^N[/3_9ZUYM"\D<\;P%A*K H5ZAL\8]ZZJ=&\ZO.MV_N,Y/ M]VDM]3Z(\->!8],^/^NZG+&$L;&(WD+$,]3UD8'>?"S_F@_ /0[[Q1IO]I:>L$2M;^0DV6).#M<@<5S, M_P =O"NBZ3/#X(\+O9W$N2 UO%;Q!L8#$1D[L>G'3K7):U\2-(U+X+V'A&"V MOEO[81!Y'C01':%4Y3=1/XG]Q:ERQC;L>\?LYW,MYJOBBZN M7,DTWDR2.?XF+2$G\ZY+0MD^ 9=6;6+>]F%ZD2Q_941L;=V<[F7^\*X6SU6XTS7HM5T]S M'/;W GB8]B&R,UJJ+]O.5M+*WW";O3:ZMGTYXSA>3QA!<#XHVGAM;55(TN1D M /)_C-X.N+"_T_4O-9TNA;3I*#Y8WQ[MI/?(YZXK M"O/BI\._$\EIJ/C+PC=S:K;J!N@VM&<^)= M"^)T=OI.IW%I;6443I!&Y6.4D9.]1]X=L'TK T3QOJWCGXP^&;W6OLX>&Z2. M-8(M@5=V>O)/XD_SKHKGXL?#[Q-)9ZCXR\)74VK6J@!H-KQG'/.77<,]F!QF MN>UGXIV6M?$[1O$#:0+.PTR8.5A13/*,Y)8\ GT&<#GGFM:,'%1@Z>JOK_6] MR*KYHR:>Z.N\;?\ )SOAWZ6__H3U;\3?\G3:!_U[I_Z#+7#>(OB1I&K_ !BT MKQ9;6UZMA9B(21R1H)3M+$X 8COZU/K'Q.T;4/C1IGBZ&VOET^TB5)(WC02D M@..!OQ_$.]1"C42A=;)CDTW/S2.B^*?COQ!I/Q=L-/TS4I[6SM?()@C;:DI8 MY;Z5;7L,>GEO-%S&BELLI^7:Q_NGKB MJHT91=%VVO?[A59751+JE8[SXS64&I?$KP-97@#6]Q/YGV1^(?A>YNM0L\;9;3!5CW/WT M.#UVG(K.G1G"%-RC>U[KU9)?C##?^+M&U30M"@M;?2)-\8D51+,"NTJ6 ^4;> !GL?:M[6/C!X$O=3A\0 MQ>$KJY\0P(JQ27158T(Z'(S:_P"')ZN[Z&E\5XT7 MXX>"I H#M+ &;')Q/Q_.N8_:+_Y*#9?]@Y/_ $8]1>-_B;H/B7QSX9UZQMM1 MC32YD:YCFB0%E60/\F'.3UZX[5A?%?QKIWCKQ1;ZEI$-U##%:+"RW2*K%@S' M^%B,?,.]*A2J1]E=;$)K6[*X!BL;>WW>Q=&) _ U@_#/Q->> M+_CXNLZ@%22>&4+&IRL:!,*H^@_,YKQZNM^&GBJR\&^-H-8U2*XEMXXI$*VZ MJSY9<#AB!^M2\+"$9..K::%*3:2\U^9Z-XB\=>((_P!H>UTR#4KB+3X;Z"U^ MR(Y$;J^W=N7HQ^8\GI4/QCAU ?&S1'\/6RSZHUM"\*&,,'<2/C(/'&.IZ8SV MKA=6\7V%_P#& >*X8;E;$7\-SY;*OF[4VY&-V,_*>]=!XG^+-E>_%72?%NA6 M5P8K"W$+P785&?)<-C:6QP_!]>U80HRC[)J.J3OZVZ_,TE)/VGX??_D=[;R^ M*D^(.ER^,/'&EZ=<*\48T33Y)'\\,<8>/H"V1\QSCKQBL[XBZ]8>%/V@-"UG M4H"]O'8CS2BY9OQ:+/J%K;VY@N;+4%6,-R2"I1VR?F/48X_+* MG2J.<7*-M&GLNG]:L;<>66O1?F>HSQ6OC'63JO@CXGW5K=R*&2Q\]98E&,?\ M>[8(SGN#@_E7(>$?"^L6O[0:Q^-KD:E>PVC7<%P6W+*!\J, 1QC)XQP1^-5( M/B!\([;5H=8M_!E_!J,!$D8B55B5QT(42[?QV^]]^"_C*YO)I)YY6N6DEE8LSG[.O)) MY-> UZ9X$^(^D>&/AQKOA^_MKV2[U$R^4\$:&-=\00;B6!ZCL#73BZ;G2?*M M?^"32=JD6]KGF=%%%=9D=Y\$_P#DL6B?]M__ $GDK@Z[SX)_\EBT3_MO_P"D M\E<'6*_BR]%^;*Z' MY&G6\N[*@K\SL&X&*\(\ >(;7PKXZT[6M0CFDMK5G+K H+G*,O ) ZGUJ;XC M^)K/Q?XYO-9TV*>*WG6,*MPH5QM0*<@$CJ/6N>M1=2O%O:WZE0:2D='\3_BW M_P )O8PZ3I-D]CI<3B1O-(WRD#"Y X4#/3)_2O0?&GB+4?#G[/OAZ31[F2UN M+JWM8#-$VUT4P[C@]0?EQD(OA;H?AJRM[V.\T\0>;),B"- MMD10[2&)ZGN!2J8>,8PA!:76LSO>7"QN/.F;< M[;)OE)/4D</!\+S'!JFE^'/#SL=FHW;F"8 OR49>22<@$\GH#TK(T MWXD:19_!*Z\'2VU\=0F$@658T\H;I-PR=V>GM6IX>^+/AF;X>P>%O'6AW5[# M;*L:&UP0ZJ?E)RZE6'3(//XXK*5.<>?EC=.5_EW0)JT;OO\ \ [G7,7'[.>H M";6QXB,<+#^T"I_>%9>.6Y.,8W=\9K*\(^,?"_B+X::=X:IX8M]#N]+BDC:&Q2V5'15X*ER6!! M+9S@'KU)K&\.^,OAP/#,.F>*_!3//$ &N;'EYB/XBQ=67/.0&(_D,XT9,K3P6;D^+Y/$.@6Y4NC@+(%W85F89\W!/))ST M./3N;O2H;3X3:#IMAXN@\(1-!$6O&*JTQ*;BH8NF"2=Q(.>*\L\7?%71I_ _ M_")>!=&FTW39.)'N2-VW.X@#?UV86FX1;=]7UM^A,VK)':_#_X=7/C":2]OIAIV MA6?S7=](0H R54GC.._0?D#K?$[X@Z?K&GV?A7PC&8= TW #\C[0RC ..NT M01744C9( M1PQQ[&O1/B[\0])\?3:2VCV]Y"+))%D^U(BYW;<8VLW]TUCB:3J3IKIK?[AT MW9R?E^IO>,OC=IM[X3F\/^"]&DTZWN(S"[RHD0C0]51$)'(R,YX]/3H?AAJD M^B_L]:OJ5F0+BU:YDB)&<,%&#^=?/%>F>'/B1I&D?!W5/"=S;7K7]X)A')'& MAB&\ #)+ ]O2LZV&4:+C36[0U-N<;[([WX$>(]6\2:;XBM]>O[C45C\ME-S( M9"-X<,!GM\HXZ5Q'PD_X36$ZNW@Y=-@LNEU>:BNV.,@''SCYL@$G'('?KS6^ M$GQ%TGP%'K"ZQ;WLQOA$(_LJ(V-N_.=S+_>'K4WPS^*>G>$=*U'1?$&F2WNF M7LC2GR0K-EE"LI5B 00!WX]ZFI2DIU>2.C4;=O,<9+E2?<]<^%_G'2=6M;_Q ME'XJD^5I"CM*L&Y6!4.WW@<'@8QCIS7GWP@\;>'=+\-ZIX:UG4)-%GNIW>.^ MC.SAE X?!"LNW@GCFK?AWXR^!_"\D]AHGAB^L-*D7>7C*O-)(3_$&?H!G^(_ M05Q?@WQ;X*T=+ZS\3>%1JD$TKF*\V SA#T!5FPIQW5ACWZUDJ,G[3FB[-+LM MOP*YDHK75,]+U;P=XKNO"MV?!7Q&GUNQD1BT,\RRO(,8*K."3R,C;P,U)\([ M"&R^"=W=6^IPZ+##2WC9"G& W+N6QDX' KGOAS\4(?"NFWFA^(=/;4]%O6+/$N"R$C#8#<, M" .,CUH]C6E3G&W:VB3?<.:*<7YGK6AR:'8^%]4T7Q+\3-+\207L;*C7-W$' MC!!!&XRL3V(],5\P,-K$ Y .,^M>I:SXU^&<7AVXL?"_@=FN)@=LVH=8B1C( M82,_'H"!7EE=6%IN,I2=];;V7Y$R:Y4CJ-'\(:XFEP>+)-%:\T*UD6:9C(F) M$5\,NTG)'!!X..]>RO=0?%OX.WRZ+!+X=7368"Q@9#!(47>%.%&5QZ8P?7%< M#\,OBXG@[2YM$UZQDO\ 29&+((\%X]WWEVL0&4]<9'.?6MKQ5\;]+;PM+H?@ M/17TN*X1HVD>*.$1*WWMB(2,GGG(Q6.(C6G+E4=GH_\ ,=)Q33?S/%J[SQ;_ M ,D=^'W_ '$O_2A:X.N\\6_\D=^'W_<2_P#2A:[:GQ0]?T9FMF=3^S=_R-FK M_P#7D/\ T,5TVDZA!\3M \2^!]6E U*PNIFLI7/)59&V'_@)^4_[)%>9_"3Q MWIG@+6[^\UB"[FCN+<1(+5%8@[@>=S+QQ6#:>++C2/B!)XETCZC]BMHHW26S@EC+JN-P#O]>< \U@J=54TW M'7FO8U3C%JVW*TXE^)RS0JQBAM)3,P' ! S^./RJ_KN@Q^,?VEKG3 MXU$EL+B-[K'39'&N\'ZD;?J:VKOX[^&=&TB:#P+X8:RGEZ;[>*"-6_O%8R=W MZ5R7PO\ B'HOA#5=6UCQ'!?WNIWW"2P1HV 26RJ2KDZ;\3]#E^#DO@[Q%:W\UTL3QP30Q(Z+SNC)RX/RG Z=!4+#U:4826MNEN^_ MJ:<\7-KH]/\ (Q?@G_R6+1/^V_\ Z3R5P==Y\$_^2Q:)_P!M_P#TGDK@Z[U_ M%EZ+\V8]#TWX _\ )4H_^O.;^E>J7MN/&:?$/PF&!GCN(IH W\),2%?_ !Z, M_G7AWPP\6V'@KQFFKZK%<2VZP/&5ME5GRV,<,0.WK74Z!\6]-TGXLZYXDFM[ MUM+U2/:(41/-!&W:2"V.Q[]ZX\11G.JY17V?Q33*A+E7S7Y6/7K&[AL?BGIG MABT.V#3?#[D(O3)DC4?HGZUY?IX\6CX\>)7\$V]I).)G6XDO$!BC0D'ENHR1 MT7D_AQ0TKXLZ;;?&74O%M[;7K6%S;&WAB1%,JK\F,@N /NGOWI?#7Q?LO#_Q M$\0:LUA<3Z5K4P=EPHFCQG:<9VG[QR,_C6,*-6.O+=\K^]N]BY2CRN*[K\$> ME?#6345\4ZFFL>.;77KN:-I)-/M)'EBMB''*L>% SC: .OM7,_"=%C^.GC%( MU"JIN !P/WXJIHWQ?\ 7AC6I)?#GA2\M+>\+/>3_*92>H5%+D!<]MP ["L M#PC\2M!\-_%#7_$,MOJ,MAJ0:I9PYW OC Y'!/:B-*I>3Y=XVZ?H*3 M7*U?[29D>/O%NLZU\0M1L[K4[I["'43'':>:PA4(^U3LZ9XZXS7TSJ>E:1<^ M)=%U'4Y(_MEJ)8["*1@-TC*"2!W(5#],DU\?:MJ<-_XMO=4A618+B]>X56 W M!6Q\3ZGH&H>&(KZUN=)D>7==(BY)*$8VL;Q':M'\3K7PJMM&K+I[,B[SD_,P,J[@>F",<5Y'\1?B1H?BZ31]9T M:UOK#Q!I[*6D>-/+('S8#!B3M;ID=":V[KXK> /%<5G=>._"=U<:I;*!OM<% M#@YZ^8A*YYVL"!D]:B5.JXTWR_#=/;[[/34;DG*3[K^D:?Q3UG2Y_%WA35O# M&OVLVH"<6MS)IMVI M/?B?X,\<>'2;G0K]==C@,=O,Y7RX6)!/(?YAQW7\J<:,H>RERMVOVOKL',N9 MJ^Z1X_7UK\$_^2.Z)_VW_P#2B2ODJOK7X)_\D=T3_MO_ .E$E7F/\)>OZ,FE MN=Y1117A'0%<'\;/^2.ZW_VP_P#2B.N\K@_C9_R1W6_^V'_I1'6U#^+'U7YD MRV9\E4445]2<@4444 %%%% !1110!T_@WX@Z]X&FF;1)HS#.09;>=-\;D=#C M((/;((KIM6^/GC'5=.EM(QI]AYBE6FM(7$@!ZX+.V/J!FO,J*QG0I3?-*-V5 M&3CL!.>M%%%;""BBB@04444 %%%% !7>?\VZ_P#%H62Y5F0J2#T5@0S:W)$J0 B*WMT*QIGJ<$DDGCDD]*YFBBE"$8+EB MK(;;>K"BBBJ$=Y\+/^9R_P"Q5OO_ &2N#KO/A9_S.7_8JWW_ +)7!UC#^)+Y M%/9!1116Q(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '>?"S_F< MO^Q5OO\ V2N#KO/A9_S.7_8JWW_LE<'6,/XDOD4]D%%%%;$A1110 4444 %% M%% !1110 4444 %%%% !1110!WGP3_Y+%HG_ &W_ /2>2N#KO/@G_P EBT3_ M +;_ /I/)7!UBOXLO1?FRN@4445L2%%%% !1110 4444 %%%% !1110 4444 M %=Y_P VZ_\ ?\VZ_]S5_[:5C5^SZHI'!T445L2%%%% !1110 M4444 %%%% !1110 4444 %=YXM_Y([\/O^XE_P"E"UP==YXM_P"2._#[_N)? M^E"UC4^*'K^C*6S.#HHHK8D**** "BBB@ HHHH [SX)_\EBT3_MO_P"D\E<' M7>?!/_DL6B?]M_\ TGDK@ZQ7\67HOS970****V)"BBB@ HHHH **** "BBB@ M HHHH *^M?@G_P D=T3_ +;_ /I1)7R57UK\$_\ DCNB?]M__2B2O-S'^$O7 M]&:TMSO****\(Z KB_B]87>J?"O5[/3K:6ZN9?)\N&)2S-B="< => 3^%=I4 M%W_J1_O54)J?^ K_ .%'_" >+O\ H6]4_P# 5_\ M"OKVBC^TI_RH/9(^0O\ A /%W_0MZI_X"O\ X4?\(!XN_P"A;U3_ ,!7_P * M^O:*/[2G_*@]DCY"_P"$ \7?]"WJG_@*_P#A1_P@'B[_ *%O5/\ P%?_ KZ M]HH_M*?\J#V2/D+_ (0#Q=_T+>J?^ K_ .%'_" >+O\ H6]4_P# 5_\ "OKV MBC^TI_RH/9(^0O\ A /%W_0MZI_X"O\ X4?\(!XN_P"A;U3_ ,!7_P *^O:* M/[2G_*@]DCY"_P"$ \7?]"WJG_@*_P#A1_P@'B[_ *%O5/\ P%?_ KZ]HH_ MM*?\J#V2/D+_ (0#Q=_T+>J?^ K_ .%'_" >+O\ H6]4_P# 5_\ "OKVBC^T MI_RH/9(^0O\ A /%W_0MZI_X"O\ X4?\(!XN_P"A;U3_ ,!7_P *^O:*/[2G M_*@]DCY"_P"$ \7?]"WJG_@*_P#A7J&C?"OQ!K'P1AT@FVT^\EUMM0\N^9XR MD8B,6& 4D,2,@=-I!SVKVVI?^73_ ('_ $K.>/J32TL-4TCYT_X9V\5?]!30 M_P#P(E_^-4?\,[>*O^@IH?\ X$2__&J^AJ*7U^N'LXGSS_PSMXJ_Z"FA_P#@ M1+_\:H_X9V\5?]!30_\ P(E_^-5]#44?7ZX>SB?//_#.WBK_ *"FA_\ @1+_ M /&J/^&=O%7_ $%-#_\ B7_ .-5]#44?7ZX>SB?//\ PSMXJ_Z"FA_^!$O_ M ,:H_P"&=O%7_04T/_P(E_\ C5?0U%'U^N'LXGSS_P ,[>*O^@IH?_@1+_\ M&J/^&=O%7_04T/\ \")?_C5?0U%'U^N'LXGSS_PSMXJ_Z"FA_P#@1+_\:H_X M9V\5?]!30_\ P(E_^-5]#44?7ZX>SB?//_#.WBK_ *"FA_\ @1+_ /&J/^&= MO%7_ $%-#_\ B7_ .-5]#44?7ZX>SB?//\ PSMXJ_Z"FA_^!$O_ ,:H_P"& M=O%7_04T/_P(E_\ C5?0U%'U^N'LXGSS_P ,[>*O^@IH?_@1+_\ &J/^&=O% M7_04T/\ \")?_C5?0U%'U^N'LXGSS_PSMXJ_Z"FA_P#@1+_\:H_X9V\5?]!3 M0_\ P(E_^-5]#44?7ZX>SB?//_#.WBK_ *"FA_\ @1+_ /&J/^&=O%7_ $%- M#_\ B7_ .-5]#44?7ZX>SB?//\ PSMXJ_Z"FA_^!$O_ ,:H_P"&=O%7_04T M/_P(E_\ C5?0U%'U^N'LXGSS_P ,[>*O^@IH?_@1+_\ &J/^&=O%7_04T/\ M\")?_C5?0U%'U^N'LXGSS_PSMXJ_Z"FA_P#@1+_\:H_X9V\5?]!30_\ P(E_ M^-5]#44?7ZX>SB?//_#.WBK_ *"FA_\ @1+_ /&J/^&=O%7_ $%-#_\ B7_ M .-5]#44?7ZX>SB?//\ PSMXJ_Z"FA_^!$O_ ,:H_P"&=O%7_04T/_P(E_\ MC5?0U%'U^N'LXGSS_P ,[>*O^@IH?_@1+_\ &JZ;XB_!GQ!XL\?:CK6GW^E0 MV]UY6Q+B:17&V)$.0$(ZJ>_2O8*EN?\ CX;\/Y5/UVMS*O\ H*:'_P"!$O\ \:KZ&HH^OUP]G$^>?^&=O%7_ M $%-#_\ B7_ .-4?\,[>*O^@IH?_@1+_P#&J^AJ*/K]*O^@IH?\ X$2__&J^AJ*/K]?\ AG;Q5_T%-#_\")?_ M (U1_P ,[>*O^@IH?_@1+_\ &J^AJ*/K]?^&=O%7_04T/_ ,")?_C5'_#. MWBK_ *"FA_\ @1+_ /&J^AJ*/K]?^&=O%7_04T/\ \")?_C5'_#.WBK_H*:'_ .!$O_QJOH:BCZ_7#V<3YY_X M9V\5?]!30_\ P(E_^-4?\,[>*O\ H*:'_P"!$O\ \:KZ&HH^OUP]G$^>?^&= MO%7_ $%-#_\ B7_ .-4?\,[>*O^@IH?_@1+_P#&J^AJ*/K]*O^@IH?\ X$2__&J^AJ*/K]_X2#[9 M?Z5)_:6B7.GQ>3-(=LDFW!;*#"\*O^@IH?\ X$2__&J^BX/^ M6G^X:BJ5C:R;?*O^@IH?_@1+_\ &J/^&=O%7_04T/\ \")? M_C5?0U%5]?KB]G$^>?\ AG;Q5_T%-#_\")?_ (U1_P ,[>*O^@IH?_@1+_\ M&J^AJ*/K]?^&=O%7_04T/_ ,")?_C5'_#.WBK_ *"FA_\ @1+_ /&J^AJ* M/K]?^&=O%7_04T/\ \")?_C5'_#.WBK_H*:'_ .!$O_QJOH:BCZ_7#V<3 MYY_X9V\5?]!30_\ P(E_^-4?\,[>*O\ H*:'_P"!$O\ \:KZ&HH^OUP]G$\? M^'7P9\0>$_'VG:UJ%_I4UO:^;O2WFD9SNB=!@% .K#OTKF?^&=O%7_04T/\ M\")?_C5?1=M_Q\+^/\JBJ?KM;FYA^SB?//\ PSMXJ_Z"FA_^!$O_ ,:H_P"& M=O%7_04T/_P(E_\ C5?0U%5]?KB]G$^>?^&=O%7_ $%-#_\ B7_ .-4?\,[ M>*O^@IH?_@1+_P#&J^AJ*/K]*O^@I MH?\ X$2__&J^AJ*/K]?\ AG;Q5_T%-#_\")?_ (U1_P ,[>*O^@IH?_@1 M+_\ &J^AJ*/K]<8QCO7L%2_P#+I_P/^E3+&UI6N/V<3YT_ MX9V\5?\ 04T/_P ")?\ XU1_PSMXJ_Z"FA_^!$O_ ,:KZ&HJOK]<7LXGSS_P MSMXJ_P"@IH?_ ($2_P#QJC_AG;Q5_P!!30__ (E_P#C5?0U%'U^N'LXGSS_ M ,,[>*O^@IH?_@1+_P#&J/\ AG;Q5_T%-#_\")?_ (U7T-11]?KA[.)\\_\ M#.WBK_H*:'_X$2__ !JC_AG;Q5_T%-#_ / B7_XU7T-11]?KA[.)\\_\,[>* MO^@IH?\ X$2__&J/^&=O%7_04T/_ ,")?_C5?0U%'U^N'LXGSS_PSMXJ_P"@ MIH?_ ($2_P#QJC_AG;Q5_P!!30__ (E_P#C5?0U%'U^N'LXGSS_ ,,[>*O^ M@IH?_@1+_P#&J/\ AG;Q5_T%-#_\")?_ (U7T-11]?KA[.)\\_\ #.WBK_H* M:'_X$2__ !JNFUSX,^(-2\ ^%=%@O]*6XTC[7Y[O-($?S90Z["$R< ?^&=O%7_ $%-#_\ B7_ .-4?\,[>*O^@IH? M_@1+_P#&J^AJ*/K]*O^@IH?\ X$2_ M_&J^AJ*/K]*O\ MH*:'_P"!$O\ \:H_X9V\5?\ 04T/_P ")?\ XU7T-15?7ZXO9Q/GG_AG;Q5_ MT%-#_P# B7_XU1_PSMXJ_P"@IH?_ ($2_P#QJOH:BCZ_7#V<3YY_X9V\5?\ M04T/_P ")?\ XU1_PSMXJ_Z"FA_^!$O_ ,:KZ&HH^OUP]G$^>?\ AG;Q5_T% M-#_\")?_ (U1_P ,[>*O^@IH?_@1+_\ &J^AJ*/K]?^&=O%7_04T/_ ,") M?_C5'_#.WBK_ *"FA_\ @1+_ /&J^AJ*/K]Y_#KP[=^$_ .G:+J$L$UQ:^;O>W8LAW2NXP2 >C#MUK3J];?\ 'NOX M_P ZQJXJI6CRR*C%1V):***YB@J"[_U(_P!ZIZ@N_P#4C_>H IT444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 5+_P NG_ _Z5%4O_+I_P # M_I0!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5+<_\ 'PWX?RJ*I;G_ (^&_#^5 $5( M3@4M(WW30!SFN:W<67_ &GC M?^?LOO9?)'L;7_"4ZC_>7_OD4?\ "4ZC_>7_ +Y%8M%']IXW_G[+[V')'L;7 M_"4ZC_>7_OD4?\)3J/\ >7_OD5BT4?VGC?\ G[+[V')'L;7_ E.H_WE_P"^ M11_PE.H_WE_[Y%8M%']IXW_G[+[V')'L;7_"4ZC_ 'E_[Y%'_"4ZC_>7_OD5 MBT4?VGC?^?LOO8QM?\)3J/]Y?^^11_P )3J/]Y?\ OD5BT4?VGC?^?LOO M8QM?\)3J/]Y?^^11_PE.H_P!Y?^^16+11_:>-_P"?LOO8QM?\ "4ZC M_>7_ +Y%'_"4ZC_>7_OD5BT4?VGC?^?LOO8QM?\)3J/\ >7_OD4?\)3J/ M]Y?^^16+11_:>-_Y^R^]AR1[&VOBS4ESM=1D8/RBD_X2G4?[R_\ ?(K%HH_M M/&_\_9?>PY(]C:_X2G4?[R_]\BC_ (2G4?[R_P#?(K%HH_M/&_\ /V7WL.2/ M8VO^$IU'^\O_ 'R*/^$IU'^\O_?(K%HH_M/&_P#/V7WL.2/8VO\ A*=1_O+_ M -\BC_A*=1_O+_WR*Q:*/[3QO_/V7WL.2/8VO^$IU'^\O_?(H_X2G4?[R_\ M?(K%HH_M/&_\_9?>PY(]C:_X2G4?[R_]\BC_ (2G4?[R_P#?(K%HH_M/&_\ M/V7WL.2/8VO^$IU'^\O_ 'R*/^$IU'^\O_?(K%HH_M/&_P#/V7WL.2/8VO\ MA*=1_O+_ -\BC_A*=1_O+_WR*Q:*/[3QO_/V7WL.2/8VO^$IU'^\O_?(H_X2 MG4?[R_\ ?(K%HH_M/&_\_9?>PY(]C:_X2G4?[R_]\BC_ (2G4?[R_P#?(K%H MH_M/&_\ /V7WL.2/8VU\6:DN=KJ,C!^44G_"4ZC_ 'E_[Y%8M%']IXW_ )^R M^]AR1[&U_P )3J/]Y?\ OD4?\)3J/]Y?^^16+11_:>-_Y^R^]AR1[&U_PE.H M_P!Y?^^11_PE.H_WE_[Y%8M%']IXW_G[+[V')'L;7_"4ZC_>7_OD4?\ "4ZC M_>7_ +Y%8M%']IXW_G[+[V')'L;7_"4ZC_>7_OD4?\)3J/\ >7_OD5BT4?VG MC?\ G[+[V')'L;7_ E.H_WE_P"^11_PE.H_WE_[Y%8M%']IXW_G[+[V')'L M;7_"4ZC_ 'E_[Y%'_"4ZC_>7_OD5BT4?VGC?^?LOO8QM?\)3J/]Y?^^11 M_P )3J/]Y?\ OD5BT4?VGC?^?LOO8QM?\)3J/]Y?^^11_PE.H_P!Y?^^1 M6+11_:>-_P"?LOO8QMKXLU)&#*Z@C_9%)_P )3J/]Y?\ OD5BT4?VGC?^ M?LOO8QM?\)3J/]Y?^^11_PE.H_P!Y?^^16+11_:>-_P"?LOO8QM?\ M"4ZC_>7_ +Y%'_"4ZC_>7_OD5BT4?VGC?^?LOO8QM?\)3J/\ >7_OD4?\ M)3J/]Y?^^16+11_:>-_Y^R^]AR1[&U_PE.H_WE_[Y%'_ E.H_WE_P"^16+1 M1_:>-_Y^R^]AR1[&U_PE.H_WE_[Y%'_"4ZC_ 'E_[Y%8M%']IXW_ )^R^]AR M1[&U_P )3J/]Y?\ OD4?\)3J/]Y?^^16+11_:>-_Y^R^]AR1[&U_PE.H_P!Y M?^^11_PE.H_WE_[Y%8M%']IXW_G[+[V')'L;7_"4ZC_>7_OD4O\ PEFI;-N] M<9SC:*Q**/[3QO\ S]E][#DCV-K_ (2G4?[R_P#?(H_X2G4?[R_]\BL6BC^T M\;_S]E][#DCV-K_A*=1_O+_WR*/^$IU'^\O_ 'R*Q:*/[3QO_/V7WL.2/8VO M^$IU'^\O_?(H_P"$IU'^\O\ WR*Q:*/[3QO_ #]E][#DCV-K_A*=1_O+_P!\ MBC_A*=1_O+_WR*Q:*/[3QO\ S]E][#DCV-K_ (2G4?[R_P#?(H_X2G4?[R_] M\BL6BC^T\;_S]E][#DCV-K_A*=1_O+_WR*/^$IU'^\O_ 'R*Q:*/[3QO_/V7 MWL.2/8VO^$IU'^\O_?(H_P"$IU'^\O\ WR*Q:*/[3QO_ #]E][#DCV-K_A*= M1_O+_P!\BE/BS4BH4NN%Z?**Q**/[3QO_/V7WL.2/8VO^$IU'^\O_?(K3T?Q M,TTWE7Q +?=;&*Y*E!(.1P:VH9QC:513=1NW1O0'3BT>I*P905.0:6N3T#7] MN+:[/^ZQKJP0P!'(-?HV!QU+&TO:4_FNQRRBXNS%HHHKN)"BBB@"6V_X^%_' M^515+;?\?"_C_*HJ "BBB@ HHHH **** "BBB@ HHHH **** "KUM_Q[K^/\ MZHU>MO\ CW7\?YT 2T444 %07?\ J1_O5/4%W_J1_O4 4Z*** /-/COXHU?P MM\.&N-!DD@GNKE+=[F/[T*$,20>Q. ,]L^N*\GT#X,/XHTJ/Q!HGQ&M[S6WB M$ICB!,B2;?N-)YF]3CC)7\*]K^*/B_P[X6\/Q1>,=)NM2TW4G,#)!$CJ"!D; MMS+CID$>E>?ZA^SWX0U;3AK?A#Q%<:;"ZB>&5I%G@C'!R#D,/J6.#^52M.9_ MCV_KGC.W\$R6?Q!MVCO[9F2&9YXY7FBV\%BC'D'(R>3Q7SQ\ M,_@__P ++MM4NO[<_LS['<"/;]D\[?D$YSO7%>K_ !\7:OK>F:]HNLW[:FN MDNHM[QG+ET;<,;CR1\N1GG!KRCX9_!__ (67;:I=?VY_9GV.X$>W[)YV_()S MG>N*MZS;\D2M*=O/]&;^@6VL?!_XV:3X9L]?.J6%])&D\,>50B1BOS1Y8*XP M#D'./K3?VAKB]L_C)IUUI9D6[M]/BFB:($LI5Y&S^&,UZ?\ #[X"Z+X(UB+5 M[J_FU;48,^2[Q"*.,G^()DG..,EC]/3F_&ZJ_P"U=X61U#*UH@((R"/WM/5N M"OK??\A:)3=M+'9'QA;>./@'JVLVY599-*N$N8@<^5*(R&7\^1[$5G_LX?\ M)(XO^OV;^8K@/$LU== M\$+R]T_]G^]O-*M_M-[;R74EO!L9_,D RJ[5Y.3@8'-)-/FFMK+\]4.47:$/ M[S_+0]HKYMT7PS_PN;Q_XI7QMKE_;#2K@I:V$$JIY2[F&=K C "C.!DD\FND M\'_$SXI:MXNL+'Q#X*^PZ;-(1<7/]E747EKM)SN=BHY ZURWA3PG:?'GQ9XB MU[Q-=2V(MI5A@M[!(XW"\[2Y*G=@#&3R?4 4N7WK^3_ $'?W?FOU.M^ >L: MN]]XGT"YU"75M-TFXV6=W(Q;/S,N Q/0A0<=OQK UOX/^-?&NJ:QK?C?Q#'I M*6\C/91%O/B"8R-N' C48 SC)()QZ['P/UJ?0M<\4>")S%\E*.NB_X<(Z-Q>FO](I?L^^*]8U;P)J9\07$MW#IDVV"ZF;6 -G(R2>:ZWX,^ M(+R]TWQ5X'$L-W::5#*EA=V\2Q[U)9.=O!SPP/)Y.2:L_LT:G:P> -8M;B:. M*6TOFFF5VP40QK\Q]!\K?E5.TI.7]U-?E-#%O52 5>/>H'M3HZ*#V7YCK:SJ+?5_(Q/VF;?[??>#[;=Y?VB6:/= MC.W<8AG'?K5*Z_9DU72;9[_P_P"+_,U"!2\*"T:W+''02"0D$].E:W[1G_(Q M>!_^ON3_ -#BKV_4-0M-*T^:]U&XCMK:%"\DLC!54 9ZU"TIN2TU8W=R47KH MOS9YA\!?'NH>+?#EYINORO-JFDR!'FD^_)&V<%O5@003].]>L5X#^SA&]]XB M\7ZW$C+9W,ZK&2.I+N^/P!'YU[]6DM;-[M(S5DVELF%%%%24%%%% !1110 4 M444 %%%% !1110 5+<_\?#?A_*HJEN?^/AOP_E0!%2-]TTM(WW30!P_B/_CX M/^__ $K$K;\1_P#'P?\ ?_I6)7Y;G?\ O]3^NAUT_A"BBBO'- HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!02#D<&NO\ M#FISR1K#<#*_PL>]MO^/=?Q_G0!+1110 5!=_Z MD?[U3U!=_P"I'^]0!3HHHH Q_%'A?2O&&@S:1KD'G6TN""IPT;#HRGL17B\G M[*UD=0WQ>*KA;/-?[6\G^SHEC^Q?9MWF8W\[]PQ]_P#N MGI7>44EHT^P^C7%GTF]D^S2JXDM[H1[S X[XR,@C((R.M-^' M'@C_ (5]X170_P"T/[0VSO+YWD>5]['&W2Z[\"8I M]>NM6\'>*=2\+SWK%KF.UR4?/) "NA )YP21Z 5ZU12LKW'?2QQWP^^&VD?# MRQN(].DFN[N[8-C:[KKNQ+161R?@'X=:+\.])DM-'$DLL[!KBZG(,D MI'0< 9X K@_%G[-VC>(/$4FJ:7J\VDI<2&2XMA;B522KNP6BLC \&>#M+\#>'(M'T57\I6+R2R$%Y7/5F(QSP!] *WZ**;;;NQ) M);!4O_+I_P #_I452_\ +I_P/^E(9%1110 4444 %%%% !1110 4444 %%%% M !1110!P?@WX9_\ ")>.O$'B/^UOM?\ ;+NWV?[-Y?D[I"_WMYW=<=!7>444 M=$NP/5N75GG?Q5^%/_"S1IG_ !.?[,^P>9_RZ^=YF_;_ +:XQM]^M^+99H!]](=/$;'Z,9& _(U]!T4DK;#;;W,?PMX6TKP=H$.CZ' 8;6+) MRQW,['JS'N36Q115-MN[)22T04444AA1110 4444 %%%% !1110 4444 %2W M/_'PWX?RJ*I;G_CX;\/Y4 14C?=-+2$9% '$^((WDN6$:,QW=AGM6/\ 9I_^ M>,G_ 'P:[#4] ^VW!D#E<^E4?^$3/_/5J^7QO#ZQ>(E6]I:_E_P3:-3E5K'. M_9I_^>,G_?!H^S3_ //&3_O@UT7_ B9_P">K4?\(F?^>K5Q_P"JR_Y^_A_P M1^V\CG?LT_\ SQD_[X-'V:?_ )XR?]\&NB_X1,_\]6H_X1,_\]6H_P!5E_S] M_#_@A[;R.=^S3_\ /&3_ +X-'V:?_GC)_P!\&NB_X1,_\]6H_P"$3/\ SU:C M_59?\_?P_P""'MO(YW[-/_SQD_[X-'V:?_GC)_WP:Z+_ (1,_P#/5J/^$3/_ M #U:C_59?\_?P_X(>V\CG?LT_P#SQD_[X-'V:?\ YXR?]\&NB_X1,_\ /5J/ M^$3/_/5J/]5E_P _?P_X(>V\CG?LT_\ SQD_[X-'V:?_ )XR?]\&NB_X1,_\ M]6H_X1,_\]6H_P!5E_S]_#_@A[;R.=^S3_\ /&3_ +X-'V:?_GC)_P!\&NB_ MX1,_\]6H_P"$3/\ SU:C_59?\_?P_P""'MO(YW[-/_SQD_[X-'V:?_GC)_WP M:Z+_ (1,_P#/5J/^$3/_ #U:C_59?\_?P_X(>V\CG?LT_P#SQD_[X-'V:?\ MYXR?]\&NB_X1,_\ /5J/^$3/_/5J/]5E_P _?P_X(>V\CG?LT_\ SQD_[X-' MV:?_ )XR?]\&NFB\)$[_ -ZWW#4?_")G_GJU'^JR_P"?OX?\$/;>1SOV:?\ MYXR?]\&C[-/_ ,\9/^^#71?\(F?^>K4?\(F?^>K4?ZK+_G[^'_!#VWD<[]FG M_P">,G_?!H^S3_\ /&3_ +X-=%_PB9_YZM1_PB9_YZM1_JLO^?OX?\$/;>1S MOV:?_GC)_P!\&C[-/_SQD_[X-=%_PB9_YZM1_P (F?\ GJU'^JR_Y^_A_P $ M/;>1SOV:?_GC)_WP:/LT_P#SQD_[X-=%_P (F?\ GJU'_")G_GJU'^JR_P"? MOX?\$/;>1SOV:?\ YXR?]\&C[-/_ ,\9/^^#71?\(F?^>K4?\(F?^>K4?ZK+ M_G[^'_!#VWD<[]FG_P">,G_?!H^S3_\ /&3_ +X-=%_PB9_YZM1_PB9_YZM1 M_JLO^?OX?\$/;>1SOV:?_GC)_P!\&C[-/_SQD_[X-=%_PB9_YZM1_P (F?\ MGJU'^JR_Y^_A_P $/;>1SOV:?_GC)_WP:/LT_P#SQD_[X-=%_P (F?\ GJU' M_")G_GJU'^JR_P"?OX?\$/;>1SOV:?\ YXR?]\&C[-/_ ,\9/^^#71?\(F?^ M>K4?\(F?^>K4?ZK+_G[^'_!#VWD<[]FG_P">,G_?!H^S3_\ /&3_ +X-=-%X M2)W_ +UON&H_^$3/_/5J/]5E_P _?P_X(>V\CG?LT_\ SQD_[X-'V:?_ )XR M?]\&NB_X1,_\]6H_X1,_\]6H_P!5E_S]_#_@A[;R.=^S3_\ /&3_ +X-'V:? M_GC)_P!\&NB_X1,_\]6H_P"$3/\ SU:C_59?\_?P_P""'MO(YW[-/_SQD_[X M-'V:?_GC)_WP:Z+_ (1,_P#/5J/^$3/_ #U:C_59?\_?P_X(>V\CG?LT_P#S MQD_[X-'V:?\ YXR?]\&NB_X1,_\ /5J/^$3/_/5J/]5E_P _?P_X(>V\CG?L MT_\ SQD_[X-'V:?_ )XR?]\&NB_X1,_\]6H_X1,_\]6H_P!5E_S]_#_@A[;R M.=^S3_\ /&3_ +X-'V:?_GC)_P!\&NB_X1,_\]6H_P"$3/\ SU:C_59?\_?P M_P""'MO(YW[-/_SQD_[X-'V:?_GC)_WP:Z+_ (1,_P#/5J/^$3/_ #U:C_59 M?\_?P_X(>V\CG?LT_P#SQD_[X-'V:?\ YXR?]\&NB_X1,_\ /5J/^$3/_/5J M/]5E_P _?P_X(>V\CG?LT_\ SQD_[X-'V:?_ )XR?]\&NF@\)$S*/-;_ "*C M_P"$3/\ SU:C_59?\_?P_P""'MO(YW[-/_SQD_[X-'V:?_GC)_WP:Z+_ (1, M_P#/5J/^$3/_ #U:C_59?\_?P_X(>V\CG?LT_P#SQD_[X-'V:?\ YXR?]\&N MB_X1,_\ /5J/^$3/_/5J/]5E_P _?P_X(>V\CG?LT_\ SQD_[X-'V:?_ )XR M?]\&NB_X1,_\]6H_X1,_\]6H_P!5E_S]_#_@A[;R.=^S3_\ /&3_ +X-'V:? M_GC)_P!\&NB_X1,_\]6H_P"$3/\ SU:C_59?\_?P_P""'MO(YW[-/_SQD_[X M-'V:?_GC)_WP:Z+_ (1,_P#/5J/^$3/_ #U:C_59?\_?P_X(>V\CG?LT_P#S MQD_[X-'V:?\ YXR?]\&NB_X1,_\ /5J/^$3/_/5J/]5E_P _?P_X(>V\CG?L MT_\ SQD_[X-'V:?_ )XR?]\&NB_X1,_\]6H_X1,_\]6H_P!5E_S]_#_@A[;R M.=^S3_\ /&3_ +X-'V:?_GC)_P!\&NB_X1,_\]6J3_A$C]FSYK??_I1_JLO^ M?OX?\$/;>1S/V:?_ )XR?]\&C[-/_P \9/\ O@UT7_")G_GJU'_")G_GJU'^ MJR_Y^_A_P0]MY'._9I_^>,G_ 'P:/LT__/&3_O@UT7_")G_GJU'_ B9_P"> MK4?ZK+_G[^'_ 0]MY'._9I_^>,G_?!H^S3_ //&3_O@UT7_ B9_P">K4?\ M(F?^>K4?ZK+_ )^_A_P0]MY'._9I_P#GC)_WP:/LT_\ SQD_[X-=%_PB9_YZ MM1_PB9_YZM1_JLO^?OX?\$/;>1SOV:?_ )XR?]\&C[-/_P \9/\ O@UT7_") MG_GJU'_")G_GJU'^JR_Y^_A_P0]MY'._9I_^>,G_ 'P:/LT__/&3_O@UT7_" M)G_GJU'_ B9_P">K4?ZK+_G[^'_ 0]MY'._9I_^>,G_?!H^S3_ //&3_O@ MUT7_ B9_P">K4?\(F?^>K4?ZK+_ )^_A_P0]MY'._9I_P#GC)_WP:/LT_\ MSQD_[X-=%_PB9_YZM4C^$B(8SYK1S/V:?_GC)_P!\ M&I8;5MP\Q#N/W8SP3]?:MW_A$S_SU:M#3O#T=K+O_M32N[ 6:*X?\ X2GQY_T3G_RN0?X4?\)3X\_Z M)S_Y7(/\*U]C+NOO7^9/,CN**X?_ (2GQY_T3G_RN0?X4?\ "4^//^B<_P#E M<@_PH]C+NOO7^8?]$Y_\KD'^%'_ E/CS_HG/\ Y7(/\*/8R[K[ MU_F',CN**X?_ (2GQY_T3G_RN0?X4?\ "4^//^B<_P#E<@_PH]C+NOO7^8?]$Y_\KD'^%'_ E/CS_HG/\ Y7(/\*/8R[K[U_F',CN**X?_ (2G MQY_T3G_RN0?X4?\ "4^//^B<_P#E<@_PH]C+NOO7^8/?L^/^%;\;^O]NP>GTH]C+NOO7^8 M?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_T3G_ M ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ RN0? MX4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE M/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ MHG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ ME<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_" MCV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K M[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8< MR.XHKA_^$I\>?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN M'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*? M'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y M_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD M'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\ M)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE/CS_ M *)S_P"5R#_"CV,NZ^]?YAS([BI;G_CX;\/Y5P7_ E/CS_HG/\ Y7(/\*DG M\5>/3,Q;X;[3Z?V[ ?Z4>QEW7WK_ ##F1VE%O\ ,.9'<45P_P#PE/CS_HG/_E<@_P */^$I\>?] M$Y_\KD'^%'L9=U]Z_P PYD=Q17#_ /"4^//^B<_^5R#_ H_X2GQY_T3G_RN M0?X4>QEW7WK_ ##F1W%%O\ ,.9'<45P_P#PE/CS_HG/_E<@_P */^$I\>?]$Y_\KD'^%'L9=U]Z M_P PYD=Q17#_ /"4^//^B<_^5R#_ H_X2GQY_T3G_RN0?X4>QEW7WK_ ##F M1W%%O\ ,.9'<45P M_P#PE/CS_HG/_E<@_P */^$I\>?]$Y_\KD'^%'L9=U]Z_P PYD=Q17#_ /"4 M^//^B<_^5R#_ H_X2GQY_T3G_RN0?X4>QEW7WK_ ##F1W%%O\ ,.9'<45P_P#PE/CS_HG/_E<@ M_P */^$I\>?]$Y_\KD'^%'L9=U]Z_P PYD=Y!_RT_P!PU'7%Q>*O'HW[?AOG MY#G_ (GL''Z5'_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_T3G_ M ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ RN0? MX4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE M/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ MHG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ ME<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_" MCV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K M[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8< MR.XHKA_^$I\>?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([R#_ M ):?[AJ.N+B\5>/1OV_#?/R'/_$]@X_2H_\ A*?'G_1.?_*Y!_A1[&7=?>O\ MPYD=Q17#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X4>QEW7WK_,.9'<45 MP_\ PE/CS_HG/_E<@_PH_P"$I\>?]$Y_\KD'^%'L9=U]Z_S#F1W%%O\PYD=Q17#_P#"4^//^B<_ M^5R#_"C_ (2GQY_T3G_RN0?X4>QEW7WK_,.9'<45P_\ PE/CS_HG/_E<@_PH M_P"$I\>?]$Y_\KD'^%'L9=U]Z_S#F1W%%O\PYD=Q17#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_R MN0?X4>QEW7WK_,.9'<45P_\ PE/CS_HG/_E<@_PH_P"$I\>?]$Y_\KD'^%'L M9=U]Z_S#F1WEM_Q\+^/\JCKBX/%7CT3*5^&^X^G]NP#^E1_\)3X\_P"B<_\ ME<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_" MCV,NZ^]?YAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K M[U_F',CN**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8< MR.XHKA_^$I\>?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN M'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*? M'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y M_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BI/^73_ ('_ $K@_P#A M*?'G_1.?_*Y!_A4G_"5>/?L^/^%;\;^O]NP>GTH]C+NOO7^8?\ 1.?_ "N0?X4?\)3X\_Z)S_Y7(/\ "CV,NZ^]?YAS([BBN'_X2GQY_P!$ MY_\ *Y!_A1_PE/CS_HG/_E<@_P */8R[K[U_F',CN**X?_A*?'G_ $3G_P K MD'^%'_"4^//^B<_^5R#_ H]C+NOO7^8?\ 1.?_ "N0?X4? M\)3X\_Z)S_Y7(/\ "CV,NZ^]?YAS([BBN'_X2GQY_P!$Y_\ *Y!_A1_PE/CS M_HG/_E<@_P */8R[K[U_F',CN**X?_A*?'G_ $3G_P KD'^%'_"4^//^B<_^ M5R#_ H]C+NOO7^8?\ 1.?_ "N0?X4?\)3X\_Z)S_Y7(/\ M"CV,NZ^]?YAS([BI)/\ CWB_'^=<'_PE/CS_ *)S_P"5R#_"I'\5>/?)C!^& M^ ,X/]NP<_I1[&7=?>O\PYD=I17#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_R MN0?X4>QEW7WK_,.9'<45P_\ PE/CS_HG/_E<@_PH_P"$I\>?]$Y_\KD'^%'L M9=U]Z_S#F1W%%O\ MPYD=Q17#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X4>QEW7WK_,.9'>VW M_'POX_RJ*N+@\5>/1,I7X;[CZ?V[ /Z5'_PE/CS_ *)S_P"5R#_"CV,NZ^]? MYAS([BBN'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN M**X?_A*?'G_1.?\ RN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BBN'_X2GQY_ MT3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*/8R[K[U_F',CN**X?_A*?'G_1.?\ MRN0?X4?\)3X\_P"B<_\ E<@_PH]C+NOO7^8?]$Y_P#*Y!_A M1_PE/CS_ *)S_P"5R#_"CV,NZ^]?YAS([BKUM_Q[K^/\Z\Y_X2GQY_T3G_RN M0?X5V.@:AJ]Y96+:IHG]G/-%,]POVM)?L[K(H1,J/FWJ6;(^[MP>M3*G**N[ M?>O\QW-JBBBLQA4%W_J1_O5/4%W_ *D?[U %.BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "I?^73_@?]*BJ7_ET_X'_2@"*BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ J6Y_X^&_#^515+<_\ 'PWX?RH BHHHH **I7.K6=I)LN)@ MC8S@U#_PD&F_\_*_G7++&8:$G&51)KS0^5FG169_PD&F_P#/ROYT?\)!IO\ MS\K^=3]?PG_/V/WH?*^QIT5F?\)!IO\ S\K^='_"0:;_ ,_*_G1]?PG_ #]C M]Z#E?8TZ*S/^$@TW_GY7\Z/^$@TW_GY7\Z/K^$_Y^Q^]!ROL:=%9G_"0:;_S M\K^='_"0:;_S\K^='U_"?\_8_>@Y7V-.BLS_ (2#3?\ GY7\Z/\ A(--_P"? ME?SH^OX3_G['[T'*^QIT5F?\)!IO_/ROYT?\)!IO_/ROYT?7\)_S]C]Z#E?8 MTZ*S/^$@TW_GY7\Z/^$@TW_GY7\Z/K^$_P"?L?O0F+OS@Y7V- M.BLS_A(--_Y^5_.C_A(--_Y^5_.CZ_A/^?L?O0\7X_SH BHHHH **** "BBB@ MHHHH EMO^/A?Q_E452VW_'POX_RJ*@ HHHH **** "BBB@ HHHH **** "BB MB@ J];?\>Z_C_.J-7K;_ (]U_'^= $M%%% !4%W_ *D?[U3U!=_ZD?[U %.B MBB@ K'/B_P -#4?[//B'2OMN=OV;[;'YF<9QMW9Z5PG[0UYJ]G\+)3H[2I') M21$@K"0<\CL6V@_7'>O)_#GP^^%'B/P[#Y/C>YM-;DB ,5[)' BS$?=V MLF6&>.&/UI)MW\AM)6\SZJR-NQKYY^&?@OP-XIMM4F\;>) M?[&F@N L"?;X+?S%())Q(I)Y]*;^)I"7PSTO MP3\?]#L_AYKLFKV5Q)''/(LJR J[$.A9 %8 -TX_"KO[0MK?7OQDT^'28Y) M+S^SHWB6(_-E6D;(]^,T]+1?1NWW!9WDNRO]Y]/W%Q#:6TEQ=31P01*7DED8 M*J*!DDD\ #UJ#3=5T_6;,7>D7]K?VQ8J)K6994R.HW*2,UYKI?C>/QW^S]K. MH.R_;H=+N(+U!_#*(CS]&&#^/M3?VE%]%^HF_=C+NVO MN1ZO6=JGB'1=#V?VUJ]AIWF?<^UW*1;OIN(S6C7S+H&D>%=<^)?C#_A<=TD% M]%<'[+%?WC6R>7N;!5MRYPNW Z8/0U'6Q72Y]+03Q7,"36TJ31.,J\;!E8>H M(ZU2U3Q#HNA[/[:U>PT[S/N?:[E(MWTW$9KQW]GE+N"X\5PZ6\T_AN.Z(TUY M>%=@S6EU-.3;_9+B)]XY^;)#84< +A3@ M4WNK=KB76_>Q]!0S17$*RP2)+&XRKHP(8>Q%4=1\0Z+I%Q%!JVKV%C-.<11W M-RD;2?[H8C/7M7B?[/\ CW7C/35NY+S1=*E)@?JA92X)7M\RJ"0/:N:^' MOPUB^,EOKWBGQ/JE['=2W;1P^05P&VAOFW*JDK; M"3?4*E_Y=/\ @?\ 2HJE_P"73_@?]*D9%1110 4444 %%%% ",RHA9V"JHR2 M3@ 5SW_"PO!?_0WZ#_X,X?\ XJMC4_\ D$W?_7!__037R]\&OA!H'Q$\-WVH M:U=ZE!+;W?DHMI+&JE=BGGN?@#\2M%U'1-1N+G1]0;9*DWWF0$!T?;@-PP(.!SVXY M]Q\>?$C2/ 5A;27LWAVVEC;#,DQ]?8:S]3L**\L\- M?&V._P#$%MHOB_PSJ/A6\O6VVAO Q24\ #+(A!)..A'O5[XA?%VU^'GB?2M, MU#3&GM;Z,R2W2SX,*AL'";3N_,4GI;S#OY'HM%>.K^T"EGK%NGB3P=K&B:3= M,!;ZA=*1NSCDH5 QW^5FX[5U/Q+^)4?P\T'3]533AJD5]<"(;;CR@JE2VX': MV>G2CI<.MCN:*\_\(?$V[\7Z_<10>%;^RT%(6FAUJZ+)'.H(&0"@'/)^\>!R M!7/7WQ]$NHW"^$_!VJ^(=-M'*7.H6X8(N.I "-D8R?F*T;!N>PT5R_AWXAZ! MXE\&2^)K*Y,5C;(S70F&'MRHRP8#/./3K7GS?M 7]TCWVA_#O6M0T5"#6\27%O>:7:11O),E]"8WC"C) M..X]",YKSAOV@+^Z1[[0_AWK6H:*A.=0RRKM!^8X6-EX_P![\J'H[ M5='LL M\\5M;R3W,J10Q*7>21@JHH&223T ]:KZ9J^FZU:_:M'U"UU"WW%/.M9EE3<. MHRI(SS7/)XILO$GPRU#6I=)O8[8V4YFL;U&MY' 0[ESZ$=&&>OK6#\&=;\/S M?#2XU'2-'7PYIL%S*TL+WKW 7:JEG+N >G;VHZR3Z*X=(M=78]+HKQJ7]H(W MEU-)X4\$:SKFEV[E9[^-64(!U.%1NW/S%3ZXKT'P5XZT;QYH)U/0Y'PAV302 MC;)"^,X8?U&0:.EP>CL=)17C&F_M#QZI;WD-CX1U&]U>&5DBT^P9IRZ ?ZQF M$8VC/' 8UTOPV^+=C\0;F[T^33IM)U:S!:6TF??\H;:2&P#D'&00,9[TTK[! M+W=ST*BBBD 4444 %%%% !4MS_Q\-^'\JBJ6Y_X^&_#^5 $5,E.(S3Z9+_JF M^E '!:XY>ZRQS\S#^59=:6L_\?/_ -OZ5FU^49O_O\ 5]3LA\*"BBBO,+"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH D@GDMYA)$VU MA7<:)K4>H0A)#MF'4'O7!U)!/);S"2)MK"O5RW,JF J76L7NB)P4D>H45CZ+ MK2:A"$D.)AU'K6Q7Z=A\13Q--5:3NF+\?YT 14444 %%%% !1110 4444 2VW_'POX_RJ*I;;_CX7\?Y5%0 M4444 %%%% !1110 4444 %%%% !1110 5>MO^/=?Q_G5&KUM_P >Z_C_ #H MEHHHH *@N_\ 4C_>J>H+O_4C_>H IT444 <)\5?'K> -!MKR70%UFRNI3;SJ MT_EB/(R,@HP8'!';]:X#5/"GP+\3:4=3M]8T_19)HQ(1:WZQ2(<=/(UCN[.==LD,@R&']#[]J\MD_9I\#/J'VA9=6CBW _95 MN5\O [9*%L'_ 'LU-M[E7T5C%_9NU.]FTKQ'I?VB:ZTBRE4V4L@(QNW9 !Z9 M 4X[9]ZXGX/?";0OB-9:Q=:W=ZA ]IP:+<7LZWLHED-VZ,00,<;57C MGWK1VZ@]< */3(&KJ.GQB.**-T$+ ;OO M J3_ !GH1VI)^_%OH#2Y))=4>-?$6RG^$OBC6KG3X';P[XMLIX)(D/\ J;@H MV,>F&;(]F8=JZKX(?VE_PS_>_P!@_P#(3\RZ^R?=_P!;CY/O?+UQUX]:]-\7 M>$M,\;>')]%UI9/L\I#!XB!)&P.0RD@@'\.YJ'P5X,T_P'X=71=(FNIK996E M#73JSY;KRJJ,<>E*.D6GVLOO*D[N+7>[^ZQYEX//QU'BZP/BT9T82'[4/]!Y M7:?^>?S=<=*YWX;:'I/Q<\4^)=2^(K27VH6\@2&S>X>(6\>6^Z%(.%/&.G<\ MFOI"O-_%GP*\&^+M5DU*XBN]/NYGWS26$H3S3ZE65AGW &:.NPNF_8Y3X$ZI M';=[-+@'S9P^Z9V( MQN+'/([=AZ5YZ?V8?!C,6;5->))R2;B'G_R%0]6D];+[P6EVM+O[CK/"&E^# MK/P3>>&_ ^IZ??J+=Q.;:[2:1V=2N]RIZG\!V%>;? #QIH7ACP?K.E>(]4M= M,NK6]>;RKJ41LXV*"%S]X@H1@<]*]+\ ?"C0_AS=WEQHEUJ$[WB*D@O)$8 * M21C:B^M9_BCX$^#?%6NMJUU%>6=S*^^<64P1)V[E@5."?5<9S3;?,VNJL_O! M)6L^C.3_ &;HGO)O%NO;"L%]>J(R>Y!=R/PWBO=*S= \/Z9X8T6#2M#M5M;. M '9&I)R3U))Y)/J:TJ MD=W=QQ,R^6HR Q&1[U[]/"MQ;R0N2%D0H2.N",5X[_PS!X+_ .@GKW_@1#_\ M:HBVF_-?J#U2\CE/C;K^F_$/QAX8\,^%+N+4Y5F8236S>8@+E1@,.#@*2<=! M3OC1#J]O\;_##:7?V^G2FTC2RO+W!@BD#N"3E6'=>QZBO6?!7PE\*>!)_M6C MVDDU]MV_;+N3S) .^, *OIP!6MXO\$:%XYTM;'Q%9^>D;;HI$8I)$?56'\NA MH^%*W1W'=RO?M;]3Q;Q-\.?BGXFO-.M_$_C/PU/<6\GVBSC,GDR9R 679 I( MSCVZ4_XYSVME\7/!$^KE?LL(C>X8C*[1,"Q^E=OX;_9_\$^'-4COQ'>ZG-$P M>(7\RNJ,.^U54'\<]*XSXYVT-Y\9O ]M=1)-!,\4 M//A[I/Q"TJUT_69[RWAM9O.0V;HI)VE<'3[)K[QGB&S MFC^#VH6>EJPE717CA6+@Y$. !7A7PFL?B7?^"W/@;Q;HFG:?#,_FVMRB&2-N MI9LPL<$="3TKZ>AA6"WCA7)6- @SW &*\QU_]GKP1KNJR7X6^TUY6+R1V,RK M&S'J=K*V/H,"AZSD^Y,5:$8]O\C-^%OPUO=+\.^)K3Q/JVEZEIFO("7TRY+* M,AM[9VJ%R&4C'I6%;?#SX@^"]/FF^''CRSO='MV=C!.Z[4*DY7#!T!ZYY7G] M/7-%^'WAC0/#5QH.G:5$-/N@13[>G:N'N?V:? T]]Y\4NK6T> M0?LT5RIC^F60MS_O42OS:=DAJUM>Y;^&WBY_BY\-]6@\4VT4."]G?$'P7I\TWPX\>6=[H]NSL8)W7:A4G*X8.@/7/*\_I M[)IO@OP]I/A5O#EEID*Z5(I62W?+"3/4L3R2?6O/[G]FGP-/?>?%+JUM'D'[ M-%VAAO+.VN('> $)(/)) M! ).#SSS_A7$>$(KN;]DOQ&NGEO,%Q(S;>IC!C+_ /CH->[6'@O1-)\'S^&M M)MC9:=/"\3B)LN=ZX9MS9RW/4YJ'P5X&TOP+X5I6-XRNQ+ C MY5 QQZ42LW.W5)?.X)M*%^C;_ YOX':EI#_!_3193P)]D1Q>C< 8Y-Q)+^F1 M@Y/:N.^! %U\1/'6H:7_ ,@>6X80LOW&)ERD>V*] \/^&])\+:-'I>@V:6EI'T1>2Q[LQ/)/N: M;?,W/JTU]_\ 6A-K1Y%M=?A_6IXQ^S-#'YWBV?;^\-U&F[V^G%VFGVC;\+%2U4O-W_$ MZVBBBI **** "BBB@ J6Y_X^&_#^515+<_\ 'PWX?RH BIDO^J;Z4^F2_P"J M;Z4 Y_N?_ %Z[<%@JN,JJG37J^Q,I**NR71K1DO$."7R,XZ+[ M?6NX7[HS5+3]/2T@4=\J>H+O_ %(_WJ *=%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %2_\NG_ _P"E15+_ ,NG_ _Z4 14444 M%%%% !1110 4444 %%%% !6?>Z#H^I7UO>ZCI5C=W5L08)Y[9'DB(.1M8C*\ M\\5H44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!4MS_P ?#?A_*HJEN?\ CX;\/Y4 14R7F,T^B@#@M5CS>.'BD;#$@J<=?PJC MY*_\\)O^^Q_A7HK6L3MED!/TIOV.'_GFOY5Y57)\%6J.I4A=OS?^9:G)*R// M/)7_ )X3?]]C_"CR5_YX3?\ ?8_PKT/['#_SS7\J/L$W_ 'V/\*/)7_GA-_WV/\*]#^QP_P#/-?RH^QP_\\U_ M*C^PLO\ ^??XO_,/:2[GGGDK_P \)O\ OL?X4>2O_/";_OL?X5Z']CA_YYK^ M5'V.'_GFOY4?V%E__/O\7_F'M)=SSSR5_P">$W_?8_PH\E?^>$W_ 'V/\*]# M^QP_\\U_*C['#_SS7\J/["R__GW^+_S#VDNYYYY*_P#/";_OL?X4>2O_ #PF M_P"^Q_A7H?V.'_GFOY4?8X?^>:_E1_867_\ /O\ %_YA[27<\\\E?^>$W_?8 M_P */)7_ )X3?]]C_"O0_L>>2O_/";_OL?X4>2O\ SPF_[['^%>A_8X?^>:_E1]CA_P">:_E1_867_P#/ MO\7_ )A[27<\\\E?^>$W_?8_PH\E?^>$W_?8_P *]#^QP_\ /-?RH^QP_P#/ M-?RH_L++_P#GW^+_ ,P]I+N>>>2O_/";_OL?X4>2O_/";_OL?X5Z']CA_P"> M:_E1]CA_YYK^5']A9?\ \^_Q?^8>TEW//EMU;/[B;@9^\/\ "F^2O_/";_OL M?X5Z1!90?O/W:_A_8X?\ GFOY4?8X?^>:_E1_867_ //O\7_F'M)=SSSR M5_YX3?\ ?8_PH\E?^>$W_?8_PKT/['#_ ,\U_*C['#_SS7\J/["R_P#Y]_B_ M\P]I+N>>>2O_ #PF_P"^Q_A1Y*_\\)O^^Q_A7H?V.'_GFOY4?8X?^>:_E1_8 M67_\^_Q?^8>TEW///)7_ )X3?]]C_"CR5_YX3?\ ?8_PKT/['#_SS7\J/LA_8X? M^>:_E1]CA_YYK^5']A9?_P ^_P 7_F'M)=SSSR5_YX3?]]C_ H\E?\ GA-_ MWV/\*]#^QP_\\U_*C['#_P \U_*C^PLO_P"??XO_ ##VDNYYYY*_\\)O^^Q_ MA1Y*_P#/";_OL?X5Z']CA_YYK^5'V.'_ )YK^5']A9?_ ,^_Q?\ F'M)=SSS MR5_YX3?]]C_"CR5_YX3?]]C_ KT/['#_P \U_*C['#_ ,\U_*C^PLO_ .?? MXO\ S#VDNYYYY*_\\)O^^Q_A1Y*_\\)O^^Q_A7H?V.'_ )YK^5'V.'_GFOY4 M?V%E_P#S[_%_YA[27<\^6W5L_N)N!G[P_P *;Y*_\\)O^^Q_A7I$%E!^\_=K M]P]JB^QP_P#/-?RH_L++_P#GW^+_ ,P]I+N>>>2O_/";_OL?X4>2O_/";_OL M?X5Z']CA_P">:_E1]CA_YYK^5']A9?\ \^_Q?^8>TEW///)7_GA-_P!]C_"C MR5_YX3?]]C_"O0_LA_8X?^>:_E1]CA_YYK^5']A9?_S[_%_YA[27 M<\\\E?\ GA-_WV/\*/)7_GA-_P!]C_"O0_L>>2O\ SPF_[['^%'DK_P \)O\ OL?X5Z']CA_YYK^5'V.'_GFO MY4?V%E__ #[_ !?^8>TEW///)7_GA-_WV/\ "CR5_P">$W_?8_PKT/['#_SS M7\J/LTEW///)7_GA-_WV/\*/ M)7_GA-_WV/\ "O0_L$W_?8_P *](MK*#[0O[M>_;VJ+['#_P \U_*C^PLO M_P"??XO_ ##VDNYYYY*_\\)O^^Q_A1Y*_P#/";_OL?X5Z']CA_YYK^5'V.'_ M )YK^5']A9?_ ,^_Q?\ F'M)=SSSR5_YX3?]]C_"CR5_YX3?]]C_ KT/['# M_P \U_*C['#_ ,\U_*C^PLO_ .??XO\ S#VDNYYYY*_\\)O^^Q_A1Y*_\\)O M^^Q_A7H?V.'_ )YK^5'V.'_GFOY4?V%E_P#S[_%_YA[27<\\\E?^>$W_ 'V/ M\*/)7_GA-_WV/\*]#^QP_P#/-?RH^QP_\\U_*C^PLO\ ^??XO_,/:2[G$6%D M99P(H74GC.,Y50/PJ6O0PV#H86/+1C9$.3>X M4445U""BBB@ J7_ET_X'_2HJE_Y=/^!_TH BHHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *ED_P"/>+\?YU%4LG_'O%^/\Z (J*** "BBB@ HHHH **** M );;_CX7\?Y5%4MM_P ?"_C_ "J*@ HHHH **** "BBB@ HHHH **** "BBB M@ J];?\ 'NOX_P ZHU>MO^/=?Q_G0!+1110 5A^++_5M.TF*;0=%_MFX:<*U MO]K2WVIM8E]S<'D 8]_:MRH+O_4C_>IIV=[ >=_\)3X\_P"B<_\ E<@_PH_X M2GQY_P!$Y_\ *Y!_A7<45K[2/\B_'_,FS[G#_P#"4^//^B<_^5R#_"C_ (2G MQY_T3G_RN0?X5W%%'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y M_P#*Y!_A7<44>TC_ "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ M "N0?X5W%%'M(_R+\?\ ,+/NTC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%% M'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ M "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ "N0?X5W%%'M(_R+ M\?\ ,+/NTC_(OQ_S" MS[G#_P#"4^//^B<_^5R#_"I/^$J\>_9\?\*WXW]?[=@]/I7:5+_RZ?\ _Z4 M>TC_ "+\?\PL^YP7_"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ "N0?X5W%%'M M(_R+\?\ ,+/NTC_(O MQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%%'M(_R+\?\PL^ MYP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ "+\?\PL^YP_ M_"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ "N0?X5W%%'M(_R+\?\ ,+/NTC_(OQ_S"S[G#_P#"4^// M^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%%'M(_R+\?\PL^YP__ E/CS_HG/\ MY7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ "+\?\PL^YP__"4^//\ HG/_ )7( M/\*/^$I\>?\ 1.?_ "N0?X5W%%'M(_R+\?\ ,+/NTC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2G MQY_T3G_RN0?X5W%%'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y M_P#*Y!_A7<44>TC_ "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ M "N0?X5W%%'M(_R+\?\ ,+/NTC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%% M'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ M "+\?\PL^YP__"4^//\ HG/_ )7(/\*DG\5>/3,Q;X;[3Z?V[ ?Z5VE2W/\ MQ\-^'\J/:1_D7X_YA9]S@O\ A*?'G_1.?_*Y!_A1_P )3X\_Z)S_ .5R#_"N MXHH]I'^1?C_F%GW.'_X2GQY_T3G_ ,KD'^%'_"4^//\ HG/_ )7(/\*[BBCV MD?Y%^/\ F%GW.'_X2GQY_P!$Y_\ *Y!_A1_PE/CS_HG/_E<@_P *[BBCVD?Y M%^/^86??]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"NXHH]I'^1?C_ )A9]SA_^$I\ M>?\ 1.?_ "N0?X4?\)3X\_Z)S_Y7(/\ "NXHH]I'^1?C_F%GW.'_ .$I\>?] M$Y_\KD'^%'_"4^//^B<_^5R#_"NXHH]I'^1?C_F%GW.'_P"$I\>?]$Y_\KD' M^%'_ E/CS_HG/\ Y7(/\*[BBCVD?Y%^/^86?TC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2G MQY_T3G_RN0?X5W%%'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y M_P#*Y!_A7<44>TC_ "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ M "N0?X5W%%'M(_R+\?\ ,+/NTC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%% M'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ M "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ "N0?X5W%%'M(_R+ M\?\ ,+/NTC_(OQ_S" MS[G%Q>*O'HW[?AOGY#G_ (GL''Z5'_PE/CS_ *)S_P"5R#_"N]@_Y:?[AJ*C MVD?Y%^/^86??]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"NXHH]I'^1?C_ )A9]SA_ M^$I\>?\ 1.?_ "N0?X4?\)3X\_Z)S_Y7(/\ "NXHH]I'^1?C_F%GW.'_ .$I M\>?]$Y_\KD'^%'_"4^//^B<_^5R#_"NXHH]I'^1?C_F%GW.'_P"$I\>?]$Y_ M\KD'^%'_ E/CS_HG/\ Y7(/\*[BBCVD?Y%^/^86?TC_(OQ_P PL^YP_P#PE/CS_HG/_E<@ M_P */^$I\>?]$Y_\KD'^%=Q11[2/\B_'_,+/NTC_(OQ_S"S[G#_\ "4^//^B<_P#E<@_PH_X2GQY_ MT3G_ ,KD'^%=Q11[2/\ (OQ_S"S[G#_\)3X\_P"B<_\ E<@_PH_X2GQY_P!$ MY_\ *Y!_A7<44>TC_(OQ_P PL^YP_P#PE/CS_HG/_E<@_P */^$I\>?]$Y_\ MKD'^%=Q11[2/\B_'_,+/NTC_(OQ_S"S[G#_\ "4^//^B<_P#E<@_PJ3_A*O'OV?'_ K?C?U_MV#T M^E=I4O\ RZ?\#_I1[2/\B_'_ #"S[G!?\)3X\_Z)S_Y7(/\ "C_A*?'G_1.? M_*Y!_A7<44>TC_(OQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X M5W%%'M(_R+\?\PL^YP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44 M>TC_ "+\?\PL^YP__"4^//\ HG/_ )7(/\*/^$I\>?\ 1.?_ "N0?X5W%%'M M(_R+\?\ ,+/NTC_(O MQ_S"S[G#_P#"4^//^B<_^5R#_"C_ (2GQY_T3G_RN0?X5W%%'M(_R+\?\PL^ MYP__ E/CS_HG/\ Y7(/\*/^$I\>?]$Y_P#*Y!_A7<44>TC_ "+\?\PL^YP_ M_"4^//\ HG/_ )7(/\*D?Q5X]\F,'X;X S@_V[!S^E=I4LG_ ![Q?C_.CVD? MY%^/^86??]$Y_P#*Y!_A1_PE/CS_ *)S_P"5R#_"NXHH]I'^1?C_ )A9 M]SA_^$I\>?\ 1.?_ "N0?X4?\)3X\_Z)S_Y7(/\ "NXHH]I'^1?C_F%GW.'_ M .$I\>?]$Y_\KD'^%'_"4^//^B<_^5R#_"NXHH]I'^1?C_F%GW.+@\5>/1,I M7X;[CZ?V[ /Z5'_PE/CS_HG/_E<@_P *[VV_X^%_'^514>TC_(OQ_P PL^YP M_P#PE/CS_HG/_E<@_P */^$I\>?]$Y_\KD'^%=Q11[2/\B_'_,+/NTC_(OQ_S"S[G#_\ "4^//^B< M_P#E<@_PH_X2GQY_T3G_ ,KD'^%=Q11[2/\ (OQ_S"S[G#_\)3X\_P"B<_\ ME<@_PH_X2GQY_P!$Y_\ *Y!_A7<44>TC_(OQ_P PL^YP_P#PE/CS_HG/_E<@ M_P */^$I\>?]$Y_\KD'^%=Q11[2/\B_'_,+/NTC_(OQ_S"S[G#_\ "4^//^B<_P#E<@_PKL= U#5[ MRRL6U31/[.>:*9[A?M:2_9W610B94?-O4LV1]W;@]:GJ];?\>Z_C_.IE.+6D M4OO_ ,QV\R6BBBLQA4%W_J1_O5/4%W_J1_O4 4Z*** "BHKFY@L[:2XNYHX( M(E+22R,%5 .I)/ %<4?C5\/!J/V+_A)[?S5)Y?3/^LV[/QS1UL'2YW5% M0V]Y;7EG'=VD\<]O(F])8F#*Z^H(ZBN";X\?#=6*MXCP0<'_ $&Y_P#C='6P M=+GH=%I%.SNEW%=6OV.EHJMJ%_;:7IMS?W\GE6M MK$TTTFTMM11DG R3P.U4O#?B?2/%VD#5/#UW]KLR[1B7RGC^8=1AP#^E(>QK M445ROB3XF^#O"-X+37]<@MKD]841Y77_ 'E125_'% '545GZ-KNE^(M.6_T. M_@OK5C@2P.& /H?0^QYI->U_3/#.C3:KKMVMI908\R5E+8R< 84$DY/0"AZ; M@M=C1HJC9:S8:AH46LV<_F6$T'VA)MC#,>,YVD9Z=L9KB?\ A?7PV_Z&3_R1 MN?\ XW1L[!TN>B45S?A7X@^&/&TES'X8U/[M.SM<"U11574M1M=(TNYU'4 M9?)M+6)I9I-I;:BC). "3QZ4M@W+5%<]9^.O#E_X0F\46FH^9HT 8R7/D2#: M%.&^4KN_2K^@>(-,\4:+#JVA7/VJQG+".7RV3=M)4\, >H/:G9@:5%%%( HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *EN?^/AOP_E452W/_ !\-^'\J M (J**1ONF@#)U/7H].D"F,R9[@]*H_\ "8P_\^[?]]?_ %JR_$1S<'_?_I6) M7PF9YQC,/BYTJ2.B%.+C=G7_ /"8P_\ /NW_ 'U_]:C_ (3&'_GW;_OK M_P"M7(45YO\ K!F'\_X+_(OV43K_ /A,8?\ GW;_ +Z_^M1_PF,/_/NW_?7_ M -:N0HH_U@S#^?\ !?Y![*)U_P#PF,/_ #[M_P!]?_6H_P"$QA_Y]V_[Z_\ MK5R%%'^L&8?S_@O\@]E$Z_\ X3&'_GW;_OK_ .M1_P )C#_S[M_WU_\ 6KD* M*/\ 6#,/Y_P7^0>RB=?_ ,)C#_S[M_WU_P#6H_X3&'_GW;_OK_ZURB=?_ ,)C#_S[M_WU_P#6H_X3&'_G MW;_OK_ZURB=?_ ,)C#_S[ MM_WU_P#6H_X3&'_GW;_OK_ZU+\?YU%4LG_ ![Q?C_.@"*BBB@ HHHH **** "BBB@"6V_X^%_' M^515+;?\?"_C_*HJ "BBB@ HHHH **** "BBB@ HHHH **** "KUM_Q[K^/\ MZHU>MO\ CW7\?YT 2T444 %07?\ J1_O5/4%W_J1_O4 4Z*** /+OV@],UC4 M_A=(FBI)*L5RDMW%$"6>( ]AU ;:3],]J\E\.2_ W5?#L-EK%G?Z1JK1"-[R M>29QYF/OC8Q7&?51].]>U_%[QEXC\"^&[;6/#EE9W<*S^7>"YB=_+4CY6&UE MP,\9&N"?Q3^S M_2.[^%'A>+PIX%DM+'Q+%XBT^:1IK:>&((D8(Y48=L\@GKU)KY]^&?\ PJ[[ M-JG_ LW_CY^T#[+_P ?7W,'/^IXZ^M>B_LU"Z_LWQ.T"S+HK3K]D$QR0V&S M^.W9G'M6!\"?AWX6\:Z;KD_B;2_MLMM=JD3?:)8]H()(^1AG\:T=W-OR1*LH M6_O?HS'TL>'#^T%X?_X5.+@Z>)HS)N\S Y/FX\SYMNSU]ZU/C[HU[X@^-6G: M9I:A[N?34$2DXW$-(V,^O'%>_>&O ?ACP>&/AS1K>R=AM:49>0C.<%V);'MF MO*/&O_)V/A3_ *]8_P".&\9? +Q!%J#$:OI>F MSVUZC\,2(V"N1[@<^X-7?V(K_P 3:!"#I/B2 MTFLM0MUX5)74C=[9/S#W##O71_!"TO=0_9_O;/2KC[+>W$EU';S[V3RY",*V MY>1@X.1S0I M\M#.>V".,5U/@_X:_%31O%UAJ&O^-/M^G02%I[;^U;J7S!M M(QM=0IYQU-*/%)=9LX);3P[J%S_Q+8I2?F57;Y@/8$#/?\*X_XO:/ MX\UO0M5\1^+;I;'2-/O/*T[347'FJTFP2$ \'!SELGK@ &NB^ 4^?'OC&#P^ M9#X864M; YV*V\[-N?5<^^ ,UUO[0O\ R1K4?^N\'_HQ:53X8OR7Z#C?FDO- MG0?#>&.Y^$?A^"9=T=!R3],=Z]*^&'_)*_#?_8.A_P#017FGCE_^$P_:3\->&Y/GLM)0 M7,J=B^/,.?P5!^)K2K'FK./=_@33=J?,^B.P^#/P\B\"^#XY+F/_ (F^HHLM MVQZIW6/_ (#GGW)KT6BBE*7,[A%605+_ ,NG_ _Z5%4O_+I_P/\ I4C(J*** M "BBB@ HHHH **** "OFGXO?\(__ ,-$Z9_PF7_($^PQ_:O]9T_>8_U?S=<= M*^EJ^:?B]_PC_P#PT3IG_"9?\@3[#']J_P!9T_>8_P!7\W7'2E]N/]=&/[,O M0O?\8V_Y_M&O1/B#XH?X:?"NTO\ PC;6KPP&"WMHKH2.@B(X_B#9P!U/UKSO M_C&W_/\ :-;_ ,<=2TW5_@+;7VAR^=ITMQ!]G?:RY09 X8 ]N]$VU#3N@C9R M^3*TOQ;^)%YX>A\2Z-X'MVT&*(27$\\GSR@ ;V1 X95SNP\&^K-RSUS_ (2']EO6]0_LO3=+WP7"_9M,M_)A7#8R%R>3 MWK0^$_B&Q\*?LZ6>M:JS+:V@G9@HRS'SF 4>Y) _&N;\(_\ )H>L?]>W]W]10U4;]V;R_%SXE2Z8 M?%,7@2U/A4*90QA%YF0%0 S="#WI37+&2[?YE4_>G' MSW+-E\6_B3XA\,0ZUX7\$VMQ:0)_IES*Q E9?O\ E1^8&P.F?G_I7:^$?BQI M7B;X>7WBB6%[4Z8CF^M@=QC*KN^4]P1T/^%KY![ \U@_ :TLW\)^,M8\0)%;Z!J$VQOM)VQ[ &W\],8< M#([TY+6:717N1%W46^]K&A8_%+XK>);#^W?"O@C3IM#+-MWS;YF"G# ?O%)/ M'9/SKLM:\8^++3X2W7B2+P['INLVB^9+87I\Y?+!&YAL8'[N3S@C!X[UY+/X M+\(:;'A69ES@ JRL1U ^5L@]3W]'^"/BC6/'GP_OAX ML/VO9.UJ+AHPOGQE1D' .,XS^?-2U>+4=T5>TDY;'4^#O&L'B/X;6OBB[,< M(-LTET$R%C=,[P,DD#(.,GI6/\(?&^O^/M$OM7UNTLK6T%P8;,6T;JS@?>+% MF;/4#C'(->)W&N77@?P=XQ^&R^8;Z74TALESDO#+UQ]55?\ ONOH_P #^'(_ M"7@C2]%C4!K:!1*1_%(>7/XL35Z.\UL[6^>K^[83O&T'OK?TV7W[F_1114#" MBBB@ HHHH **** "I;G_ (^&_#^515+<_P#'PWX?RH BI&^Z:6D;[IH X;Q# M_P ?#?[_ /2L6MKQ#_Q\-_O_ -*Q:_+<[_W^I_70ZZ?PA1117CF@4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 5/:3S07*M;D[\\ =ZB56=@J#)/0" MM73M.>>41Q#.?OR?T'M7I9;@:V,K)4M+;OL1*2BM3L-,NVN[4-)C=WQ5VJMC M:"T@""K5?JT(N,5%N]CC"BBBJ **** "BBB@ J7_ )=/^!_TJ*I?^73_ ('_ M $H BHHHH **** "BBB@ HHHH **** "BBB@ HHHH *ED_X]XOQ_G452R?\ M'O%^/\Z (J*** "BBB@ HHHH **** );;_CX7\?Y5%4MM_Q\+^/\JBH **** M "BBB@ HHHH **** "BBB@ HHHH *O6W_'NOX_SJC5ZV_P"/=?Q_G0!+1110 M 5!=_P"I'^]4]07?^I'^]0!3HHHH CG@BNK=X+F))H9%*O'(H96!Z@@]17#R M?!/X=RZA]L;PS;B7<&VK-*L>1_TS#;<>V,&N\HHZW#I8JV.FV6F:?'8Z=:0V MEI&NU(8$"*H]@*R_"_@K0/!D-S%X:L/L273B28>=))N8# /SLHHZW#I8S]$=(&E^'K3[)9AVD$7FO)\ MQZG+DG]:UJ*-@W"N5\1_#+P=XMO/M>OZ%;W-SQNG1GB=\# W,A4MQZYKJJ* M,_1M"TOP[IRV&AV$%C:J*]&DTK7[7[792LK/%Y MC)DJXMM4# &223^)K+ MB\$^'H?&4GBJ/3\:U*FQ[KSY#D;0N-F[;T '2M^BG=WN'2P4444@"I?^73_@ M?]*BJ7_ET_X'_2@"*BBB@ HHHH **** "BBB@ KDO$OPN\'^,-6&I>(M'^V7 M8C$0D^U31_*,D#".!W/:NMHH \[_ .%"_#;_ *%O_P GKG_XY7/?'?1['0/@ M;%I>DP?9[*UNX4ABWLVT98XRQ)/7N:]EHI25U;T_ <79W/,/"OPS\'>)O _A M?5-;T&WNKU--MSYNYDWXC7&\*0'Z?Q UZ#=:-IUYH4NC3VJ?V=+ ;=K>/,:^ M61C:-N,#'IBKU%7.7,WV9,=+>1SUGX%\.6'A";PO::=Y>C3AA);>?(=P8Y;Y MBV[]:O:%X=TKPUH<6CZ+:"WL(MVR$NT@&XDGEB2&+7SMV[:CR+'G_KF&V?ABL[XVVMO8_ W5[6S@CM[>)($CBB4*J*)4P ! MP!7I-%)J\>4J,K24CQ[X<_#OPGXO^$_AJ[\1:+!>7$4#!9MS1L0)&P"4(+#V M.17J]KIEC8Z8FG6EG!#9(GEK;I&!&%]-O3%6J*N3YFWW,XQY4EV.$N?@G\.[ MJ^^UR^&;=9,@[8II8X^/]A6"_IS70W]SI?@?PA'(O^%P_'B'Q;;:1<6F@Z/.>/[@)!(+;C MT!. M?1M%%/[*BN@NK;"BBBD,**** "BBB@ HHHH *EN?^/AOP_E452W/_'P MWX?RH BI&^Z:6B@#B->56NV5V9><@A<]JR?*B_YZM_W[->A3:?;SONDC4GW% M1_V/:?\ /)?RKQ<1DF$Q-5U:E[OS-%4DE9' ^5%_SU;_ +]FCRHO^>K?]^S7 M??V/:?\ /)?RH_L>T_YY+^5<_P#JY@.S^\?M9' ^5%_SU;_OV:/*B_YZM_W[ M-=]_8]I_SR7\J/['M/\ GDOY4?ZN8#L_O#VLC@?*B_YZM_W[-'E1?\]6_P"_ M9KOO['M/^>2_E1_8]I_SR7\J/]7,!V?WA[61P/E1?\]6_P"_9H\J+_GJW_?L MUWW]CVG_ #R7\J/['M/^>2_E1_JY@.S^\/:R.!\J+_GJW_?LT>5%_P ]6_[] MFN^_L>T_YY+^5']CVG_/)?RH_P!7,!V?WA[61P/E1?\ /5O^_9H\J+_GJW_? MLUWW]CVG_/)?RH_L>T_YY+^5'^KF [/[P]K(X'RHO^>K?]^S1Y47_/5O^_9K MOO['M/\ GDOY4?V/:?\ /)?RH_U'M9' ^5%_SU;_OV:/*B_P">K?\ M?LUWW]CVG_/)?RH_L>T_YY+^5'^KF [/[P]K(X'RHO\ GJW_ '[-'E1?\]6_ M[]FN^_L>T_YY+^5']CVG_/)?RH_U'M9'!""-LXE;@9_P!6:3RHO^>K M?]^S7H4.CVG[S]ROW#VJ/^Q[3_GDOY4?ZN8#L_O#VLC@?*B_YZM_W[-'E1?\ M]6_[]FN^_L>T_P">2_E1_8]I_P \E_*C_5S =G]X>UD<#Y47_/5O^_9H\J+_ M )ZM_P!^S7??V/:?\\E_*C^Q[3_GDOY4?ZN8#L_O#VLC@?*B_P">K?\ ?LT> M5%_SU;_OV:[[^Q[3_GDOY4?V/:?\\E_*C_5S =G]X>UD<#Y47_/5O^_9H\J+ M_GJW_?LUWW]CVG_/)?RH_L>T_P">2_E1_JY@.S^\/:R.!\J+_GJW_?LT>5%_ MSU;_ +]FN^_L>T_YY+^5']CVG_/)?RH_U'M9' ^5%_SU;_ +]FCRHO M^>K?]^S7??V/:?\ /)?RH_L>T_YY+^5'^KF [/[P]K(X'RHO^>K?]^S1Y47_ M #U;_OV:[[^Q[3_GDOY4?V/:?\\E_*C_ %'M9' ^5%_P ]6_[]FCRH MO^>K?]^S7??V/:?\\E_*C^Q[3_GDOY4?ZN8#L_O#VLC@?*B_YZM_W[-'E1?\ M]6_[]FN^_L>T_P">2_E1_8]I_P \E_*C_5S =G]X>UD<$((VSB5N!G_5FD\J M+_GJW_?LUZ%#H]I^\_T_YY+^5'^KF [/[P]K(X'RHO^>K?]^S1 MY47_ #U;_OV:[[^Q[3_GDOY4?V/:?\\E_*C_ %'M9' ^5%_P ]6_[] MFCRHO^>K?]^S7??V/:?\\E_*C^Q[3_GDOY4?ZN8#L_O#VLC@?*B_YZM_W[-' ME1?\]6_[]FN^_L>T_P">2_E1_8]I_P \E_*C_5S =G]X>UD<#Y47_/5O^_9H M\J+_ )ZM_P!^S7??V/:?\\E_*C^Q[3_GDOY4?ZN8#L_O#VLC@?*B_P">K?\ M?LT>5%_SU;_OV:[[^Q[3_GDOY4?V/:?\\E_*C_5S =G]X>UD<#Y47_/5O^_9 MH\J+_GJW_?LUWW]CVG_/)?RH_L>T_P">2_E1_JY@.S^\/:R.!\J+_GJW_?LT M>5%_SU;_ +]FN^_L>T_YY+^5']CVG_/)?RH_U'M9' ^5%_SU;_ +]F MCRHO^>K?]^S7??V/:?\ /)?RH_L>T_YY+^5'^KF [/[P]K(X)8(V; E;/_7, MTGE1?\]6_P"_9KT*WT>T-PO[E>_;VJ/^Q[3_ )Y+^5'^KF [/[P]K(X'RHO^ M>K?]^S1Y47_/5O\ OV:[[^Q[3_GDOY4?V/:?\\E_*C_5S =G]X>UD<#Y47_/ M5O\ OV:/)B_YZM_W[-=]_8]I_P \E_*C^Q[3_GDOY4?ZN8#L_O#VLCD-/L#< M,$AW88_,Y&"1Z"NRL;".TC 0QA<+2PE/V=)61FVV[L* M***ZA!1110 4444 %%%% !4O_+I_P/\ I452_P#+I_P/^E $5%%% !1110 4 M444 %%%% !1110 4444 %%%% !4LG_'O%^/\ZBJ63_CWB_'^= $5%%% !111 M0 4444 %%%% $MM_Q\+^/\JBJ6V_X^%_'^514 %%%% !1110 4444 %%%% ! M1110 4444 %7K;_CW7\?YU1J];?\>Z_C_.@"6BBB@ J"[_U(_P!ZIZP_%G_" M0?V3%_PBO]F_;//&_P#M+S/+\O:V<;.=V=OMC--*[L!9HKA_^+J?]2?_ .35 M'_%U/^I/_P#)JM?9?WE]Y-SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E_>7W MA<[BBN'_ .+J?]2?_P"35'_%U/\ J3__ ":H]E_>7WA<[BBN'_XNI_U)_P#Y M-4?\74_ZD_\ \FJ/9?WE]X7.XHKA_P#BZG_4G_\ DU1_Q=3_ *D__P FJ/9? MWE]X7.XHKA_^+J?]2?\ ^35'_%U/^I/_ /)JCV7]Y?>%SN**X?\ XNI_U)__ M )-4?\74_P"I/_\ )JCV7]Y?>%SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E M_>7WA<[BBN'_ .+J?]2?_P"35'_%U/\ J3__ ":H]E_>7WA<[BI?^73_ ('_ M $K@O^+J?]2?_P"352?\76^S_P#,F[=__3UG.*/9?WE]X7.THKA_^+J?]2?_ M .35'_%U/^I/_P#)JCV7]Y?>%SN**X?_ (NI_P!2?_Y-4?\ %U/^I/\ _)JC MV7]Y?>%SN**X?_BZG_4G_P#DU1_Q=3_J3_\ R:H]E_>7WA<[BBN'_P"+J?\ M4G_^35'_ !=3_J3_ /R:H]E_>7WA<[BBN'_XNI_U)_\ Y-4?\74_ZD__ ,FJ M/9?WE]X7.XHKA_\ BZG_ %)__DU1_P 74_ZD_P#\FJ/9?WE]X7.XHKA_^+J? M]2?_ .35'_%U/^I/_P#)JCV7]Y?>%SN**X?_ (NI_P!2?_Y-4?\ %U/^I/\ M_)JCV7]Y?>%SN**X?_BZG_4G_P#DU1_Q=3_J3_\ R:H]E_>7WA<[BBN'_P"+ MJ?\ 4G_^35'_ !=3_J3_ /R:H]E_>7WA<[BBN'_XNI_U)_\ Y-4?\74_ZD__ M ,FJ/9?WE]X7.XHKA_\ BZG_ %)__DU1_P 74_ZD_P#\FJ/9?WE]X7.XHKA_ M^+J?]2?_ .35'_%U/^I/_P#)JCV7]Y?>%SN**X?_ (NI_P!2?_Y-4?\ %U/^ MI/\ _)JCV7]Y?>%SN**X?_BZG_4G_P#DU1_Q=3_J3_\ R:H]E_>7WA<[BBN' M_P"+J?\ 4G_^35'_ !=3_J3_ /R:H]E_>7WA<[BI;G_CX;\/Y5P7_%U/^I/_ M /)JI)_^%K>%SM**X?\ XNI_U)__ )-4?\74_P"I M/_\ )JCV7]Y?>%SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E_>7WA<[BBN'_ M .+J?]2?_P"35'_%U/\ J3__ ":H]E_>7WA<[BBN'_XNI_U)_P#Y-4?\74_Z MD_\ \FJ/9?WE]X7.XHKA_P#BZG_4G_\ DU1_Q=3_ *D__P FJ/9?WE]X7.XH MKA_^+J?]2?\ ^35'_%U/^I/_ /)JCV7]Y?>%SN**X?\ XNI_U)__ )-4?\74 M_P"I/_\ )JCV7]Y?>%SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E_>7WA<[B MBN'_ .+J?]2?_P"35'_%U/\ J3__ ":H]E_>7WA<[BBN'_XNI_U)_P#Y-4?\ M74_ZD_\ \FJ/9?WE]X7.XHKA_P#BZG_4G_\ DU1_Q=3_ *D__P FJ/9?WE]X M7.]@_P"6G^X:BKBXO^%K?/M_X0W[ASG[5TJ/_BZG_4G_ /DU1[+^\OO"YW%% MR_O+[PN=Q17#_ /%U/^I/_P#)JC_BZG_4G_\ DU1[+^\OO"YW M%%R_O+[PN=Q17#_\ %U/^I/\ _)JC_BZG_4G_ /DU1[+^\OO" MYW%%R_O+[PN=Q17#_ /%U/^I/_P#)JC_BZG_4G_\ DU1[+^\O MO"YWL'_+3_<-15Q<7_"UOGV_\(;]PYS]JZ5'_P 74_ZD_P#\FJ/9?WE]X7.X MHKA_^+J?]2?_ .35'_%U/^I/_P#)JCV7]Y?>%SN**X?_ (NI_P!2?_Y-4?\ M%U/^I/\ _)JCV7]Y?>%SN**X?_BZG_4G_P#DU1_Q=3_J3_\ R:H]E_>7WA<[ MBBN'_P"+J?\ 4G_^35'_ !=3_J3_ /R:H]E_>7WA<[BBN'_XNI_U)_\ Y-4? M\74_ZD__ ,FJ/9?WE]X7.XHKA_\ BZG_ %)__DU1_P 74_ZD_P#\FJ/9?WE] MX7.XHKA_^+J?]2?_ .35'_%U/^I/_P#)JCV7]Y?>%SN**X?_ (NI_P!2?_Y- M4?\ %U/^I/\ _)JCV7]Y?>%SO;;_ (^%_'^515Q<'_"UO.79_P (;GMG[54? M_%U/^I/_ /)JCV7]Y?>%SN**X?\ XNI_U)__ )-4?\74_P"I/_\ )JCV7]Y? M>%SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E_>7WA<[BBN'_ .+J?]2?_P"3 M5'_%U/\ J3__ ":H]E_>7WA<[BBN'_XNI_U)_P#Y-4?\74_ZD_\ \FJ/9?WE M]X7.XHKA_P#BZG_4G_\ DU1_Q=3_ *D__P FJ/9?WE]X7.XHKA_^+J?]2?\ M^35'_%U/^I/_ /)JCV7]Y?>%SN**X?\ XNI_U)__ )-4?\74_P"I/_\ )JCV M7]Y?>%SN*E_Y=/\ @?\ 2N"_XNI_U)__ )-5)_Q=;[/_ ,R;MW_]/67WA<[2BN'_XNI_U)_\ Y-4?\74_ZD__ ,FJ/9?WE]X7.XHKA_\ BZG_ %)_ M_DU1_P 74_ZD_P#\FJ/9?WE]X7.XHKA_^+J?]2?_ .35'_%U/^I/_P#)JCV7 M]Y?>%SN**X?_ (NI_P!2?_Y-4?\ %U/^I/\ _)JCV7]Y?>%SN**X?_BZG_4G M_P#DU1_Q=3_J3_\ R:H]E_>7WA<[BBN'_P"+J?\ 4G_^35'_ !=3_J3_ /R: MH]E_>7WA<[BBN'_XNI_U)_\ Y-4?\74_ZD__ ,FJ/9?WE]X7.XJ63_CWB_'^ M=<%_Q=3_ *D__P FJD?_ (6MY,>?^$-QSC'VJCV7]Y?>%SM**X?_ (NI_P!2 M?_Y-4?\ %U/^I/\ _)JCV7]Y?>%SN**X?_BZG_4G_P#DU1_Q=3_J3_\ R:H] ME_>7WA<[BBN'_P"+J?\ 4G_^35'_ !=3_J3_ /R:H]E_>7WA<[BBN'_XNI_U M)_\ Y-4?\74_ZD__ ,FJ/9?WE]X7.]MO^/A?Q_E45<7!_P +6\Y=G_"&Y[9^ MU5'_ ,74_P"I/_\ )JCV7]Y?>%SN**X?_BZG_4G_ /DU1_Q=3_J3_P#R:H]E M_>7WA<[BBN'_ .+J?]2?_P"35'_%U/\ J3__ ":H]E_>7WA<[BBN'_XNI_U) M_P#Y-4?\74_ZD_\ \FJ/9?WE]X7.XHKA_P#BZG_4G_\ DU1_Q=3_ *D__P F MJ/9?WE]X7.XHKA_^+J?]2?\ ^35'_%U/^I/_ /)JCV7]Y?>%SN**X?\ XNI_ MU)__ )-4?\74_P"I/_\ )JCV7]Y?>%SN*O6W_'NOX_SKSG_BZG_4G_\ DU78 MZ!_PD/V*Q_MW^S/,\J;[7]C\S'F>8OE>7N_AV;]V>=VW'&:F4.5;H=S:HHHK M,85!=_ZD?[U3U!=_ZD?[U %.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "I?\ ET_X'_2HJE_Y=/\ @?\ 2@"*BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ J6Y_P"/AOP_E452W/\ Q\-^'\J (J*** "BDR!U-&X>M "T4FX>M&X> MM "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X> MM "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M $T'_+3_<-15) P_><_P&HM MP]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HHHH ** M** "BBB@ HHHH **** )8/\ EI_N&HJE@_Y:?[AJ*@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** );;_CX7\?Y5%4MM_P ?"_C_ "J*@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH *E_Y=/^!_TJ*I?^73_@?]* (J*** M"BBB@ HHHH **** "BBB@ HHHH **** "I9/^/>+\?YU%4LG_'O%^/\ .@"* MBBB@ HHHH **** "BBB@"6V_X^%_'^515+;?\?"_C_*HJ "BBB@ HHHH *** M* "BBB@ HHHH **** "KUM_Q[K^/\ZHU>MO^/=?Q_G0!+1110 5!=_ZD?[U3 MU!=_ZD?[U %.BBB@ HKS3X[^*-7\+?#AKC09)()[JY2W>YC^]"A#$D'L3@#/ M;/KBO)] ^##^*-*C\0:)\1K>\UMXA*8X@3(DFW[C2>9O4XXR5_"DG>[Z(;5K M>9]1T5POPO3QG;^"9+/X@V[1W]LS)#,\\"Q1CR#D9/)XKYX^&?P?\ M^%EVVJ77]N?V9]CN!'M^R>=OR"HE\/,^]OZ^X^P:*^7= MM8^ M#_QLTGPS9Z^=4L+Z2-)X8\JA$C%?FCRP5Q@'(.?4E%><'QA;>./@'JVLVY599 M-*N$N8@<^5*(R&7\^1[$5G_LX?\ )(XO^OV;^8I\KYI1?05_=C+NVOP/5Z** M\O\ C1XXNM$T>/PYX;#3>(-81EC2(_-##@[Y/8X! /U/:HD[(N*NSU"BO%?V M8/\ DGFI_P#83;_T7'5_XY>.;K3-(_X17PUNEUG4H'DF\H_-;VRJ2[>Q(!'T M!/I5U/<_KRN3#WCUNBO(/V;BR_"68QKN<7\VU,D43]UZ[6N*'OJ_G8^D:*\J_9\\2: MSXC^'TK:[++5V"+NKA4O_ "Z?\#_I M452_\NG_ /^E2,BHHHH **** "BBB@ HHKA/C'XJ_X1/X9:CP3D@@*9.4'U# M #_@5>R?'?\ Y(OK?_;'_P!')5S]V-_ZO>Q-/WY_45X/??\GCV/_7G_ .V[UZ%\8O\ MDC_B+_KU_P#9A6?\ MP^^ ?_"=^#+;7O\ A)/L'GNZ^1]@\S;M8K][S!UQZ5I*+4Y1[$)WBGW/JZBO MG3P-JOB7X5_%NW\"^)=2;4-+OU5+9V1M*]/TKMOCW<277AC2/ M#-L?W^O:I#;X'78#DG\]M*U[./5V_&P^K3Z:_J>JT5X;\6O%NNQ^(=(^&O@. M4VEU:-R^W,R MA#M*?=M?<5U:[*Y[=17S)!\#]5M-,;7_ (<^.XM9U)<, MJV)$)E^89'FB4CJ.C8SCFO?_ ;-KTWA&P;Q=:BUU@1[;I Z."P)&[*$KR # M@=,T[:$WU-RBBBD,**** "BBB@ J6Y_X^&_#^515+<_\?#?A_*@"*D)PII:1 MONF@#CO$5Y,+@;'*[3MXK%^W77_/9JTO$/\ Q\-_O_TK%K\QSJI../J)-_TC MKII/[:I_,_O+LBQ]NNO\ GLU'VZZ_Y[-5>BCV MU3^9_>%D6/MUU_SV:C[==?\ /9JKT4>VJ?S/[PLBQ]NNO^>S4?;KK_GLU5Z* M/;5/YG]X618^W77_ #V:C[==?\]FJO11[:I_,_O"R+'VZZ_Y[-1]NNO^>S57 MHH]M4_F?WA9%C[==?\]FH^W77_/9JKT4>VJ?S/[PLBQ]NNO^>S4?;KK_ )[- M5>BCVU3^9_>%D6/MUU_SV:C[==?\]FJO11[:I_,_O"R+'V^Z_P">[?G1]NNO M^>S57HH]M4_F?WA9%C[==?\ /9J/MUU_SV:J]%'MJG\S^\+(L?;KK_GLU'VZ MZ_Y[-5>BCVU3^9_>%D6/MUU_SV:C[==?\]FJO11[:I_,_O"R+'VZZ_Y[-2KJ M%TC!A,V0M;=>70S/!*)(FVL*[?0] M9%_"$DR)!P?>OOI3MJC:HHHKZ@Q"BBB@ HHHH ** M** )8/\ EI_N&HJE@_Y:?[AJ*@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** );;_CX7\?Y5%4MM_P ?"_C_ "J*@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH *E_Y=/^!_TJ*I?^73_@?]* (J*** "BBB@ HHHH **** M"BBB@ HHHH **** "I9/^/>+\?YU%4LG_'O%^/\ .@"*BBB@ HHHH **** " MBBB@"6V_X^%_'^515+;?\?"_C_*HJ "BBB@ HHHH **** "BBB@ HHHH *** M* "KUM_Q[K^/\ZHU>MO^/=?Q_G0!+1110 5!=_ZD?[U3U!=_ZD?[U %.BBB@ M#A_BCXO\.^%O#\47C'2;K4M-U)S R01(Z@@9&[3]E:R.H;XO%5PMGN'[IK)6DV]QOW@9]]OX&I2U?YE-Z(UO@#XNU M?6],U[1=9OVU-=)=1;WC.7+HVX8W'DCYC^ _#[:7H:R8E.Z:>8[I)6QC)Q@?0#BLKX7 M_#7_ (5O9:E;_P!K?VE]NG67=]F\G9@$8^\V>OM5NSDWY+[R4VH67?\ "S,7 MX?? 71?!&L1:O=7\VK:C!GR7>(11QD_Q!,DYQQDL?IZ:X/6OAG_;'Q8TKQK_:WD_V=$L?V+[-N\S&_G?N&/O_ -T]*$[S MBWLA6]V26[1Y+XECD^#NO^)=$82?\(SXHT^WFE6_VF]MY+J2W@V,_F2 95=J\G)P,#FN^^(?@.Q^(7A9])O9/ MLTJN)+>Z$>\P..^,C((R",CK3?AQX(_X5]X170_[0_M#;.\OG>1Y7WL<;=S> MGK2C>TD^UE]Y4GK%KO=_=^IYMX=^*WQ0N-=@3Q+X(-GI8#O M=RHZ8YK@O#/Q8T.+7O$7B7Q=;ZC=ZYJD3V]J+>*-HK6(K@*"S@^@X'0=\FOK M*H+ZV^VZ?<6N_9Y\31[L9VY&,X_&IEL_2P+='S=\!/B+IOAOPQK&CW%K=RWJ M"XU-2BKY92.%25)+9#':>V/>N>\/?%#0X8?%>K>)X-1O/$NO02V\9MW;-RE&[^UV_GZB\BQJ8_* 7('S;BWMC\:ZJ^/@W]H'PY M)LU'4+*#2+AR>8XVSMXD93N^3&GK7G_B/]F71=5UI[W1=9FTB"5R\EK]G$RKGLAW*5'7@YZ^U%2TG; MR7WDP]U?-EG]GSQ9=ZG8:MX;N7@N+?1'5+2Y@B6,21EF R%X_ASGJ<\DU[-7 M,>!? .C?#[1&T_15D8RMOGN)B#),W3)QP .P'^-=/3D[L458*E_Y=/\ @?\ M2HJE_P"73_@?]*DHBHHHH **** "BBB@ KYN^/>NW&O?$C2/#&F:?5Y M9LD [VSP HZ<"A?&GVU^?0=[1?\ 7J>+?%?Q3XD\7:7IUY<_#K6/#K:-(9%O MI$E*1H<<',2A>0ISGM[UZ-X]\2)XM_9?GUI"-US!!YH'\,@F17'_ 'T#7JNN M:3!KV@WVDWG^HO8'A?C. PQG\.M>;:9\%+C3_A;JW@J3Q-Y\&H3I-'L91]'_ )CC93C+M^1T7P?('P?\.DG %IR3_O&O+I[J M#Q1^UU9RZ+(MQ#I\8$\T9RN4C;=R/=@OUI/^&4_^IR_\I?\ ]NKU/X>_"W0O MAU!.=*\ZYO+@!9KNX(+E0$O^$X_:37 M0/MOV'[5:(?/\KS-NV(M]W(STQUJOXQ_9U_X1+P?J.N_\)1]K^PQ>9Y']G[- M_(&-WFG'7T->SS_#/SOC)!X\_M;;Y,/E?8?LV<_NRF?,W>^?NUT/C'P[_P ) M;X/U'0OM7V3[=%Y?G^7OV<@YVY&>GJ*QM:FE'?7\V:W3GKMH>6>'/^30;G_L M&7?_ *,>NB_9]_Y(UIG_ %VG_P#1C5JZ=\.O[/\ A!)X&_M3S/,MI;?[;]GQ MC>S'/E[NV[IN[5Y=_P ,I?\ 4Y?^4O\ ^W5M*5ZDVMG_ ,$SBOB_P Z[#7,>(_VE="T_&Z#P_I\E[(. MPD?@?^R&MGX=?!_0OAW+)=VDLU_J4B>6UW. -J\9"*/N@D>Y]ZT_#W@;^Q/' M?B'Q/<:A]LGUDH$C\C9]G11C;G<=W1><#I2C:/*NUW\V.33Z U[GK_B?2_#OAJXUN_NH1:0Q&16 M\P8E..%4]R>@Q5#QOX!T3Q_I"V.NPMNC):"YB(62$GNIQT]0>#7E5I^RQID> MI^9>^)KJ>RW$B".U6.3&> 9"Q'3_ &1^%0K\O)VOJ6VN;F]-/0]#\->.;?X@ M_#O4M7L]/NK&(131;;C:=Y",_#/P+'X\^ ^M648"ZA;ZF\]C) MW$@B3Y<^C=#^![5]$VGAZPTSPO\ V#I$2V=FENT$2J,[ 01GW/.3ZUS_ ,+_ M (>?\*W\.W.E_P!J?VEY]T;CS?L_D[N>]5I>=NJ5O5,E-I1OW? MY'SUJ7C2;Q9X@^']KJBR)K&CW@M+Y9%()831A6/N0#D>H->W?$[Q-X(&K6'A M#Q]I=S-%J&V2&\*JL,))*[O,WAE([D#H?2JOB7X&66N?$BW\6V&J_P!FLD\5 MQ/:BU\P32(P);=O&W( SP>>:ZOQ[\.]$^(>E1VFM+)'+ Q:WNH"!)$3U R"" M#CD&AN\%==6VON!)*3L^FAY%XP^ VD^%]%NO$WA;Q7=:8UG$T\1N) 0WRY"I M(NT@GH#SG/XUZ-\$O%>I>+OAM!>:T[37<$SVS3L.9@N"&/O@X)]JX*U_96L$ MOM][XIN)K7)_=0V:QOCM\Y=A_P".U[9X>\/Z=X7T*VTC18/(L[9<(NU9/D1_\]O\ R&:_.\VR M_%U<;.=.FVGY'3"45'5D%%3^1'_SV_\ (9H\B/\ Y[?^0S7E?V5CO^?3^XOG MCW(**G\B/_GM_P"0S1Y$?_/;_P AFC^RL=_SZ?W!SQ[D%%3^1'_SV_\ (9H\ MB/\ Y[?^0S1_96._Y]/[@YX]R"BI_(C_ .>W_D,T>1'_ ,]O_(9H_LK'?\^G M]P<\>Y!14_D1_P#/;_R&:/(C_P">W_D,T?V5CO\ GT_N#GCW(**G\B/_ )[? M^0S1Y$?_ #V_\AFC^RL=_P ^G]P<\>Y!14_D1_\ /;_R&:/(C_Y[?^0S1_96 M._Y]/[@YX]R"BI_(C_Y[?^0S1Y$?_/;_ ,AFC^RL=_SZ?W!SQ[D%%3^1'_SV M_P#(9H\B/_GM_P"0S1_96._Y]/[@YX]R"BK MXVSB;H,_P"K-)Y$?_/;_P A MFC^RL=_SZ?W!SQ[D%%3^1'_SV_\ (9H\B/\ Y[?^0S1_96._Y]/[@YX]R"BI M_(C_ .>W_D,T>1'_ ,]O_(9H_LK'?\^G]P<\>Y!14_D1_P#/;_R&:/(C_P"> MW_D,T?V5CO\ GT_N#GCW(**G\B/_ )[?^0S3DMXBPS*Q'H$.33_LK'?\^G]P M<\>XR"#S/F?Y8QU/K["NJT2PE$BRMA$ ^5!V%0Z3I/VG;+,FU%^ZG8"NGCC6 M-0JC %?=93E,,%#GGK-_AY(YYSYAU+117O&84444 %%%% !1110!+!_RT_W# M452P?\M/]PU%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $MM_ MQ\+^/\JBJ6V_X^%_'^514 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M4O\ RZ?\#_I452_\NG_ _P"E $5%%% !1110 4444 %%%% !1110 4444 %% M%% !4LG_ ![Q?C_.HJED_P"/>+\?YT 14444 %%%% !1110 4444 2VW_'PO MX_RJ*I;;_CX7\?Y5%0 4444 %%%% !1110 4444 %%%% !1110 5>MO^/=?Q M_G5&KUM_Q[K^/\Z ):*** "H+O\ U(_WJGJ"[_U(_P!Z@"G1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !4O_+I_P #_I452_\ +I_P/^E M$5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !4MS_Q\-^'\JBJ6Y_X^&_#^5 $5%%% %:6 MQAF;:_E1_9=M_SS7\JNT4 4O[+MO\ GFOY4?V7;?\ /-?RJ[10!2_LNV_YYK^5 M']EVW_/-?RJ[10!2_LNV_P">:_E1_9=M_P \U_*KM% %+^R[;_GFOY4?V7;? M\\U_*KM% %+^R[;_ )YK^5']EVW_ #S7\JNT4 4O[+MO^>:_E1_9=M_SS7\J MNT4 4O[+MO\ GFOY4?V7;?\ /-?RJ[10!7ATNV_>?NU^X>U1?V7;?\\U_*M* M#_EI_N&HJ *7]EVW_/-?RH_LNV_YYK^57:* *7]EVW_/-?RH_LNV_P">:_E5 MVB@"E_9=M_SS7\J/[+MO^>:_E5VB@"E_9=M_SS7\J5=,MU.1&OY5\ M7X_SH BHHHH **** "BBB@ HHHH EMO^/A?Q_E452VW_ !\+^/\ *HJ "BBB M@ HHHH **** "BBB@ HHHH **** "KUM_P >Z_C_ #JC5ZV_X]U_'^= $M%% M% !6'XL\2Z3X5TF*]UZ[^RV\DXA5_+=\N58@84$]%/Y5N5!=_P"I'^]35KZ@ M>=_\+C\!_P#0=_\ ).?_ .(H_P"%Q^ _^@[_ .2<_P#\17<45KS4OY7]Z_R) M]XX?_AO\@]XX?_A< M?@/_ *#O_DG/_P#$4?\ "X_ ?_0=_P#).?\ ^(KN**.:E_*_O7^0>\O\@]XX?\ X7'X M#_Z#O_DG/_\ $4?\+C\!_P#0=_\ ).?_ .(KN**.:E_*_O7^0>\.'_P"%Q^ _^@[_ .2<_P#\11_PN/P'_P!!W_R3G_\ B*[BBCFI?RO[U_D' MO'#_ /"X_ ?_ $'?_).?_P"(H_X7'X#_ .@[_P"2<_\ \17<44O\ M(/>.'_X7'X#_ .@[_P"2<_\ \11_PN/P'_T'?_).?_XBNXHHYJ7\K^]?Y![Q MP_\ PN/P'_T'?_).?_XBC_A.'_X M7'X#_P"@[_Y)S_\ Q%'_ N/P'_T'?\ R3G_ /B*[BBCFI?RO[U_D'O'#_\ M"X_ ?_0=_P#).?\ ^(H_X7'X#_Z#O_DG/_\ $5W%%'-2_E?WK_(/>.'_ .%Q M^ _^@[_Y)S__ !%'_"X_ ?\ T'?_ "3G_P#B*[BBCFI?RO[U_D'O'#_\+C\! M_P#0=_\ ).?_ .(H_P"%Q^ _^@[_ .2<_P#\17<44O\@]XX?_ (7' MX#_Z#O\ Y)S_ /Q%'_"X_ ?_ $'?_).?_P"(KN**.:E_*_O7^0>\O\@]XX?_A." M_P"%Q^ _^@[_ .2<_P#\11_PN/P'_P!!W_R3G_\ B*[BBCFI?RO[U_D'O'#_ M /"X_ ?_ $'?_).?_P"(H_X7'X#_ .@[_P"2<_\ \17<44O\ (/>. M'_X7'X#_ .@[_P"2<_\ \11_PN/P'_T'?_).?_XBNXHHYJ7\K^]?Y![QP_\ MPN/P'_T'?_).?_XBC_A.'_X7'X# M_P"@[_Y)S_\ Q%'_ N/P'_T'?\ R3G_ /B*[BBCFI?RO[U_D'O'#_\ "X_ M?_0=_P#).?\ ^(H_X7'X#_Z#O_DG/_\ $5W%%'-2_E?WK_(/>.'_ .%Q^ _^ M@[_Y)S__ !%'_"X_ ?\ T'?_ "3G_P#B*[BBCFI?RO[U_D'O'#_\+C\!_P#0 M=_\ ).?_ .(H_P"%Q^ _^@[_ .2<_P#\17<44O\@]XX?_ (7'X#_Z M#O\ Y)S_ /Q%'_"X_ ?_ $'?_).?_P"(KN**.:E_*_O7^0>\\.'_P"%Q^ _^@[_ M .2<_P#\11_PN/P'_P!!W_R3G_\ B*[BBCFI?RO[U_D'O'#_ /"X_ ?_ $'? M_).?_P"(H_X7'X#_ .@[_P"2<_\ \17<44O\ (/>.'_X7'X#_ .@[ M_P"2<_\ \11_PN/P'_T'?_).?_XBNXHHYJ7\K^]?Y![QQ<7QF\!+OW:]C*$# M_0Y__B*C_P"%Q^ _^@[_ .2<_P#\17>P?\M/]PU%1S4OY7]Z_P @]XX?_AO\@]XX?_A\O\@]XX?\ X7'X#_Z#O_DG M/_\ $4?\+C\!_P#0=_\ ).?_ .(KN**.:E_*_O7^0>\.'_ .%Q M^ _^@[_Y)S__ !%'_"X_ ?\ T'?_ "3G_P#B*[BBCFI?RO[U_D'O'#_\+C\! M_P#0=_\ ).?_ .(H_P"%Q^ _^@[_ .2<_P#\17<44O\@]XX?_ (7' MX#_Z#O\ Y)S_ /Q%'_"X_ ?_ $'?_).?_P"(KN**.:E_*_O7^0>\O\@]XX?_A\ OL^W^WN=^\< M%_PN/P'_ -!W_P DY_\ XBC_ (7'X#_Z#O\ Y)S_ /Q%=Q11S4OY7]Z_R#WC MA_\ A\ M\<%_PN/P'_T'?_).?_XBC_A.'_X M7'X#_P"@[_Y)S_\ Q%'_ N/P'_T'?\ R3G_ /B*[BBCFI?RO[U_D'O'#_\ M"X_ ?_0=_P#).?\ ^(H_X7'X#_Z#O_DG/_\ $5W%%'-2_E?WK_(/>.'_ .%Q M^ _^@[_Y)S__ !%'_"X_ ?\ T'?_ "3G_P#B*[BBCFI?RO[U_D'O'%P?&;P$ MDRLVO8 _ZVW_'POX_RJ*CFI?RO[U_D M'O'#_P#"X_ ?_0=_\DY__B*/^%Q^ _\ H._^2<__ ,17<44O\@]XX M?_A\O\@]XX?\ MX7'X#_Z#O_DG/_\ $4?\+C\!_P#0=_\ ).?_ .(KN**.:E_*_O7^0>\MO^/=?Q_G4R=.WNI_?_P!ZDM%%%9C"H+O_4C_ 'JGJ"[_ -2/]Z@" MG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4O_ "Z?\#_I M452_\NG_ /^E $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !4MS_P ?#?A_*HJEN?\ MCX;\/Y4 1444A.!0 M%8NH^(HM/G$;1%\]P:J?\ "8P_\^[?]]?_ %J\RKFV M"HS=.I4LUY/_ "+4)/4Z6BN:_P"$QA_Y]V_[Z_\ K4?\)C#_ ,^[?]]?_6K+ M^V\O_P"?GX/_ "#VSEV.EHKFO\ A,8?^?=O^^O_ *U'_"8P_P#/NW_?7_UJ/[;R_P#Y M^?@_\@]G+L=+17-?\)C#_P ^[?\ ?7_UJ/\ A,8?^?=O^^O_ *U']MY?_P _ M/P?^0>SEV.EHKFO^$QA_Y]V_[Z_^M1_PF,/_ #[M_P!]?_6H_MO+_P#GY^#_ M ,@]G+L=+17-?\)C#_S[M_WU_P#6H'C&#_GW;_OK_P"M1_;>7_\ /S\'_D'L MY=CI:*@M+N*\@$L+9!_2IZ]:,HSBI1=TR"6#_EI_N&HJE@_Y:?[AJ*J **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E@_Y:?[AJ*I8/^6G M^X:BH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6V_X^%_'^51 M5+;?\?"_C_*HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J7_ET_X' M_2HJE_Y=/^!_TH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH *ED_P"/ M>+\?YU%4LG_'O%^/\Z (J*** "BBB@ HHHH **** );;_CX7\?Y5%4MM_P ? M"_C_ "J*@ HHHH **** "BBB@ HHHH **** "BBB@ J];?\ 'NOX_P ZHU>M MO^/=?Q_G0!+1110 5!=_ZD?[U3U!=_ZD?[U %.BBB@#S_P",WCB^\!^ S?:0 MJ_;KF=;:&1UW+$2"2V.A.%.,]_6O+;/P=\:M1TJ+Q/9>-!.9H1I2-O! M7A1&%\K..W3/O7KOQ/U#P7#X;73/B%<&"QU!]L3"&1B'7G(9%.TCW]^O->:2 M? +Q%H0:\^'/CB>!&(EBAE=X=W ZO&2&R/50.WO4KJ_Q*?1?TST;X7^(_$GB M#P4[^,=+N].U6U*;;5)O!/B7^QH8+@+.GV^>W\QB"0<1J0>/6K>LV_)$K2G;S M_P SL_#7B7Q]\./BOI?A/QGK#:Q:ZDR*=\[7&!(2JNKN XPPZ'C&>.],^/'C M7Q%X6^*VGG1=8O;:"*SAF-K'<.L,C>8^=R X.0 #D5U'@3X&ZEIOBVW\3^.] M?_MC4+8[HHU=Y1O'W6:23#''7&!SWXYR_']K!??M3>&K6[B6:":R2.2-QD,I M\X$&GK>"ZW_X86EIOI;_ (<]'O/%D7B/X+:AXCT6>2!I=*FE1HW*O!((SD9' M(*L.OM63\ M5U#6?A?'=ZO?W5_:R32?":]\7^!M4 ME(T76-/N+C2IGX57,; +D]S]T^X7UKKO@AJO]A?L_P![JWD^?]ADNKCRM^W? ML&[&<'&<=<&DG&\IK:R^6NOW#<7:$.O,_GIH>T5Y]\7O'Y\$^%?*TS,FMZCF M&QB0;F4_Q28_V<\>Y%<;X8_:3C\0>([73;CPP;**;<7N!?\ F>6JJ6)V^4,] M.F:Y+0OB'X8UWQ?KWC#QMJJV]Z8)+71K!K>63R$*D!LJI4$YQUZECZ5$DVOZ M^[YE1:3_ *_K0]#_ &<]:U37/ NH7&M:E>:C,FHLBR7<[2LJ^6AP"Q) R3Q[ MUI_&CXA2>#?#/V'1V9M?&^A:!X-U?3 MM0NV6^CEFO\ [.L3DM"D2EF# ;?X3QG-86D>//#6LW7BOQ7XRU5(](],E^&.K>%X;O_B=,EU<+;^4_P!PHH#;L;>O M;.?:N"^%OPSU3XE>']0MD\1'2].LYPWV?RC*)967[Q4,N.%')SWP.M.:O-^2 M7^7]>9$':&O5O^OZZ'O?P>U?QCJ/AZ[M?'MA=07ME/Y<5SM?C1I"()W8L5PY1E#'G;D @'IS7MM$M;-= M4$=+KL%2_P#+I_P/^E15+_RZ?\#_ *5)1%1110 4444 %%%% !7ROX+^+&KZ M!\8KNW\0:S>WFCW-[+:O'=7#R);@R$*ZAB=H!P#CMFOJBOESP'X)MO'K_$?2 MI0BW0NEDM)F'^JE$DV#]#T/L:(NT[]D_T&U>%O-'H/[1FN:IHG@_2)]$U.\T M^22_VO)9W#1%U\MC@E2,BO3Y=7LM(\.Q:CK5[%:6R0H9)[B0*H) ZD]R:^5/ M&GC.;6_A/I7AW7&,>NZ%J?V:>*3AVC5&56QWQ]TGU ]:]T^)P\&2>!=,A\>R MW0A;9]EAM';S99=F/E4<-U_B&!GWIO2+MW_1"WDK]G^9J:5\8O .M:FFGZ?X MC@:YD.U%EBDA#'. SJ 22>!GFMOQ-XPT+P=:077B2^^QPW$ODQ-Y+R;GP3C M"*2. >M?.'QFM[!?#>CW.D?#Z;PO )]JW<\4,$DHV9"-&A+9XSENF/>NO_:+ M9I?A;X89R69KF,DGN3"U'V;^:0+XK=TV>L:9X_\ "^L^)I_#^EZM'=:G;AC+ M#'&Y"[<9^?&TXSV-5/$'Q4\%>%M0-CK>OP072G#PQQO,R'CAA&K;>O?%4;+P MYI7@7X9W%]X?TJTMM1MM'9C=1P*)96$>[YGZM\PSR:X'X ^#/#WB#P-?:OX@ MTJTU:^NKZ1));V(3,H !XW X)+$Y'/-%O><5T6OWV$G[JD^NWW7/;-'UK3-? MTY+_ $6^@OK5R0)8'##(Z@^A]C7/Z_\ %3P3X8U V.L^(+>&Z!PT4:/,R'T; MRU;:>>^*RI?">E_"KX=>);SP?#/'/]CDGS),TGSJAVD#H,9[#M7(_ GP'X:U M?X>?VUK6EVFK7]_<2^;)>Q+,4PV,#=G![YZ\T;MVV0]DK]6>RZ5J^GZYIZ7V MCWL%[:R9VS02!U..HR._M7D7P>UW5]3^*?CFTU+5+V\MK6Y=8(;BX>1(1YSC M"J3A> !Q6=\+(_\ A&/V@/%?A;1RPT;RVF$.25C8%",?3>5_+TJ#X13O:_$K MXEW$0R\4DSJ#ZB60BDFDU/HXM@T^5QZJ21ZMXC^)W@WPG?BQU[78+:Z[PHCR MLG^\$4[>O?%;^FZMI^L::FH:5>0WEI("5F@<.IQUY'\J^3?AWK4@MM3O[WX8 M7'CJYO+DM+?M&TJQD@$K_JG ;)SG(/(KT;X$6VO:9K_B:WO?#>IZ%I%XINK: MWO()%2%MQ&Q691D[2!TY"BBS2=][7_X -J^G>QZ''\8/ ()M?U#7=.M=2EMY4BBBNHA(B!MQ+;6R,G &?:M/0+&W\'?M63:/X> M] M.OK8F:UC^XF8M^,=L,N1Z9Q5)>\HOJK_ (7"6G,UT?ZV/5_$?Q.\&^$KW['K M^NP6US_%"B/*Z<9^945BOXXJ_H7C/P]XFTV6^T'58;Z"!=\OE9+QC&?F3&X= M.A%>#ZQX0\4^!_'NN:S/X(LO&^F:E.TRR36XN'C#,2 %^9E(S@G:1@#FNT^$ M'BSP9JFMWVG:1X2'AC73&SW%NT8.]=W*JV 0 2#M*J!VZ5,;RCYV"7NOR/1? M"_C#0O&>GRWOAJ_%[;PR>5(WE/&5; .,. >A':HSXV\/_P#"9?\ "*"_)UK9 MO-JL$AP-N[)<+M''/)KRSP&J_#SXY^)_#4Q$.F:C =0M6/P-.-I-/I:_Z?F*6E_6R_/\CVRB MBBD,**** "BBB@ J6Y_X^&_#^515+<_\?#?A_*@"*F2_ZLT^F2_ZLT <#K9S M=?\ F_I696GK7_'U_P)OZ5F5^49O_O]7U.R'PH****\PL**** "BBB@ HHH MH **** "BBB@ HHHH **** -'2=6ETV<$$F(GYEKN[2\BO(%DA;((_*O,ZWO M#\L]M<*-Y"O_ >WK7U7#^85X55AK.47^'GZ&-2*M<[N#_EI_N&HJDMSD2'_ M *9FHZ_0#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )8 M/^6G^X:BJ6#_ ):?[AJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** );;_ (^%_'^515+;?\?"_C_*HJ "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ J7_ )=/^!_TJ*I?^73_ ('_ $H BHHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *ED_X]XOQ_G452R?\ 'O%^/\Z (J*** "BBB@ HHHH *** M* );;_CX7\?Y5%4MM_Q\+^/\JBH **** "BBB@ HHHH **** "BBB@ HHHH M*O6W_'NOX_SJC5ZV_P"/=?Q_G0!+1110 5!=_P"I'^]4]07?^I'^]0!3HHHH M YGQYX'T[Q_X9DTC4V:(AA)!<(,M#(.C =^I!'<&O'$^!GQ,M --L?'HCT<8 M0(M]SMK@WE[=D-O2Z*2 MT:?8>Z:[G"?%CX0*D^$W@S4/ M?@5-%U>:UFN5N))2UJ[,F&QCEE4YX]*[>BB/NWMU!^]:_09+%'/"\4R+)&ZE M71QD,#U!'<5S-]\./",^GW$5MX4T&.:2)EC?^SHAM8C .0N1S74T4FDU8:=C MR[X3?"5?!>@7EOXHL]'U"_N)GQ<11>:?)9%4QEG0'!PV5ZZ#? MVNG>%]!M[N:VDC@F_L^)?+RJV,CITKC/$7P$U^S\0W>H_#7Q+_ &/#>L6F MMFN)8-F220&C!W+D\ CCUKWBBAZN[".BL<'\+OAA;?#G3+G?>'4-2OF#7-T5 MV@@9PJC)..2444VVQ)6"I?^73_ ('_ $J*I?\ ET_X'_2D,BHHHH * M*** "BBB@ KS3X6_#G5_!'B+Q-?ZK<64T6K3B2 6SNS* [GYMRC'#CIGO7I= M%"T=P>JL>)_%KX%WGC3Q/%KGABXL;2>9-MZEV[JKL,!67:KET4+167J.]W?Y'A'B3X,^/ M_&7AU/\ A*?&-K?ZI;./LMN$\NU09^8LRQ@LQ&,';Z\FNE^)GPWU[QSX!T'2 M+2?3K>^L'1[@RROY1(C*G:0A)Y/<"O4J*=_SO]PNMRM%:+_9B6ERJR+Y(BD7 MJ&&,$?2O&Q\(?'7@^]O$^%OBVVL=,O)#(]K?)DQ>F#Y;Y],X4X ZU[;12>KN M"T5C@O 'PXG\+Z/J-OXAUNYUV;4\BX29F\E5.=P5"3UW')[^U<=%\(?'G@ZZ MNH?ACXQM[/2[N0NUM?QY,7T.QP3[@*>!UKVZBCK<.ECA/AQ\,H? OVV^O;]] M5UO46W7=](N,\YVJ,GOR3W/Y5G?#SX;ZKX3\<^*M9U2>QFM=9F9X$@=V=09& M;#@J .&[$UZ913OK?RL'2WS/%9/A'XV\):Q?3?"OQ5:Z=I]_(9)+.^CR(CZ+ ME'!],X!Q@3U)QC& *Z^D9 M=Z%3T(Q4N_*T/>5SY3^"_AGQ)JUOK^I>"?$7]C:K;2I%MFC62"=&W'# JV"" M!@X..>*]@^''PKO?#7B"]\4>+=675_$5ZI5I8\^7&#C."0,G@#H , 5O> _ MAOI'P\COTT6YOIQ?.KR_:Y$;!7.,;57U]ZZ^KO;;M;_,EZMW[W_'0\IU_P & M?%:/7KB]\(^/H3;3L<6^HP*/)7.0 !&ZGJ><*<8ZU:^'OPNU#P_XHO/%GB_6 M5U;Q!>1^6[PIMCC! !QP,\*!T [5Z914Q]W8W/ ?VEX8;:X\/ZCIUSY6 MM.9;41Q_ZR2%UP?PR2/^!FO6_ 'AM?"?@/2='"*LL%NIGP.LK?,Y_,FN;TOX M&>$-,\7R>(F6\O+MKAKE(KF53%%(6+9554="> 2>U>CTXZ0MW_K_ #"6LK]@ MHHHI %%%% !1110 5+<_\?#?A_*HJEN?^/AOP_E0!%3)?]6:?37&4(H X#6O M^/K_ ($W]*S*Z74-)O)+IS&D;*22-RYJK_8U_P#\\8?^^!7Q&.R#$XC$SJQ: MLW_70Z(U$E8Q**V_[&O_ /GC#_WP*/[&O_\ GC#_ -\"N/\ U9Q?\T?Q_P A M^UB8E%;?]C7_ /SQA_[X%']C7_\ SQA_[X%'^K.+_FC^/^0>UB8E%;?]C7__ M #QA_P"^!1_8U_\ \\8?^^!1_JSB_P":/X_Y![6)B45M_P!C7_\ SQA_[X%' M]C7_ /SQA_[X%'^K.+_FC^/^0>UB8E%;?]C7_P#SQA_[X%']C7__ #QA_P"^ M!1_JSB_YH_C_ )![6)B45M_V-?\ _/&'_O@4?V-?_P#/&'_O@4?ZLXO^:/X_ MY![6)B45M_V-?_\ /&'_ +X%']C7_P#SQA_[X%'^K.+_ )H_C_D'M8F)16W_ M &-?_P#/&'_O@4JZ-?;AF&$?\ %'^K.+_FC^/^0>UB9]K:L64E-SM]U,=/9'<45P_\ PLS_ *DGQA_X*?\ M[.C_ (69_P!23XP_\%/_ -G1["IV#F1W%%PJ=@YD=I17#_\ "S/^I)\8?^"G_P"SH_X6 M9_U)/C#_ ,%/_P!G1["IV#F1W%%PJ=@YD=Q17 M#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ ,%/_P!G1["IV#F1W%%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ ,%/ M_P!G1["IV#F1W%%PJ=@YD=Q17#_\ "S/^I)\8 M?^"G_P"SH_X69_U)/C#_ ,%/_P!G1["IV#F1W%%PJ=@YD=Q4MS_Q\-^'\JX+_ (69_P!23XP_\%/_ -G4D_Q.W3,?^$(\9#V. MD_\ V='L*G8.9':45P__ LS_J2?&'_@I_\ LZ/^%F?]23XP_P#!3_\ 9T>P MJ=@YD=OM![4FT>E<3_PLS_J2?&'_ (*?_LZ/^%F?]23XP_\ !3_]G1["IV#F M1VVT>E&T>E<3_P +,_ZDGQA_X*?_ +.C_A9G_4D^,/\ P4__ &='L*G8.9'; M;1Z4;1Z5Q/\ PLS_ *DGQA_X*?\ [.C_ (69_P!23XP_\%/_ -G1["IV#F1V MVT>E&T>E<3_PLS_J2?&'_@I_^SH_X69_U)/C#_P4_P#V='L*G8.9';;1Z4;1 MZ5Q/_"S/^I)\8?\ @I_^SH_X69_U)/C#_P %/_V='L*G8.9';;1Z4;1Z5Q/_ M LS_J2?&'_@I_\ LZ/^%F?]23XP_P#!3_\ 9T>PJ=@YD=MM'I1M'I7$_P#" MS/\ J2?&'_@I_P#LZ/\ A9G_ %)/C#_P4_\ V='L*G8.9';;1Z4;1Z5Q/_"S M/^I)\8?^"G_[.C_A9G_4D^,/_!3_ /9T>PJ=@YD=MM'I2[1Z5Q'_ LS_J2? M&'_@I_\ LZ/^%F?]23XP_P#!3_\ 9T>PJ=@YD=Q17#_\+,_ZDGQA_P""G_[. MC_A9G_4D^,/_ 4__9T>PJ=@YD=[!_RT_P!PU%7%Q?$[;O\ ^*(\9'*$<:3T M_P#'ZC_X69_U)/C#_P %/_V='L*G8.9'<45P_P#PLS_J2?&'_@I_^SH_X69_ MU)/C#_P4_P#V='L*G8.9'<45P_\ PLS_ *DGQA_X*?\ [.C_ (69_P!23XP_ M\%/_ -G1["IV#F1W%%P?\M/]PU%7%Q?$[;O_ .*(\9'*$<:3T_\ 'ZC_ .%F?]23XP_\ M%/\ ]G1["IV#F1W%%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ ,%/_P!G1["IV#F1 MW%%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X6 M9_U)/C#_ ,%/_P!G1["IV#F1W%%PJ=@YD M=Q17#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ ,%/_P!G1["IV#F1W%%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ M ,%/_P!G1["IV#F1W%%.G^_1["IV#F1VE%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X69_U)/C#_ ,%/_P!G1["IV#F1 MW%%PJ=@YD=Q17#_\ "S/^I)\8?^"G_P"SH_X6 M9_U)/C#_ ,%/_P!G1["IV#F1W%%Z_C_.O.?\ A9G_ %)/C#_P4_\ V==CH&N_VM96+_V5J=E]JBFEVWEOY9A\ MN14VR#)VLV[\7X_SJ*I9/^/>+\?YT 14444 % M%%% !1110 4444 2VW_'POX_RJ*I;;_CX7\?Y5%0 4444 %%%% !1110 444 M4 %%%% !1110 5>MO^/=?Q_G5&KUM_Q[K^/\Z ):*** "H+O_4C_ 'JGJ"[_ M -2/]Z@"G1110 45YI\=_%&K^%OAPUQH,DD$]UA0AB2#V)P!GMGU MQ7D^@?!A_%&E1^(-$^(UO>:V\0E,<0)D23;]QI/,WJ<<9*_A23O=]$-JUO,^ MHZ*X7X7IXSM_!,EG\0;=H[^V9DAF>>.5YHMO!8HQY!R,GD\5\\?#/X/_ /"R M[;5+K^W/[,^QW CV_9/.WY!.<[UQ5->\TO42^'F?>W]?50B1BOS1Y8*XP#D'./K3?VAKB]L_C)IUUI9D6[M]/ MBFB:($LI5Y&S^&,TM+1?1NWW!9W:ZI7^\^I**\X/C"V\KT45Y?\ M&CQQ=:)H\?ASPV&F\0:PC+&D1^:&'!WR>QP" ?J>U1)V1<5=GJ%%>*_LP?\ M)/-3_P"PFW_HN.K_ ,4?FM[95)=O8D CZ GT MJZGN?UY7)A[QZW17C_[-[,GPDG9%W,M],0H[G:O%<'X+\'1_&,:]KWC?Q'?P M7]E&O#&H:S= M*6BL8&F*@X+$#A?Q.!^-?.VA>"?&'QX@N/$/B+Q&=/TUIBMM (S*@*_W(]R@ M 9QN)R>:2NW9=!Z)79].T5X/X+\)_$7X:?$.UTFUEGU[PO.%$L@.V.%#D;@K MM\C*>2%)R/7MS?[2CW4?Q+T.33_,^U1V*O$8@2P82N01COQ3;2Y>S!)OF\D? M3E%>?>&O&L/COX-W>JJRBZ6QFBO(P?N2K&<\=@>H]C7(_L]74MC\&=9N[>(S M2P7<\B1C^-EB0@?CBF_=,+G1]7EDU7PLT9$-Z]PA" M, "I5"Y=1U4KC'>FHO9Z";['L-%%%2,**** "BBB@ HHHH **** "BBB@ J6 MY_X^&_#^515+<_\ 'PWX?RH BHHI&^Z: ,K4M=BTZ0*Z%L]P:I?\)?;_ //) MOS_^M63XC.;@_P"__2L2OA3?G_ M /6H_P"$OM_^>3?G_P#6KCJ*\[_6''_S+[D5[*)V/_"7V_\ SR;\_P#ZU'_" M7V__ #R;\_\ ZU<=11_K#C_YE]R#V43L?^$OM_\ GDWY_P#UJ/\ A+[?_GDW MY_\ UJXZBC_6''_S+[D'LHG8_P#"7V__ #R;\_\ ZU'_ E]O_SR;\__ *U< M=11_K#C_ .9?<@]E$['_ (2^W_YY-^?_ -:C_A+[?_GDWY__ %JXZBC_ %AQ M_P#,ON0>RB=C_P )?;_\\F_/_P"M1_PE]O\ \\F_/_ZU<=11_K#C_P"9?<@] ME$['_A+[?_GDWY__ %J/^$OM_P#GDWY__6KCJ*/]8\7X_SJ*I9/^/>+\?YT 14444 %%%% !11 M10 4444 2VW_ !\+^/\ *HJEMO\ CX7\?Y5%0 4444 %%%% !1110 4444 % M%%% !1110 5>MO\ CW7\?YU1J];?\>Z_C_.@"6BBB@ J"[_U(_WJGJ"[_P!2 M/]Z@"G1110!P_P 4?%_AWPMX?BB\8Z3=:EINI.8&2")'4$#(W;F7'3((]*\_ MU#]GOPAJVG#6_"'B*XTV%U$\,K2+/!&.#D'(8?4L<'\J]@\4>%]*\8:#-I&N M0>=;2X(*G#1L.C*>Q%>+R?LK61U#?%XJN%L]P_=-9*TFWN-^\#/OM_ U*6K_ M #*;T1K? 'Q=J^MZ9KVBZS?MJ:Z2ZBWO&<&O*/AG\'_\ MA9=MJEU_;G]F?8[@1[?LGG;\@G.=ZXKZ;\%^ ]'\!^'VTO0UDQ*=TT\QW22M MC&3C ^@'%97PO^&O_"M[+4K?^UO[2^W3K+N^S>3LP",?>;/7VJW9R;\E]Y*; M4++O^%F8OP^^ NB^"-8BU>ZOYM6U&#/DN\0BCC)_B"9)SCC)8_3TYOQNJO\ MM7>%D=0RM:("",@C][7O-<'K7PS_ +8^+&E>-?[6\G^SHEC^Q?9MWF8W\[]P MQ]_^Z>E"=YQ;V0K>[)+=H\E\2QR?!W7_ !+HC"3_ (1GQ1I\YLR!E89BC * M/0G;]"I[5UWP0O+W3_V?[V\TJW^TWMO)=26\&QG\R0#*KM7DY.!@)?!!L]+ =[F M==*NHBBJA;[SN5'3'-<%X9^+&AQ:]XB\2^+K?4;O7-4B>WM1;Q1M%:Q%XM;N6]07&IJ45?+*1PJ2I);(8[3VQ[USWA[XH:'##XKU;Q/!J-YXEUZ M"6WCEBAC,-O&R$*H)<,!T!XZ*.M?0GPO^'G_ K?P[?=&X\W[/Y M.W*JN,;FS]WKGO73ZUIW]L:#?Z;YOD_;+:2#S-N[9N4KG&1G&>F:NKK=K72W M]?D%/2R>FM_Z_,\'_9[\>Z=8>%;[PX;:ZDO[9;C42P5?*9%5?ESNSN_#'O67 MX%^'=G\;(M;\6>)M0DM+R6[,4<.G1QQJA"@Y8%3N^\!V)QR:]J^&_@(?#[PD M^AOJ U)7G>8RF#RN& &W;N;T]:XW4?V?TBU&YF\'>+]4\.6EXQ-S9P;F1P?X M1M=..3PV[K1*SE?RM\_ZT(C=1MMK?^OS$_9[\175UI.K^&+I8'309Q%!<01! M!(A+#G'4Y4G/4YYSUKV.N8\"> =(^'VAMIVC"20ROYD]Q,09)6]\ #@ ?X MFNGIR=V"T"I?^73_ ('_ $J*I?\ ET_X'_2I*(J*** "BBB@ HHHH **** " MBBB@ HHHH XWXMZ;/JWPG\06MHI>7[+YBJ!DML8.0/P4URW[.NOZ=>_#.#28 M;B/[=82RB: L ^&M$ @@C(/45XUXN_9MT#7M2DOM#U&70Y)GW MR0K")H>>!VKA/BD ?VD/ P(R"L.1_P!MFKL?AU\%="^']W_:*SRZGJFS M8+F90JQ@]=B#.,^I)/ZU<\4?#/\ X27XD:%XL_M;[-_9 3_1?LV_S=KEOO[Q MMZXZ&J5E.#[.[)E=PFNZLCS'Q%&WP9\>:L%5U\*^*+28*%4E;>?:< >A/\ MWRW^S6O\ -6BT'X*ZSJMS#-/#9WLTTD=NH9V58T)P"0"<>]>G^//!5CX]\*7 M&C7[")F(>"XV;C!(.C 9&>X(R,@FL_X:_#Q/A]X4N-$EU :HD]P\S.UOY0PR MJI4KN;/W?7O2A=1DO*R^^Y4K-Q?G=_<>>6/P]^&?QDM)M=\.?;=&NFE;[1!$ MZ*P;^\T66 !ZC:1G-8W@J35_AC\;;'P1;^(SKFE7:[)81G;"Q#$?)N;8P(!. M#R#S6_XC_9BT74]2DN=!UJ;2(Y'+-;O;B=$SV3YE('7J374?#OX)Z%X OQJ: MW,^IZH$V+<3*$6/(^8H@Z9]R>/QS4+)WV78F5VFMWW/2:***D84444 %%%% M!1110 4444 %%%% !4MS_P ?#?A_*HJEN?\ CX;\/Y4 14C?=-+2-]TT \7X_SH BHHHH **** "BBB@ HH MHH EMO\ CX7\?Y5%4MM_Q\+^/\JBH **** "BBB@ HHHH **** "BBB@ HHH MH *O6W_'NOX_SJC5ZV_X]U_'^= $M%%% !4%W_J1_O5/4%W_ *D?[U %.BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I?^73_@?]*BJ7_E MT_X'_2@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ J6Y_X^&_#^515+<_\ 'PWX?RH MBI#RII:* .6U?3+N:Z9H51E//S*#_.L[^QM0_P">'J2YITTWZ(?,TE&T>E'U#"? M\^H_<@YGW.'_ +&U#_GG#_W[6C^QM0_YYP_]^UKN-H]*-H]*/J&$_P"?4?N0 M\7X_P Z (J*** " MBBB@ HHHH **** );;_CX7\?Y5%4MM_Q\+^/\JBH **** "BBB@ HHHH *** M* "BBB@ HHHH *O6W_'NOX_SJC5ZV_X]U_'^= $M%%% !6)XJULZ#I4=TNE: MGJA>81^3IEMYTBY5CN*Y&%XQGU(K;HIJR>H'F_\ PL>3_H1O&?\ X*/_ +*C M_A8\G_0C>,__ 4?_95Z116O/3_E_$FS[GF__"QY/^A&\9_^"C_[*C_A8\G_ M $(WC/\ \%'_ -E7I%%'/3_E_$+/N>;_ /"QY/\ H1O&?_@H_P#LJ/\ A8\G M_0C>,_\ P4?_ &5>D44<]/\ E_$+/N>;_P#"QY/^A&\9_P#@H_\ LJ/^%CR? M]"-XS_\ !1_]E7I%%'/3_E_$+/N>;_\ "QY/^A&\9_\ @H_^RH_X6/)_T(WC M/_P4?_95Z111ST_Y?Q"S[GF__"QY/^A&\9_^"C_[*C_A8\G_ $(WC/\ \%'_ M -E7I%%'/3_E_$+/N>;_ /"QY/\ H1O&?_@H_P#LJ/\ A8\G_0C>,_\ P4?_ M &5>D44<]/\ E_$+/N>;_P#"QY/^A&\9_P#@H_\ LJ/^%CR?]"-XS_\ !1_] ME7I%%'/3_E_$+/N>;_\ "QY/^A&\9_\ @H_^RH_X6/)_T(WC/_P4?_95Z111 MST_Y?Q"S[GF__"QY/^A&\9_^"C_[*G_\+*?R-G_"#>,\[L_\@CV_WJ]%HHYZ M?\OXA9]SS?\ X6/)_P!"-XS_ /!1_P#94?\ "QY/^A&\9_\ @H_^RKTBBCGI M_P OXA9]SS?_ (6/)_T(WC/_ ,%'_P!E1_PL>3_H1O&?_@H_^RKTBBCGI_R_ MB%GW/-_^%CR?]"-XS_\ !1_]E1_PL>3_ *$;QG_X*/\ [*O2**.>G_+^(6?< M\W_X6/)_T(WC/_P4?_94?\+'D_Z$;QG_ ."C_P"RKTBBCGI_R_B%GW/-_P#A M8\G_ $(WC/\ \%'_ -E1_P +'D_Z$;QG_P""C_[*O2**.>G_ "_B%GW/-_\ MA8\G_0C>,_\ P4?_ &5'_"QY/^A&\9_^"C_[*O2**.>G_+^(6?<\W_X6/)_T M(WC/_P %'_V5'_"QY/\ H1O&?_@H_P#LJ](HHYZ?\OXA9]SS?_A8\G_0C>,_ M_!1_]E1_PL>3_H1O&?\ X*/_ +*O2**.>G_+^(6?<\W_ .%CR?\ 0C>,_P#P M4?\ V5'_ L>3_H1O&?_ (*/_LJ](HHYZ?\ +^(6?<\W_P"%CR?]"-XS_P#! M1_\ 94?\+'D_Z$;QG_X*/_LJ](HHYZ?\OXA9]SS?_A8\G_0C>,__ 4?_94? M\+'D_P"A&\9_^"C_ .RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\%'_V5'_"QY/^ MA&\9_P#@H_\ LJ](HHYZ?\OXA9]SS?\ X6/)_P!"-XS_ /!1_P#94?\ "QY/ M^A&\9_\ @H_^RKTBBCGI_P OXA9]SS?_ (6/)_T(WC/_ ,%'_P!E1_PL>3_H M1O&?_@H_^RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\ !1_]E1_PL>3_ *$;QG_X M*/\ [*O2**.>G_+^(6?<\W_X6/)_T(WC/_P4?_94?\+'D_Z$;QG_ ."C_P"R MKTBBCGI_R_B%GW/-_P#A8\G_ $(WC/\ \%'_ -E3Y?B4\DI8>!O&>#ZZ1_\ M95Z+11ST_P"7\0L^YYO_ ,+'D_Z$;QG_ ."C_P"RH_X6/)_T(WC/_P %'_V5 M>D44<]/^7\0L^YYO_P +'D_Z$;QG_P""C_[*C_A8\G_0C>,__!1_]E7I%%'/ M3_E_$+/N>;_\+'D_Z$;QG_X*/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D44<]/^7\ M0L^YYO\ \+'D_P"A&\9_^"C_ .RH_P"%CR?]"-XS_P#!1_\ 95Z111ST_P"7 M\0L^YYO_ ,+'D_Z$;QG_ ."C_P"RH_X6/)_T(WC/_P %'_V5>D44<]/^7\0L M^YYO_P +'D_Z$;QG_P""C_[*C_A8\G_0C>,__!1_]E7I%%'/3_E_$+/N>;_\ M+'D_Z$;QG_X*/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D44<]/^7\0L^YYO\ \+'D M_P"A&\9_^"C_ .RH_P"%CR?]"-XS_P#!1_\ 95Z111ST_P"7\0L^YYO_ ,+' MD_Z$;QG_ ."C_P"RH_X6/)_T(WC/_P %'_V5>D44<]/^7\0L^YYO_P +'D_Z M$;QG_P""C_[*C_A8\G_0C>,__!1_]E7I%%'/3_E_$+/N>;_\+'D_Z$;QG_X* M/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D44<]/^7\0L^YYU'\2G3?GP-XS^92!_Q* M/_LJ9_PL>3_H1O&?_@H_^RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\ !1_]E1_P ML>3_ *$;QG_X*/\ [*O2**.>G_+^(6?<\W_X6/)_T(WC/_P4?_94?\+'D_Z$ M;QG_ ."C_P"RKTBBCGI_R_B%GW/-_P#A8\G_ $(WC/\ \%'_ -E1_P +'D_Z M$;QG_P""C_[*O2**.>G_ "_B%GW/-_\ A8\G_0C>,_\ P4?_ &5'_"QY/^A& M\9_^"C_[*O2**.>G_+^(6?<\W_X6/)_T(WC/_P %'_V5'_"QY/\ H1O&?_@H M_P#LJ](HHYZ?\OXA9]SS?_A8\G_0C>,__!1_]E1_PL>3_H1O&?\ X*/_ +*O M2**.>G_+^(6?<\W_ .%CR?\ 0C>,_P#P4?\ V5'_ L>3_H1O&?_ (*/_LJ] M(HHYZ?\ +^(6?<\W_P"%CR?]"-XS_P#!1_\ 94?\+'D_Z$;QG_X*/_LJ](HH MYZ?\OXA9]SS?_A8\G_0C>,__ 4?_94?\+'D_P"A&\9_^"C_ .RKTBBCGI_R M_B%GW/.H_B4Z;\^!O&?S*0/^)1_]E3/^%CR?]"-XS_\ !1_]E7I%%'/3_E_$ M+/N>;_\ "QY/^A&\9_\ @H_^RH_X6/)_T(WC/_P4?_95Z111ST_Y?Q"S[GF_ M_"QY/^A&\9_^"C_[*C_A8\G_ $(WC/\ \%'_ -E7I%%'/3_E_$+/N>;_ /"Q MY/\ H1O&?_@H_P#LJ/\ A8\G_0C>,_\ P4?_ &5>D44<]/\ E_$+/N>;_P#" MQY/^A&\9_P#@H_\ LJ/^%CR?]"-XS_\ !1_]E7I%%'/3_E_$+/N>;_\ "QY/ M^A&\9_\ @H_^RH_X6/)_T(WC/_P4?_95Z111ST_Y?Q"S[GF__"QY/^A&\9_^ M"C_[*C_A8\G_ $(WC/\ \%'_ -E7I%%'/3_E_$+/N>;_ /"QY/\ H1O&?_@H M_P#LJ/\ A8\G_0C>,_\ P4?_ &5>D44<]/\ E_$+/N>;_P#"QY/^A&\9_P#@ MH_\ LJ/^%CR?]"-XS_\ !1_]E7I%%'/3_E_$+/N>=1?$IXY0Q\#>,\#TTC_[ M*F?\+'D_Z$;QG_X*/_LJ](HHYZ?\OXA9]SS?_A8\G_0C>,__ 4?_94?\+'D M_P"A&\9_^"C_ .RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\%'_V5'_"QY/^A&\9 M_P#@H_\ LJ](HHYZ?\OXA9]SS?\ X6/)_P!"-XS_ /!1_P#94?\ "QY/^A&\ M9_\ @H_^RKTBBCGI_P OXA9]SS?_ (6/)_T(WC/_ ,%'_P!E1_PL>3_H1O&? M_@H_^RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\ !1_]E1_PL>3_ *$;QG_X*/\ M[*O2**.>G_+^(6?<\W_X6/)_T(WC/_P4?_94?\+'D_Z$;QG_ ."C_P"RKTBB MCGI_R_B%GW/-_P#A8\G_ $(WC/\ \%'_ -E1_P +'D_Z$;QG_P""C_[*O2** M.>G_ "_B%GW/-_\ A8\G_0C>,_\ P4?_ &5/_P"%E/Y&S_A!O&>=V?\ D$>W M^]7HM%'/3_E_$+/N>;_\+'D_Z$;QG_X*/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D M44<]/^7\0L^YYO\ \+'D_P"A&\9_^"C_ .RH_P"%CR?]"-XS_P#!1_\ 95Z1 M11ST_P"7\0L^YYO_ ,+'D_Z$;QG_ ."C_P"RH_X6/)_T(WC/_P %'_V5>D44 M<]/^7\0L^YYO_P +'D_Z$;QG_P""C_[*C_A8\G_0C>,__!1_]E7I%%'/3_E_ M$+/N>;_\+'D_Z$;QG_X*/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D44<]/^7\0L^Y MYO\ \+'D_P"A&\9_^"C_ .RH_P"%CR?]"-XS_P#!1_\ 95Z111ST_P"7\0L^ MYYO_ ,+'D_Z$;QG_ ."C_P"RH_X6/)_T(WC/_P %'_V5>D44<]/^7\0L^YYO M_P +'D_Z$;QG_P""C_[*GM\2G:)%'@;QGED44<]/^7\0L^YYO M_P +'D_Z$;QG_P""C_[*C_A8\G_0C>,__!1_]E7I%%'/3_E_$+/N>;_\+'D_ MZ$;QG_X*/_LJ/^%CR?\ 0C>,_P#P4?\ V5>D44<]/^7\0L^YYO\ \+'D_P"A M&\9_^"C_ .RH_P"%CR?]"-XS_P#!1_\ 95Z111ST_P"7\0L^YYU%\2GCE#'P M-XSP/32/_LJ9_P +'D_Z$;QG_P""C_[*O2**.>G_ "_B%GW/-_\ A8\G_0C> M,_\ P4?_ &5'_"QY/^A&\9_^"C_[*O2**.>G_+^(6?<\W_X6/)_T(WC/_P % M'_V5'_"QY/\ H1O&?_@H_P#LJ](HHYZ?\OXA9]SS?_A8\G_0C>,__!1_]E1_ MPL>3_H1O&?\ X*/_ +*O2**.>G_+^(6?<\W_ .%CR?\ 0C>,_P#P4?\ V5'_ M L>3_H1O&?_ (*/_LJ](HHYZ?\ +^(6?<\W_P"%CR?]"-XS_P#!1_\ 94?\ M+'D_Z$;QG_X*/_LJ](HHYZ?\OXA9]SS?_A8\G_0C>,__ 4?_94?\+'D_P"A M&\9_^"C_ .RKTBBCGI_R_B%GW/-_^%CR?]"-XS_\%'_V5;_A;QB=?O&LCX;\ M0:48XC+Y^IV'DQ-A@-H;<@/I74T4G*#6D?Q'9A11160PHHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB @@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D! end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-35518  
Entity Registrant Name SUPERNUS PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-2590184  
Entity Address, Address Line One 9715 Key West Avenue  
Entity Address, City or Town Rockville  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20850  
City Area Code 301  
Local Phone Number 838-2500  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Entity Common Stock, Shares Outstanding   54,974,254
Trading Symbol SUPN  
Security Exchange Name NASDAQ  
Entity Central Index Key 0001356576  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 63,401 $ 75,054
Marketable securities 234,335 179,820
Accounts receivable, net 147,734 144,155
Inventories, net 75,079 77,408
Prepaid expenses and other current assets 23,772 16,676
Total current assets 544,321 493,113
Long-term marketable securities 11,662 16,617
Property and equipment, net 12,969 13,530
Intangible assets, net 579,752 599,889
Goodwill 117,019 117,019
Other assets 38,367 37,505
Total assets 1,304,090 1,277,673
Current liabilities    
Accounts payable and accrued liabilities 86,402 79,569
Accrued product returns and rebates 167,226 154,274
Contingent consideration, current portion 51,379 52,070
Other current liabilities 9,547 4,283
Total current liabilities 314,554 290,196
Contingent consideration, long-term 976 1,380
Operating lease liabilities, long-term 32,994 33,196
Deferred income tax liabilities, net 19,501 24,963
Other liabilities 6,899 6,422
Total liabilities 374,924 356,157
Commitments and contingencies (Note 15)
Stockholders’ equity    
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,965,316 and 54,723,356 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 55 55
Additional paid-in capital 446,960 439,493
Accumulated other comprehensive loss, net of tax (534) (593)
Retained earnings 482,685 482,561
Total stockholders’ equity 929,166 921,516
Total liabilities and stockholders’ equity $ 1,304,090 $ 1,277,673
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Stockholders’ equity    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock shares authorized (in shares) 130,000,000 130,000,000
Common stock shares issued (in shares) 54,965,316 54,965,316
Common stock shares outstanding (in shares) 54,723,356 54,723,356
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Earnings - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues    
Total revenues $ 143,644 $ 153,764
Costs and expenses    
Cost of goods sold [1] 16,309 23,460
Research and development 24,930 21,212
Selling, general and administrative 86,516 85,597
Amortization of intangible assets 20,137 19,966
Contingent consideration gain (1,095) (1,647)
Total costs and expenses 146,797 148,588
Operating earnings (loss) (3,153) 5,176
Other income (expense)    
Interest and other income, net 3,396 5,346
Interest expense 0 (1,505)
Total other income (expense) 3,396 3,841
Earnings before income taxes 243 9,017
Income tax expense (benefit) 119 (7,931)
Net earnings $ 124 $ 16,948
Earnings per share    
Basic (in dollars per share) $ 0.00 $ 0.31
Diluted (in dollars per share) $ 0.00 $ 0.29
Weighted average shares outstanding    
Basic (in shares) 54,801,748 54,380,947
Diluted (in shares) 55,626,663 62,454,204
Net product sales    
Revenues    
Total revenues $ 138,461 $ 140,575
Royalty and licensing revenues    
Revenues    
Total revenues $ 5,183 $ 13,189
[1] Excludes amortization of acquired intangible assets
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Comprehensive Earnings - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net earnings $ 124 $ 16,948
Other comprehensive gain    
Unrealized gain on marketable securities, net of tax 59 881
Other comprehensive gain 59 881
Comprehensive earnings $ 183 $ 17,829
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Changes in Stockholder's Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional  Paid-in Capital
Accumulated Other Comprehensive Earnings (Loss)
Retained Earnings
Balance (in shares) at Dec. 31, 2022   54,253,796      
Balance at Dec. 31, 2022 $ 886,204 $ 54 $ 408,115 $ (3,210) $ 481,245
Increase (Decrease) in Stockholders' Equity          
Share-based compensation expense related to employee stock purchase plan and share-based awards 6,306   6,306    
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld (in shares)   216,826      
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld 1,811   1,811    
Net earnings 16,948       16,948
Unrealized gain on marketable securities, net of tax 881     881  
Balance (in shares) at Mar. 31, 2023   54,470,622      
Balance at Mar. 31, 2023 $ 912,150 $ 54 416,232 (2,329) 498,193
Balance (in shares) at Dec. 31, 2023 54,723,356 54,723,356      
Balance at Dec. 31, 2023 $ 921,516 $ 55 439,493 (593) 482,561
Increase (Decrease) in Stockholders' Equity          
Share-based compensation expense related to employee stock purchase plan and share-based awards 5,897   5,897    
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld (in shares)   241,960      
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld 1,570   1,570    
Net earnings 124       124
Unrealized gain on marketable securities, net of tax $ 59     59  
Balance (in shares) at Mar. 31, 2024 54,723,356 54,965,316      
Balance at Mar. 31, 2024 $ 929,166 $ 55 $ 446,960 $ (534) $ 482,685
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities    
Net earnings $ 124 $ 16,948
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization 20,749 20,601
Amortization of deferred financing costs and debt discount 0 532
Amortization of premium/discount on marketable securities 1,894 (1,056)
Change in fair value of contingent consideration (1,095) (1,647)
Other noncash adjustments, net 2,449 2,459
Share-based compensation expense 5,897 6,306
Deferred income tax benefit (5,482) (435)
Changes in operating assets and liabilities:    
Accounts receivable (3,579) 21,971
Inventories 1,990 (1,851)
Prepaid expenses and other assets (7,517) (341)
Accrued product returns and rebates 12,952 (3,813)
Accounts payable and other liabilities 10,019 (10,548)
Net cash provided by operating activities 38,401 49,126
Cash flows from investing activities    
Purchases of marketable securities (193,700) 0
Sales and maturities of marketable securities 142,324 240,058
Purchases of property and equipment (248) (278)
Net cash provided by (used in) investing activities (51,624) 239,780
Cash flows from financing activities    
Proceeds from Credit Line 0 93,000
Payments on Credit Line 0 (14,637)
Proceeds from issuance of common stock 2,910 2,256
Employee taxes paid related to net share settlement of equity awards (1,340) (445)
Net cash provided by financing activities 1,570 80,174
Net change in cash, cash equivalents, and restricted cash (11,653) 369,080
Cash and cash equivalents at beginning of year 75,054 93,120
Cash, cash equivalents, and restricted cash at end of period 63,401 462,200
Supplemental cash flow information    
Cash paid for income taxes 336 203
Cash paid for operating leases 4,002 3,457
Noncash operating and investing activities    
Lease assets obtained for new operating leases $ 2,604 $ 2,601
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Organization
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization Business Organization
Supernus Pharmaceuticals, Inc. (the "Company", see Note 2, Consolidation) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
The Company has eight commercial products that it markets: Qelbree®, GOCOVRI®, Oxtellar XR®, Trokendi XR®, APOKYN®, XADAGO®, MYOBLOC®, and Osmolex ER®. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("OFF" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.
In December 2023, the Company submitted to the U.S. Food and Drug Administration (FDA) a notification of discontinuance to withdraw Osmolex ER from distribution, stating that manufacturing has been discontinued and distribution of the product will cease by April 1, 2024.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC.
In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Reclassifications
The prior year amount related to the caption Employee taxes paid related to net share settlement of equity awards in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.
Consolidation
The Company's unaudited condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation.
The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including
the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred.
The Company incurred approximately $24.3 million and $25.9 million in advertising expense for the three months ended March 31, 2024 and 2023, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the unaudited condensed consolidated statements of earnings.
Restricted Cash
The Company had a restricted cash balance of $403.8 million as of March 31, 2023 which was held in an escrow account with Wilmington Trust, Trustee, in connection with the payoff of the 0.625% Convertible Senior Notes Due 2023 (2023 Notes) which occurred on April 1, 2023.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
Three Months Ended
March 31, 2023
End of periodBeginning of period
(unaudited)
Cash and cash equivalents$58,442 $93,120 
Restricted cash403,758—
Total cash, cash equivalents, and restricted cash per statements of cash flows$462,200 $93,120 
Recently Issued Accounting Pronouncements and Disclosure Rules
New Accounting Pronouncements Not Yet Adopted
Accounting Standards Update (ASU) 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) - The new standard, issued in November 2023, improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also clarifies that entities with a single reportable segment are subject to both new and existing reporting requirements under Topic 280. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2024. We expect ASU 2023-07 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) - The new standard, issued in December 2023, requires entities to disclose additional information with respect to the effective tax rate reconciliation and to disclose the disaggregation by jurisdiction of income tax expense and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31,
2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
SEC Final Climate Rule
In March 2024, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (Final Rule). This rule will require registrants to disclose certain climate-related information in registration statements and annual reports with staggered compliance dates for large accelerated filers for the fiscal year beginning 2025 through 2033 for the various aspects of the Final Rule. On April 4, 2024, the SEC issued an order staying the Final Rule. The SEC’s administrative stay is expected to remain in place until the completion of litigation filed in various federal courts challenging, among other things, the agency’s authority to adopt the Final Rule. The Company is currently evaluating the final rule to determine its impact on the Company's disclosures.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Disaggregated Revenues
 3 Months Ended
Mar. 31, 2024
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Net product sales
Qelbree$45,104 $25,782 
Oxtellar XR26,943 28,915 
GOCOVRI26,562 26,010 
APOKYN16,649 17,209 
Trokendi XR15,989 34,790 
Other(1)
7,214 7,869 
Total net product sales$138,461 $140,575 
Royalty and licensing revenues5,183 13,189 
Total revenues$143,644 $153,764 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
The Company recognized noncash royalty revenue of $2.3 million for the three months ended March 31, 2023. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023.
The following table shows the percentage of net product sales to total net product sales:

Percentage of Net Product Sales
Three Months Ended March 31,
20242023
(unaudited)
Qelbree33%18%
Oxtellar XR19%21%
GOCOVRI19%18%
APOKYN12%12%
Trokendi XR12%25%
Other(1)
5%6%
Total100%100%
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Each of our three major customers, Cencora, Inc., Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total gross product sales and collectively accounted for more than 70% of our total gross product sales for the three months ended March 31, 2024 and 2023.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2024December 31, 2023
(unaudited)
Corporate, U.S. government agency and municipal debt securities
Amortized cost$246,635 $197,153 
Gross unrealized gains1 5 
Gross unrealized losses(639)(721)
Total fair value$245,997 $196,437 
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2024
(unaudited)
Less than 1 year$234,335 
1 year to 2 years11,662 
Total$245,997 
As of March 31, 2024, there was no impairment due to credit loss on any available-for-sale marketable securities.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value of Financial Measurements Fair Value of Financial Measurements
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
Financial Assets and Liabilities Recorded at Fair Value
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2024 (unaudited)
Total Fair Value as of March 31, 2024
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$14,272 $14,272 $— $— 
Money market funds49,129 49,129 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities234,335 3,950 230,385 — 
Long-term marketable securities
Corporate and municipal debt securities11,662 — 11,662 — 
Other noncurrent assets
Marketable securities - restricted (SERP)612 17 595 — 
Total assets at fair value$310,010 $67,368 $242,642 $— 
Liabilities:
Contingent consideration$52,355 $— $— $52,355 
Total liabilities at fair value$52,355 $— $— $52,355 
Fair Value Measurements as of December 31, 2023
Total Fair Value as of December 31, 2023
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$35,957 $35,957 $— $— 
Money market funds39,097 39,097 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities179,820 — 179,820 — 
Long-term marketable securities
Corporate and municipal debt securities16,617 — 16,617 — 
Other noncurrent assets
Marketable securities - restricted (SERP)568 16 552 — 
Total assets at fair value$272,059 $75,070 $196,989 $— 
Liabilities:
Contingent consideration$53,450 $— $— $53,450 
Total liabilities at fair value$53,450 $— $— $53,450 
The fair value of restricted marketable securities is recorded in Other assets on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, accrued expenses, and line of credit approximate fair value due to their short-term maturities.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingent Consideration
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Contingent Consideration Contingent Consideration
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):
March 31,
2024		December 31,
2023
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$51,379 $52,070 
Contingent consideration, long-term976 1,380 
Total$52,355 $53,450 
The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020 and the Adamas Acquisition in 2021. The contingent consideration liabilities are measured at fair value using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration (gain) expense.
USWM Contingent Consideration
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments for regulatory and development milestones and sales-based milestones. As of March 31, 2024, the remaining potential contingent consideration payments are up to $55 million in regulatory and development milestones comprised of (1) $25 million related to the FDA's approval of the SPN-830 NDA and (2) $30 million related to the subsequent commercial product launch.
The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, timing of projected revenues, and the discount rate.
Adamas Contingent Consideration
On November 24, 2021 (the Adamas Closing Date), the Company completed its acquisition of all the outstanding equity of Adamas (Adamas Acquisition). The Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, as further defined in the CVR agreement. One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated revenue projections, volatility, estimated discount rates and risk-free interest rate.
Change in the Fair Value of Contingent Consideration
The following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2023$46,400 $7,050 $53,450 
Change in fair value recognized in earnings680 (1,775)(1,095)
Balance at March 31, 2024 (unaudited)$47,080 $5,275 $52,355 
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2022$46,270 $8,697 $54,967 
Change in fair value recognized in earnings(1,710)63 (1,647)
Balance at March 31, 2023 (unaudited)$44,560 $8,760 $53,320 
The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:
•The Company recorded a $0.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2024. The change in fair value of contingent consideration for the USWM milestones was primarily due to passage of time.
•The Company recorded a $1.7 million gain due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2023. The change in the fair value of contingent consideration for the USWM milestones was primarily due to the change in timing of the regulatory and developmental milestone achievement and estimated discount rates.
The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:
•The Company recorded a $1.8 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2024. The change in fair value of contingent consideration was primarily due to passage of time.
•The Company recorded a $0.1 million expense due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2023. The change in fair value was primarily due to the passage of time and estimated discount rates.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net Intangibles Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2024		December 31,
2023
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights6.61661,311 (208,667)452,644 661,311 (190,395)470,916 
Capitalized patent defense costs0.4243,820 (40,712)3,108 43,820 (38,847)4,973 
Total intangible assets6.57$829,131 $(249,379)$579,752 $829,131 $(229,242)$599,889 
Amortization expense for intangible assets was $20.1 million and $20.0 million, for the three month periods ended March 31, 2024 and 2023, respectively.
U.S. patents covering Trokendi XR and Oxtellar XR will expire no earlier than 2027. The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market on January 1, 2023. The Company entered into settlement and license agreements that allows a third party to enter the Oxtellar XR market in September 2024, or sooner under certain conditions.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
Uncommitted Demand Secured Line of Credit
On February 8, 2023, the Company entered into a credit line agreement with UBS (the "Credit Line"). The Credit Line provides for a revolving line of credit of up to $150 million, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of (i) the UBS Fixed Funding Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of (i) the UBS Variable Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line.
The Credit Line is secured by a first priority lien and security interest in certain of the Company’s assets, including each account of the Company at UBS Financial Services Inc. (the “Collateral Account”), and other such collateral (collectively, the Collateral), as further defined in the Credit Line. The Company may be required to post additional collateral if the value of the Collateral declines below the required collateral maintenance requirements.
Upon certain customary events of default, all amounts due under the Credit Line will become immediately due and payable without demand, and UBS has the right, in its discretion, to liquidate, transfer, withdraw or sell all or any part of the Collateral and apply the proceeds to repay any borrowings pursuant to the Credit Line.
The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.
On March 30, 2023, the Company borrowed $93.0 million under the Credit Line, which bore a variable interest rate. The funds from this borrowing were used to repay outstanding indebtedness under the 2023 Notes. In the second quarter of 2023, the Company repaid the total principal balance of $93.0 million under the Credit Line and the interest incurred on the Credit Line of $0.7 million. As of March 31, 2024, there was no outstanding debt under the Credit Line.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Research and development$1,365 $958 
Selling, general and administrative4,532 5,348 
Total$5,897 $6,306 
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20236,583,822 $29.20 5.90
Granted 1,107,662 $27.94 
Exercised (154,567)$18.83 
Forfeited (71,499)$25.31 
Outstanding, March 31, 2024 (unaudited)7,465,418 $29.26 6.37
As of March 31, 2024 (unaudited):
Vested and expected to vest7,465,418 $29.26 6.37
Exercisable 4,715,920 $27.82 4.84
As of December 31, 2023:
Vested and expected to vest6,583,822 $29.20 5.90
Exercisable4,110,537 $26.58 4.43
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023300,141 $36.90 
Granted193,914 $27.94 
Vested(95,397)$36.87 
Forfeited(1,750)$35.86 
Nonvested, March 31, 2024396,908 $32.54 
Performance Share Units
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023251,630 $32.22 20,000 $28.63 271,630 $31.96 
Vested(39,080)$33.47 — $— (39,080)$33.47 
Forfeited(52,000)$28.93 — $— (52,000)$28.93 
Nonvested, March 31, 2024160,550$32.98 20,000$28.63 180,550$32.51 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2024 and 2023 (dollars in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
(unaudited)
Numerator:
Net earnings $124 $16,948 
After-tax interest expense for 2023 Notes— 892 
Numerator for dilutive earnings per share$124 $17,840 
Denominator:
Weighted average shares outstanding, basic54,801,748 54,380,947 
Effect of dilutive securities:
Stock options, RSUs and SARs824,915 1,289,321 
Convertible notes— 6,783,936 
Weighted average shares outstanding, diluted55,626,663 62,454,204 
Earnings per share, basic$0.00 $0.31 
Earnings per share, diluted$0.00 $0.29 
The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted EPS because their inclusion would be anti-dilutive:
Three Months Ended
March 31,
20242023
(unaudited)
Stock options, RSUs, PSUs520,152 240,398 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Tax Expense (Benefit)
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Tax Expense (Benefit) Income Tax Expense (Benefit)
The following table provides information regarding the Company’s income tax expense (benefit) for the three months ended March 31, 2024 and 2023 (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Income tax expense (benefit)
$119 $(7,931)
Effective tax rate49.0 %(88.0)%
Income tax expense was $0.1 million for the three months ended March 31, 2024, as compared to an income tax benefit of $7.9 million for the three months ended March 31, 2023. The change was primarily due to almost break-even pre-tax income for the three months ended March 31, 2024 and greater full year 2024 forecasted losses as compared to the same period in 2023. The effective tax rate for the three months ended March 31, 2024 was higher compared to the same period in 2023 primarily due to near break-even pre-tax losses forecasted for the full year 2023. The annual forecasted earnings represent the Company's best estimate as of March 31, 2024 and 2023, are subject to change and could have a material impact on the effective tax rate in subsequent periods. Accounting Standard Codification (ASC) 740, Income Taxes (ASC 740), requires the Company to estimate the annual effective income tax rate for the full year and apply it to pre-tax income (loss) for each interim period, taking into account year-to-date amounts and projected results for the full year.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases Leases
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2024December 31, 2023
(unaudited)
Assets
Operating lease assetsOther assets$29,748 $28,994 
Total lease assets$29,748 $28,994 
Liabilities
Operating lease liabilities, current portionAccounts payable and accrued liabilities$9,133 $8,331 
Operating lease liabilities, long-termOperating lease liabilities, long-term32,994 33,196 
Total lease liabilities$42,127 $41,527 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Other Balance Sheet Items Composition of Other Balance Sheet Items
The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of March 31, 2024 and December 31, 2023, the Company has reduced accounts receivable by approximately $12.0 million and $10.7 million, respectively for prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues and represent estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
Inventories, Net
March 31,
2024		December 31,
2023
(unaudited)
Raw materials$18,803 $16,274 
Work in process23,246 31,212 
Finished goods33,030 29,922 
Total$75,079 $77,408 
Property and Equipment, Net
March 31,
2024		December 31,
2023
(unaudited)
Lab equipment and furniture$13,120 $13,069 
Leasehold improvements14,023 14,023 
Software883 883 
Computer equipment960 960 
28,986 28,935 
Less accumulated depreciation and amortization(16,017)(15,405)
Property and equipment, net$12,969 $13,530 
Depreciation and amortization expense on property and equipment was approximately $0.6 million and $0.6 million for the three months ended March 31, 2024, and 2023, respectively.
Accounts Payable and Accrued Liabilities
March 31,
2024		December 31,
2023
(unaudited)
Accounts payable$14,397 $1,964 
Accrued compensation, benefits, & related accruals16,444 20,722 
Accrued sales & marketing13,263 11,666 
Accrued manufacturing expenses9,118 11,652 
Accrued R&D expenses9,092 10,530 
Operating lease liabilities, current portion (2)
9,133 8,331 
Accrued royalties (1)
6,963 7,918 
Other accrued expenses7,992 6,786 
Total$86,402 $79,569 
_______________________________
(1) Refer to Note 15, Commitments and Contingencies.
(2) Refer to Note 12, Leases.
Accrued Product Returns and Rebates
March 31,
2024		December 31,
2023
(unaudited)
Accrued product rebates$107,681 $96,984 
Accrued product returns59,545 57,290 
Total$167,226 $154,274 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Interest Expense
 3 Months Ended
Mar. 31, 2024
Other Income and Expenses [Abstract]  
Interest Expense Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Interest expense$— $(656)
Interest expense on nonrecourse liability related to sale of future royalties— (317)
Noncash interest expense on debt— (532)
Total$— $(1,505)

Noncash interest expense on debt is related to amortization of deferred financing costs on the 2023 Notes. The Company fully amortized the deferred financing costs on the 2023 Notes in the first quarter of 2023.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
USWM Enterprise Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply.
MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services which was effective in April 2019. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit which was denied on November 3, 2022. On December 23, 2022, the defendants filed renewed motions to dismiss directed to the remaining unresolved issue. On March 20, 2023, the District Court entered an order and final judgement dismissing with prejudice the FCA claim while declining to exercise supplemental jurisdiction over the state false claims act claims which were dismissed without prejudice. On April 19, 2023, the plaintiff appealed the District Court's dismissal of the Federal False Claims Act claim. On February 20, 2024, the plaintiff filed a motion for an indicative ruling and to set aside the judgment in the District Court, based on the same arguments raised in his appeal. That motion was fully briefed and the District Court determined that the motion for an indicative ruling was suitable for determination without a hearing. On May 7, 2024, the District Court denied the plaintiff’s motion for an indicative ruling. The plaintiff’s appeal remains pending in the United States Court of Appeals for the Ninth Circuit.
APOKYN Litigation
On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No.22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. On January 10, 2023, the Company filed motions to dismiss all claims and the lawsuit in its entirety. As of April 12, 2023, briefing on those motions is now complete. Those motions remain pending. On April 10, 2023, the Court issued a scheduling order that provides for a Pretrial Conference on March 7, 2025, and a jury trial beginning on March 24, 2025. Pretrial discovery is ongoing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
SPN-830 Regulatory Development
In April 2024, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for SPN-830. The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA. The first area relates to product quality. Prior to the issuance of the CRL, the Company submitted additional product quality data to the FDA, which it had not yet reviewed at the time of the CRL's issuance. The second relates to the master file for the infusion device, which is proprietary to the device manufacturer. No clinical safety or efficacy issues were identified as a requirement for approval.
The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we may identify indicators of impairment for the related IPR&D asset, which represents an estimate of the fair value of SPN-830, resulting from the receipt of the CRL. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration liabilities related to the milestone payments due upon the achievement of certain FDA regulatory approvals and the commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, any potential adjustments would be recognized and reported within the second quarter of 2024. Any material adjustments to the fair value of the IPR&D asset or the fair value of contingent consideration liabilities could impact the Company’s results of operations and financial condition.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net earnings $ 124 $ 16,948
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC.
In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Reclassifications
Reclassifications
The prior year amount related to the caption Employee taxes paid related to net share settlement of equity awards in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.
Consolidation
Consolidation
The Company's unaudited condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation.
The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including
the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
Advertising Expense
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred.
Recently Issued Accounting Pronouncements and Disclosure Rules
Recently Issued Accounting Pronouncements and Disclosure Rules
New Accounting Pronouncements Not Yet Adopted
Accounting Standards Update (ASU) 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) - The new standard, issued in November 2023, improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also clarifies that entities with a single reportable segment are subject to both new and existing reporting requirements under Topic 280. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2024. We expect ASU 2023-07 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) - The new standard, issued in December 2023, requires entities to disclose additional information with respect to the effective tax rate reconciliation and to disclose the disaggregation by jurisdiction of income tax expense and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31,
2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
Three Months Ended
March 31, 2023
End of periodBeginning of period
(unaudited)
Cash and cash equivalents$58,442 $93,120 
Restricted cash403,758—
Total cash, cash equivalents, and restricted cash per statements of cash flows$462,200 $93,120 
Restrictions on cash and cash equivalents
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
Three Months Ended
March 31, 2023
End of periodBeginning of period
(unaudited)
Cash and cash equivalents$58,442 $93,120 
Restricted cash403,758—
Total cash, cash equivalents, and restricted cash per statements of cash flows$462,200 $93,120 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Disaggregated Revenues (Tables)
 3 Months Ended
Mar. 31, 2024
Disaggregation of Revenue [Abstract]  
Summary of disaggregation of revenues by nature
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Net product sales
Qelbree$45,104 $25,782 
Oxtellar XR26,943 28,915 
GOCOVRI26,562 26,010 
APOKYN16,649 17,209 
Trokendi XR15,989 34,790 
Other(1)
7,214 7,869 
Total net product sales$138,461 $140,575 
Royalty and licensing revenues5,183 13,189 
Total revenues$143,644 $153,764 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
The following table shows the percentage of net product sales to total net product sales:

Percentage of Net Product Sales
Three Months Ended March 31,
20242023
(unaudited)
Qelbree33%18%
Oxtellar XR19%21%
GOCOVRI19%18%
APOKYN12%12%
Trokendi XR12%25%
Other(1)
5%6%
Total100%100%
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of unrestricted available-for-sale marketable securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2024December 31, 2023
(unaudited)
Corporate, U.S. government agency and municipal debt securities
Amortized cost$246,635 $197,153 
Gross unrealized gains1 5 
Gross unrealized losses(639)(721)
Total fair value$245,997 $196,437 
Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2024
(unaudited)
Less than 1 year$234,335 
1 year to 2 years11,662 
Total$245,997 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of fair value of the financial assets and liabilities
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2024 (unaudited)
Total Fair Value as of March 31, 2024
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$14,272 $14,272 $— $— 
Money market funds49,129 49,129 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities234,335 3,950 230,385 — 
Long-term marketable securities
Corporate and municipal debt securities11,662 — 11,662 — 
Other noncurrent assets
Marketable securities - restricted (SERP)612 17 595 — 
Total assets at fair value$310,010 $67,368 $242,642 $— 
Liabilities:
Contingent consideration$52,355 $— $— $52,355 
Total liabilities at fair value$52,355 $— $— $52,355 
Fair Value Measurements as of December 31, 2023
Total Fair Value as of December 31, 2023
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$35,957 $35,957 $— $— 
Money market funds39,097 39,097 — — 
Marketable securities
Corporate, U.S. government agency and municipal debt securities179,820 — 179,820 — 
Long-term marketable securities
Corporate and municipal debt securities16,617 — 16,617 — 
Other noncurrent assets
Marketable securities - restricted (SERP)568 16 552 — 
Total assets at fair value$272,059 $75,070 $196,989 $— 
Liabilities:
Contingent consideration$53,450 $— $— $53,450 
Total liabilities at fair value$53,450 $— $— $53,450 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingent Consideration (Tables)
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of business acquisitions by acquisition, contingent consideration
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):
March 31,
2024		December 31,
2023
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$51,379 $52,070 
Contingent consideration, long-term976 1,380 
Total$52,355 $53,450 
Reconciliation of the beginning and ending balances related to the contingent consideration
The following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2023$46,400 $7,050 $53,450 
Change in fair value recognized in earnings680 (1,775)(1,095)
Balance at March 31, 2024 (unaudited)$47,080 $5,275 $52,355 
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2022$46,270 $8,697 $54,967 
Change in fair value recognized in earnings(1,710)63 (1,647)
Balance at March 31, 2023 (unaudited)$44,560 $8,760 $53,320 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2024		December 31,
2023
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights6.61661,311 (208,667)452,644 661,311 (190,395)470,916 
Capitalized patent defense costs0.4243,820 (40,712)3,108 43,820 (38,847)4,973 
Total intangible assets6.57$829,131 $(249,379)$579,752 $829,131 $(229,242)$599,889 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense
Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Research and development$1,365 $958 
Selling, general and administrative4,532 5,348 
Total$5,897 $6,306 
Summary of stock options and SAR activities
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20236,583,822 $29.20 5.90
Granted 1,107,662 $27.94 
Exercised (154,567)$18.83 
Forfeited (71,499)$25.31 
Outstanding, March 31, 2024 (unaudited)7,465,418 $29.26 6.37
As of March 31, 2024 (unaudited):
Vested and expected to vest7,465,418 $29.26 6.37
Exercisable 4,715,920 $27.82 4.84
As of December 31, 2023:
Vested and expected to vest6,583,822 $29.20 5.90
Exercisable4,110,537 $26.58 4.43
Summary of restricted stock units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023300,141 $36.90 
Granted193,914 $27.94 
Vested(95,397)$36.87 
Forfeited(1,750)$35.86 
Nonvested, March 31, 2024396,908 $32.54 
Summary of performance stock unit
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 2023251,630 $32.22 20,000 $28.63 271,630 $31.96 
Vested(39,080)$33.47 — $— (39,080)$33.47 
Forfeited(52,000)$28.93 — $— (52,000)$28.93 
Nonvested, March 31, 2024160,550$32.98 20,000$28.63 180,550$32.51 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of computation of basic and diluted earnings per share
The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2024 and 2023 (dollars in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
(unaudited)
Numerator:
Net earnings $124 $16,948 
After-tax interest expense for 2023 Notes— 892 
Numerator for dilutive earnings per share$124 $17,840 
Denominator:
Weighted average shares outstanding, basic54,801,748 54,380,947 
Effect of dilutive securities:
Stock options, RSUs and SARs824,915 1,289,321 
Convertible notes— 6,783,936 
Weighted average shares outstanding, diluted55,626,663 62,454,204 
Earnings per share, basic$0.00 $0.31 
Earnings per share, diluted$0.00 $0.29 
Schedule of common stock equivalents excluded in the calculation of diluted earnings per share
The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted EPS because their inclusion would be anti-dilutive:
Three Months Ended
March 31,
20242023
(unaudited)
Stock options, RSUs, PSUs520,152 240,398 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Tax Expense (Benefit) (Tables)
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation
The following table provides information regarding the Company’s income tax expense (benefit) for the three months ended March 31, 2024 and 2023 (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Income tax expense (benefit)
$119 $(7,931)
Effective tax rate49.0 %(88.0)%
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of balance sheet information related to leases
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2024December 31, 2023
(unaudited)
Assets
Operating lease assetsOther assets$29,748 $28,994 
Total lease assets$29,748 $28,994 
Liabilities
Operating lease liabilities, current portionAccounts payable and accrued liabilities$9,133 $8,331 
Operating lease liabilities, long-termOperating lease liabilities, long-term32,994 33,196 
Total lease liabilities$42,127 $41,527 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories, Net
March 31,
2024		December 31,
2023
(unaudited)
Raw materials$18,803 $16,274 
Work in process23,246 31,212 
Finished goods33,030 29,922 
Total$75,079 $77,408 
Schedule of property and equipment
Property and Equipment, Net
March 31,
2024		December 31,
2023
(unaudited)
Lab equipment and furniture$13,120 $13,069 
Leasehold improvements14,023 14,023 
Software883 883 
Computer equipment960 960 
28,986 28,935 
Less accumulated depreciation and amortization(16,017)(15,405)
Property and equipment, net$12,969 $13,530 
Schedule of accrued expenses and other current liabilities
Accounts Payable and Accrued Liabilities
March 31,
2024		December 31,
2023
(unaudited)
Accounts payable$14,397 $1,964 
Accrued compensation, benefits, & related accruals16,444 20,722 
Accrued sales & marketing13,263 11,666 
Accrued manufacturing expenses9,118 11,652 
Accrued R&D expenses9,092 10,530 
Operating lease liabilities, current portion (2)
9,133 8,331 
Accrued royalties (1)
6,963 7,918 
Other accrued expenses7,992 6,786 
Total$86,402 $79,569 
_______________________________
(1) Refer to Note 15, Commitments and Contingencies.
(2) Refer to Note 12, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
March 31,
2024		December 31,
2023
(unaudited)
Accrued product rebates$107,681 $96,984 
Accrued product returns59,545 57,290 
Total$167,226 $154,274 
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Interest Expense (Tables)
 3 Months Ended
Mar. 31, 2024
Other Income and Expenses [Abstract]  
Schedule of interest expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Interest expense$— $(656)
Interest expense on nonrecourse liability related to sale of future royalties— (317)
Noncash interest expense on debt— (532)
Total$— $(1,505)
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Organization (Details)
 3 Months Ended
Mar. 31, 2024
product
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of commercial products 8
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Basis of Presentation (Details)
 3 Months Ended
Mar. 31, 2024
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Advertising Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accounting Policies [Abstract]    
Advertising costs $ 24.3 $ 25.9
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2018
Notes payable          
Cash and cash equivalents $ 63,401 $ 75,054 $ 58,442 $ 93,120  
Restricted cash     403,758 0  
Total cash, cash equivalents, and restricted cash per statements of cash flows $ 63,401 $ 75,054 $ 462,200 $ 93,120  
Convertible Debt          
Notes payable          
Debt instrument, interest rate, stated percentage         0.625%
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Disaggregated Revenues - Summary of Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenues $ 143,644 $ 153,764
Net product sales    
Disaggregation of Revenue [Line Items]    
Total revenues $ 138,461 $ 140,575
Net product sales | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 100.00% 100.00%
Qelbree    
Disaggregation of Revenue [Line Items]    
Total revenues $ 45,104 $ 25,782
Qelbree | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 33.00% 18.00%
Oxtellar XR    
Disaggregation of Revenue [Line Items]    
Total revenues $ 26,943 $ 28,915
Oxtellar XR | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 19.00% 21.00%
GOCOVRI    
Disaggregation of Revenue [Line Items]    
Total revenues $ 26,562 $ 26,010
GOCOVRI | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 19.00% 18.00%
APOKYN    
Disaggregation of Revenue [Line Items]    
Total revenues $ 16,649 $ 17,209
APOKYN | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 12.00% 12.00%
Trokendi XR    
Disaggregation of Revenue [Line Items]    
Total revenues $ 15,989 $ 34,790
Trokendi XR | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 12.00% 25.00%
Other    
Disaggregation of Revenue [Line Items]    
Total revenues $ 7,214 $ 7,869
Other | Revenue from Contract with Customer Benchmark | Product Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 5.00% 6.00%
Royalty and licensing revenues    
Disaggregation of Revenue [Line Items]    
Total revenues $ 5,183 $ 13,189
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Disaggregated Revenues - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Non-cash royalty revenue   $ 2.3
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | AmerisourceBergen Drug Corporation | Net product sales    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 20.00% 20.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Cardinal Health | Net product sales    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 20.00% 20.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | McKesson | Net product sales    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 20.00% 20.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Three Major Customers | Net product sales    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 70.00% 70.00%
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Unrestricted Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Amortized cost $ 246,635 $ 197,153
Gross unrealized gains 1 5
Gross unrealized losses (639) (721)
Total fair value $ 245,997 $ 196,437
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Contractual Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Less than 1 year $ 234,335  
1 year to 2 years 11,662  
Total $ 245,997 $ 196,437
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
USD ($)
Investments, Debt and Equity Securities [Abstract]  
Impairment due to credit losses $ 0
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Measurements (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Liabilities:    
Contingent consideration $ 52,355 $ 53,450
Recurring    
Other noncurrent assets    
Marketable securities - restricted (SERP) 612 568
Total assets at fair value 310,010 272,059
Liabilities:    
Contingent consideration 52,355 53,450
Total liabilities at fair value 52,355 53,450
Recurring | Corporate, U.S. government agency and municipal debt securities    
Marketable securities    
Corporate, U.S. government agency and municipal debt securities 234,335 179,820
Recurring | Corporate and municipal debt securities    
Long-term marketable securities    
Corporate and municipal debt securities 11,662 16,617
Recurring | Cash    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 14,272 35,957
Recurring | Money market funds    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 49,129 39,097
Recurring | Level 1    
Other noncurrent assets    
Marketable securities - restricted (SERP) 17 16
Total assets at fair value 67,368 75,070
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 1 | Corporate, U.S. government agency and municipal debt securities    
Marketable securities    
Corporate, U.S. government agency and municipal debt securities 3,950 0
Recurring | Level 1 | Corporate and municipal debt securities    
Long-term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 1 | Cash    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 14,272 35,957
Recurring | Level 1 | Money market funds    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 49,129 39,097
Recurring | Level 2    
Other noncurrent assets    
Marketable securities - restricted (SERP) 595 552
Total assets at fair value 242,642 196,989
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 2 | Corporate, U.S. government agency and municipal debt securities    
Marketable securities    
Corporate, U.S. government agency and municipal debt securities 230,385 179,820
Recurring | Level 2 | Corporate and municipal debt securities    
Long-term marketable securities    
Corporate and municipal debt securities 11,662 16,617
Recurring | Level 2 | Cash    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 0 0
Recurring | Level 2 | Money market funds    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 0 0
Recurring | Level 3    
Other noncurrent assets    
Marketable securities - restricted (SERP) 0 0
Total assets at fair value 0 0
Liabilities:    
Contingent consideration 52,355 53,450
Total liabilities at fair value 52,355 53,450
Recurring | Level 3 | Corporate, U.S. government agency and municipal debt securities    
Marketable securities    
Corporate, U.S. government agency and municipal debt securities 0 0
Recurring | Level 3 | Corporate and municipal debt securities    
Long-term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 3 | Cash    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds 0 0
Recurring | Level 3 | Money market funds    
Cash and cash equivalents    
Cash, Restricted Cash and Money market funds $ 0 $ 0
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingent Consideration - Current and Long-Term Contingent Consideration (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]    
Contingent consideration, current portion $ 51,379 $ 52,070
Contingent consideration, long-term 976 1,380
Contingent consideration $ 52,355 $ 53,450
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingent Consideration - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Nov. 24, 2021
USD ($)
right
$ / shares
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Business Acquisition [Line Items]      
Fair value gain (loss) recognized in earnings   $ 1,095 $ 1,647
USWM Acquisition      
Business Acquisition [Line Items]      
Additional cash payments upon milestone achievements maximum   55,000  
Fair value gain (loss) recognized in earnings   (680) 1,710
USWM Acquisition | SPN-830 NDA Approval Milestone      
Business Acquisition [Line Items]      
Additional cash payments upon milestone achievements maximum   25,000  
USWM Acquisition | Subsequent Commercial Product Launch      
Business Acquisition [Line Items]      
Additional cash payments upon milestone achievements maximum   30,000  
Adamas Acquisition      
Business Acquisition [Line Items]      
Additional cash payments upon milestone achievements maximum $ 50,900    
Contingents value rights | right 2    
Contingent consideration arrangements, value (in dollars per share) | $ / shares $ 0.50    
Additional cash payments upon milestone achievements minimum $ 0    
Fair value gain (loss) recognized in earnings   $ 1,775 $ (63)
Adamas Acquisition | The Milestones      
Business Acquisition [Line Items]      
Contingent consideration arrangements, excess acquisition date fair value $ 225,000    
Contingent consideration arrangements, excess acquisition date fair value, term 12 months    
Adamas Acquisition | Milestone 2024      
Business Acquisition [Line Items]      
Contingent consideration arrangements, excess acquisition date fair value $ 150,000    
Contingent consideration arrangements, excess acquisition date fair value, term 12 months    
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period $ 53,450 $ 54,967
Change in fair value recognized in earnings (1,095) (1,647)
Balance at end of period 52,355 53,320
USWM Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period 46,400 46,270
Change in fair value recognized in earnings 680 (1,710)
Balance at end of period 47,080 44,560
Adamas Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period 7,050 8,697
Change in fair value recognized in earnings (1,775) 63
Balance at end of period $ 5,275 $ 8,760
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 6 years 6 months 25 days  
Accumulated Amortization $ (249,379) $ (229,242)
Total intangible assets, carrying amount, gross 829,131 829,131
Intangible assets, net 579,752 599,889
Acquired in-process research and development    
Indefinite-lived Intangible Assets [Line Items]    
Acquired in-process research and development $ 124,000 124,000
Acquired developed technology and product rights    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 6 years 7 months 9 days  
Carrying Amount, Gross $ 661,311 661,311
Accumulated Amortization (208,667) (190,395)
Carrying Amount, Net $ 452,644 470,916
Capitalized patent defense costs    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 5 months 1 day  
Carrying Amount, Gross $ 43,820 43,820
Accumulated Amortization (40,712) (38,847)
Carrying Amount, Net $ 3,108 $ 4,973
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 20,137 $ 19,966
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Mar. 30, 2023
Feb. 08, 2023
Notes payable          
Interest expense $ 0   $ 656,000    
Uncommitted Secured Credit Line | Line of Credit          
Notes payable          
Line of credit facility, maximum borrowing capacity         $ 150,000,000
Debt instrument, face amount       $ 93,000,000  
Revolving Credit Facility | Line of Credit          
Notes payable          
Interest expense   $ 700,000      
Short-term debt $ 0        
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based payments    
Share-based compensation expense $ 5,897 $ 6,306
Research and development    
Share-based payments    
Share-based compensation expense 1,365 958
Selling, general and administrative    
Share-based payments    
Share-based compensation expense $ 4,532 $ 5,348
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments - SAR Activity (Details) - Stock option and Stock Appreciation Rights - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Number of Options    
Outstanding at the beginning of the period (in shares) 6,583,822  
Granted (in shares) 1,107,662  
Exercised (in shares) (154,567)  
Forfeited (in shares) (71,499)  
Outstanding at the end of the period (in shares) 7,465,418 6,583,822
Vested and expected to vest (in shares) 7,465,418 6,583,822
Exercisable (in shares) 4,715,920 4,110,537
Weighted Average Exercise Price    
Outstanding at the beginning of the period (in dollars per share) $ 29.20  
Granted (in dollars per share) 27.94  
Exercised (in dollars per share) 18.83  
Forfeited (in dollars per share) 25.31  
Outstanding at the end of the period (in dollars per share) 29.26 $ 29.20
Vested and expected to vest (in dollars per share) 29.26 29.20
Exercisable (in dollars per share) $ 27.82 $ 26.58
Weighted Average Remaining Contractual Term (in years)    
Outstanding at the end of the period 6 years 4 months 13 days 5 years 10 months 24 days
Vested and expected to vest 6 years 4 months 13 days 5 years 10 months 24 days
Exercisable 4 years 10 months 2 days 4 years 5 months 4 days
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments - Restricted Stock Units (Details) - RSUs
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Number of RSUs  
Nonvested, beginning balance (in shares) | shares 300,141
Granted (in shares) | shares 193,914
Vested (in shares) | shares (95,397)
Forfeited (in shares) | shares (1,750)
Nonvested, ending balance (in shares) | shares 396,908
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 36.90
Granted (in dollars per share) | $ / shares 27.94
Vested (in dollars per share) | $ / shares 36.87
Forfeited (in dollars per share) | $ / shares 35.86
Nonvested, ending balance (in dollars per share) | $ / shares $ 32.54
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments - Performance Stock Units (Details)
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Total PSUs  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 271,630
Vested (in shares) | shares (39,080)
Forfeited (in shares) | shares (52,000)
Nonvested, ending balance (in shares) | shares 180,550
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 31.96
Vested (in dollars per share) | $ / shares 33.47
Forfeited (in dollars per share) | $ / shares 28.93
Nonvested, ending balance (in dollars per share) | $ / shares $ 32.51
Performance-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 251,630
Vested (in shares) | shares (39,080)
Forfeited (in shares) | shares (52,000)
Nonvested, ending balance (in shares) | shares 160,550
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 32.22
Vested (in dollars per share) | $ / shares 33.47
Forfeited (in dollars per share) | $ / shares 28.93
Nonvested, ending balance (in dollars per share) | $ / shares $ 32.98
Market-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 20,000
Vested (in shares) | shares 0
Forfeited (in shares) | shares 0
Nonvested, ending balance (in shares) | shares 20,000
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 28.63
Vested (in dollars per share) | $ / shares 0
Forfeited (in dollars per share) | $ / shares 0
Nonvested, ending balance (in dollars per share) | $ / shares $ 28.63
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net earnings $ 124 $ 16,948
After-tax interest expense for 2023 Notes 0 892
Numerator for dilutive earnings per share $ 124 $ 17,840
Denominator:    
Weighted average shares outstanding, basic (in shares) 54,801,748 54,380,947
Effect of dilutive securities:    
Stock options, RSUs and SARs (in shares) 824,915 1,289,321
Convertible notes (in shares) 0 6,783,936
Weighted average shares outstanding, diluted (in shares) 55,626,663 62,454,204
Earnings per share, basic (in dollars per share) $ 0.00 $ 0.31
Earnings per share, diluted (in dollars per share) $ 0.00 $ 0.29
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock options, RSUs, PSUs    
Income per share    
Common stock equivalents excluded in the calculation of diluted income per share (in shares) 520,152 240,398
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ 119 $ (7,931)
Effective tax rate 49.00% (88.00%)
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Operating lease assets $ 29,748 $ 28,994
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Other assets Other assets
Liabilities    
Operating lease liabilities, current portion $ 9,133 $ 8,331
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Operating lease liabilities, long-term $ 32,994 $ 33,196
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating lease liabilities, long-term Operating lease liabilities, long-term
Total lease liabilities $ 42,127 $ 41,527
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items - Accounts Receivables (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Allowance for expected sales discounts and allowances $ 12.0 $ 10.7
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items - Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 18,803 $ 16,274
Work in process 23,246 31,212
Finished goods 33,030 29,922
Total inventories $ 75,079 $ 77,408
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items - Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Property and equipment      
Property and equipment, gross $ 28,986   $ 28,935
Less accumulated depreciation and amortization (16,017)   (15,405)
Property and equipment, net 12,969   13,530
Depreciation and amortization expense 600 $ 600  
Lab equipment and furniture      
Property and equipment      
Property and equipment, gross 13,120   13,069
Leasehold improvements      
Property and equipment      
Property and equipment, gross 14,023   14,023
Software      
Property and equipment      
Property and equipment, gross 883   883
Computer equipment      
Property and equipment      
Property and equipment, gross $ 960   $ 960
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable $ 14,397 $ 1,964
Accrued compensation, benefits, & related accruals 16,444 20,722
Accrued sales & marketing 13,263 11,666
Accrued manufacturing expenses 9,118 11,652
Accrued R&D expenses 9,092 10,530
Operating lease liabilities, current portion 9,133 8,331
Accrued royalties 6,963 7,918
Other accrued expenses 7,992 6,786
Total $ 86,402 $ 79,569
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued product rebates $ 107,681 $ 96,984
Accrued product returns 59,545 57,290
Total $ 167,226 $ 154,274
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Other Income and Expenses [Abstract]    
Interest expense $ 0 $ (656)
Interest expense on nonrecourse liability related to sale of future royalties 0 (317)
Noncash interest expense on debt 0 (532)
Total $ 0 $ (1,505)
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details)
€ in Millions, $ in Millions
Apr. 01, 2019
USD ($)
Dec. 31, 2023
EUR (€)
NAMENDA XR/Namzaric Qui Tam Litigation    
Long-term Purchase Commitment [Line Items]    
Loss contingency, damages sought, value $ 2,500.0  
USWM Acquisition    
Long-term Purchase Commitment [Line Items]    
Annual minimum purchase quantity requirement amount | €   € 3.9
Litigation settlement $ 17.5  
EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 169 257 1 true 53 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet http://www.supernus.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings Condensed Consolidated Statements of Comprehensive Earnings Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity Condensed Consolidated Statements of Changes in Stockholder's Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Business Organization Sheet http://www.supernus.com/role/BusinessOrganization Business Organization Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Disaggregated Revenues Sheet http://www.supernus.com/role/DisaggregatedRevenues Disaggregated Revenues Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://www.supernus.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value of Financial Measurements Sheet http://www.supernus.com/role/FairValueofFinancialMeasurements Fair Value of Financial Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Contingent Consideration Sheet http://www.supernus.com/role/ContingentConsideration Contingent Consideration Notes 13 false false R14.htm 0000014 - Disclosure - Intangible Assets, Net Sheet http://www.supernus.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://www.supernus.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Share-Based Payments Sheet http://www.supernus.com/role/ShareBasedPayments Share-Based Payments Notes 16 false false R17.htm 0000017 - Disclosure - Earnings per Share Sheet http://www.supernus.com/role/EarningsperShare Earnings per Share Notes 17 false false R18.htm 0000018 - Disclosure - Income Tax Expense (Benefit) Sheet http://www.supernus.com/role/IncomeTaxExpenseBenefit Income Tax Expense (Benefit) Notes 18 false false R19.htm 0000019 - Disclosure - Leases Sheet http://www.supernus.com/role/Leases Leases Notes 19 false false R20.htm 0000020 - Disclosure - Composition of Other Balance Sheet Items Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItems Composition of Other Balance Sheet Items Notes 20 false false R21.htm 0000021 - Disclosure - Interest Expense Sheet http://www.supernus.com/role/InterestExpense Interest Expense Notes 21 false false R22.htm 0000022 - Disclosure - Commitments and Contingencies Sheet http://www.supernus.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Subsequent Events Sheet http://www.supernus.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.supernus.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.supernus.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 9954473 - Disclosure - Disaggregated Revenues (Tables) Sheet http://www.supernus.com/role/DisaggregatedRevenuesTables Disaggregated Revenues (Tables) Tables http://www.supernus.com/role/DisaggregatedRevenues 28 false false R29.htm 9954474 - Disclosure - Investments (Tables) Sheet http://www.supernus.com/role/InvestmentsTables Investments (Tables) Tables http://www.supernus.com/role/Investments 29 false false R30.htm 9954475 - Disclosure - Fair Value of Financial Measurements (Tables) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsTables Fair Value of Financial Measurements (Tables) Tables http://www.supernus.com/role/FairValueofFinancialMeasurements 30 false false R31.htm 9954476 - Disclosure - Contingent Consideration (Tables) Sheet http://www.supernus.com/role/ContingentConsiderationTables Contingent Consideration (Tables) Tables http://www.supernus.com/role/ContingentConsideration 31 false false R32.htm 9954477 - Disclosure - Intangible Assets, Net (Tables) Sheet http://www.supernus.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://www.supernus.com/role/IntangibleAssetsNet 32 false false R33.htm 9954478 - Disclosure - Share-Based Payments (Tables) Sheet http://www.supernus.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.supernus.com/role/ShareBasedPayments 33 false false R34.htm 9954479 - Disclosure - Earnings per Share (Tables) Sheet http://www.supernus.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.supernus.com/role/EarningsperShare 34 false false R35.htm 9954480 - Disclosure - Income Tax Expense (Benefit) (Tables) Sheet http://www.supernus.com/role/IncomeTaxExpenseBenefitTables Income Tax Expense (Benefit) (Tables) Tables http://www.supernus.com/role/IncomeTaxExpenseBenefit 35 false false R36.htm 9954481 - Disclosure - Leases (Tables) Sheet http://www.supernus.com/role/LeasesTables Leases (Tables) Tables http://www.supernus.com/role/Leases 36 false false R37.htm 9954482 - Disclosure - Composition of Other Balance Sheet Items (Tables) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables Composition of Other Balance Sheet Items (Tables) Tables http://www.supernus.com/role/CompositionofOtherBalanceSheetItems 37 false false R38.htm 9954483 - Disclosure - Interest Expense (Tables) Sheet http://www.supernus.com/role/InterestExpenseTables Interest Expense (Tables) Tables http://www.supernus.com/role/InterestExpense 38 false false R39.htm 9954484 - Disclosure - Business Organization (Details) Sheet http://www.supernus.com/role/BusinessOrganizationDetails Business Organization (Details) Details http://www.supernus.com/role/BusinessOrganization 39 false false R40.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails Summary of Significant Accounting Policies - Basis of Presentation (Details) Details 40 false false R41.htm 9954486 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails Summary of Significant Accounting Policies - Advertising Expense (Details) Details 41 false false R42.htm 9954487 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails Summary of Significant Accounting Policies - Restricted Cash (Details) Details 42 false false R43.htm 9954488 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails Disaggregated Revenues - Summary of Revenues (Details) Details 43 false false R44.htm 9954489 - Disclosure - Disaggregated Revenues - Narrative (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails Disaggregated Revenues - Narrative (Details) Details 44 false false R45.htm 9954490 - Disclosure - Investments - Unrestricted Marketable Securities (Details) Sheet http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails Investments - Unrestricted Marketable Securities (Details) Details 45 false false R46.htm 9954491 - Disclosure - Investments - Contractual Maturities (Details) Sheet http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails Investments - Contractual Maturities (Details) Details 46 false false R47.htm 9954492 - Disclosure - Investments - Narrative (Details) Sheet http://www.supernus.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 47 false false R48.htm 9954493 - Disclosure - Fair Value of Financial Measurements (Details) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails Fair Value of Financial Measurements (Details) Details http://www.supernus.com/role/FairValueofFinancialMeasurementsTables 48 false false R49.htm 9954494 - Disclosure - Contingent Consideration - Current and Long-Term Contingent Consideration (Details) Sheet http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails Contingent Consideration - Current and Long-Term Contingent Consideration (Details) Details 49 false false R50.htm 9954495 - Disclosure - Contingent Consideration - Narrative (Details) Sheet http://www.supernus.com/role/ContingentConsiderationNarrativeDetails Contingent Consideration - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Sheet http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Details 51 false false R52.htm 9954497 - Disclosure - Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Sheet http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Details 52 false false R53.htm 9954498 - Disclosure - Intangible Assets, Net - Narrative (Details) Sheet http://www.supernus.com/role/IntangibleAssetsNetNarrativeDetails Intangible Assets, Net - Narrative (Details) Details 53 false false R54.htm 9954499 - Disclosure - Debt (Details) Sheet http://www.supernus.com/role/DebtDetails Debt (Details) Details http://www.supernus.com/role/Debt 54 false false R55.htm 9954500 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails Share-Based Payments - Share-based Compensation Expense (Details) Details 55 false false R56.htm 9954501 - Disclosure - Share-Based Payments - SAR Activity (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails Share-Based Payments - SAR Activity (Details) Details 56 false false R57.htm 9954502 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails Share-Based Payments - Restricted Stock Units (Details) Details 57 false false R58.htm 9954503 - Disclosure - Share-Based Payments - Performance Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails Share-Based Payments - Performance Stock Units (Details) Details 58 false false R59.htm 9954504 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details) Sheet http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details) Details 59 false false R60.htm 9954505 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details) Sheet http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details) Details 60 false false R61.htm 9954506 - Disclosure - Income Tax Expense (Benefit) (Details) Sheet http://www.supernus.com/role/IncomeTaxExpenseBenefitDetails Income Tax Expense (Benefit) (Details) Details http://www.supernus.com/role/IncomeTaxExpenseBenefitTables 61 false false R62.htm 9954507 - Disclosure - Leases (Details) Sheet http://www.supernus.com/role/LeasesDetails Leases (Details) Details http://www.supernus.com/role/LeasesTables 62 false false R63.htm 9954508 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails Composition of Other Balance Sheet Items - Accounts Receivables (Details) Details 63 false false R64.htm 9954509 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails Composition of Other Balance Sheet Items - Inventories (Details) Details 64 false false R65.htm 9954510 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails Composition of Other Balance Sheet Items - Property and Equipment (Details) Details 65 false false R66.htm 9954511 - Disclosure - Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) Details 66 false false R67.htm 9954512 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) Details 67 false false R68.htm 9954513 - Disclosure - Interest Expense (Details) Sheet http://www.supernus.com/role/InterestExpenseDetails Interest Expense (Details) Details http://www.supernus.com/role/InterestExpenseTables 68 false false R69.htm 9954514 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.supernus.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.supernus.com/role/CommitmentsandContingencies 69 false false All Reports Book All Reports supn-20240331.htm supn-20240331.xsd supn-20240331_cal.xml supn-20240331_def.xml supn-20240331_lab.xml supn-20240331_pre.xml supn-20240331_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "supn-20240331.htm": { "nsprefix": "supn", "nsuri": "http://www.supernus.com/20240331", "dts": { "inline": { "local": [ "supn-20240331.htm" ] }, "schema": { "local": [ "supn-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "supn-20240331_cal.xml" ] }, "definitionLink": { "local": [ "supn-20240331_def.xml" ] }, "labelLink": { "local": [ "supn-20240331_lab.xml" ] }, "presentationLink": { "local": [ "supn-20240331_pre.xml" ] } }, "keyStandard": 238, "keyCustom": 19, "axisStandard": 21, "axisCustom": 0, "memberStandard": 28, "memberCustom": 25, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 169, "entityCount": 1, "segmentCount": 53, "elementCount": 519, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 595, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.supernus.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R3": { "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "longName": "0000004 - Statement - Condensed Consolidated Statements of Earnings", "shortName": "Condensed Consolidated Statements of Earnings", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R5": { "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings", "shortName": "Condensed Consolidated Statements of Comprehensive Earnings", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R6": { "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity", "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R8": { "role": "http://www.supernus.com/role/BusinessOrganization", "longName": "0000008 - Disclosure - Business Organization", "shortName": "Business Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.supernus.com/role/DisaggregatedRevenues", "longName": "0000010 - Disclosure - Disaggregated Revenues", "shortName": "Disaggregated Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.supernus.com/role/Investments", "longName": "0000011 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.supernus.com/role/FairValueofFinancialMeasurements", "longName": "0000012 - Disclosure - Fair Value of Financial Measurements", "shortName": "Fair Value of Financial Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.supernus.com/role/ContingentConsideration", "longName": "0000013 - Disclosure - Contingent Consideration", "shortName": "Contingent Consideration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "supn:ContingentConsiderationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "supn:ContingentConsiderationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.supernus.com/role/IntangibleAssetsNet", "longName": "0000014 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.supernus.com/role/Debt", "longName": "0000015 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.supernus.com/role/ShareBasedPayments", "longName": "0000016 - Disclosure - Share-Based Payments", "shortName": "Share-Based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.supernus.com/role/EarningsperShare", "longName": "0000017 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.supernus.com/role/IncomeTaxExpenseBenefit", "longName": "0000018 - Disclosure - Income Tax Expense (Benefit)", "shortName": "Income Tax Expense (Benefit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.supernus.com/role/Leases", "longName": "0000019 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItems", "longName": "0000020 - Disclosure - Composition of Other Balance Sheet Items", "shortName": "Composition of Other Balance Sheet Items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.supernus.com/role/InterestExpense", "longName": "0000021 - Disclosure - Interest Expense", "shortName": "Interest Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.supernus.com/role/CommitmentsandContingencies", "longName": "0000022 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.supernus.com/role/SubsequentEvents", "longName": "0000023 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.supernus.com/role/DisaggregatedRevenuesTables", "longName": "9954473 - Disclosure - Disaggregated Revenues (Tables)", "shortName": "Disaggregated Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.supernus.com/role/InvestmentsTables", "longName": "9954474 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsTables", "longName": "9954475 - Disclosure - Fair Value of Financial Measurements (Tables)", "shortName": "Fair Value of Financial Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.supernus.com/role/ContingentConsiderationTables", "longName": "9954476 - Disclosure - Contingent Consideration (Tables)", "shortName": "Contingent Consideration (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.supernus.com/role/IntangibleAssetsNetTables", "longName": "9954477 - Disclosure - Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.supernus.com/role/ShareBasedPaymentsTables", "longName": "9954478 - Disclosure - Share-Based Payments (Tables)", "shortName": "Share-Based Payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.supernus.com/role/EarningsperShareTables", "longName": "9954479 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.supernus.com/role/IncomeTaxExpenseBenefitTables", "longName": "9954480 - Disclosure - Income Tax Expense (Benefit) (Tables)", "shortName": "Income Tax Expense (Benefit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.supernus.com/role/LeasesTables", "longName": "9954481 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables", "longName": "9954482 - Disclosure - Composition of Other Balance Sheet Items (Tables)", "shortName": "Composition of Other Balance Sheet Items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.supernus.com/role/InterestExpenseTables", "longName": "9954483 - Disclosure - Interest Expense (Tables)", "shortName": "Interest Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.supernus.com/role/BusinessOrganizationDetails", "longName": "9954484 - Disclosure - Business Organization (Details)", "shortName": "Business Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "supn:NumberOfCommercialProducts", "unitRef": "product", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "supn:NumberOfCommercialProducts", "unitRef": "product", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)", "shortName": "Summary of Significant Accounting Policies - Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails", "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details)", "shortName": "Summary of Significant Accounting Policies - Advertising Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails", "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R43": { "role": "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails", "longName": "9954488 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details)", "shortName": "Disaggregated Revenues - Summary of Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R44": { "role": "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "longName": "9954489 - Disclosure - Disaggregated Revenues - Narrative (Details)", "shortName": "Disaggregated Revenues - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-9", "name": "supn:RevenueFromRoyaltyAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "supn:RevenueFromRoyaltyAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails", "longName": "9954490 - Disclosure - Investments - Unrestricted Marketable Securities (Details)", "shortName": "Investments - Unrestricted Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "longName": "9954491 - Disclosure - Investments - Contractual Maturities (Details)", "shortName": "Investments - Contractual Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.supernus.com/role/InvestmentsNarrativeDetails", "longName": "9954492 - Disclosure - Investments - Narrative (Details)", "shortName": "Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails", "longName": "9954493 - Disclosure - Fair Value of Financial Measurements (Details)", "shortName": "Fair Value of Financial Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R49": { "role": "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails", "longName": "9954494 - Disclosure - Contingent Consideration - Current and Long-Term Contingent Consideration (Details)", "shortName": "Contingent Consideration - Current and Long-Term Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "longName": "9954495 - Disclosure - Contingent Consideration - Narrative (Details)", "shortName": "Contingent Consideration - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R51": { "role": "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "longName": "9954496 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "shortName": "Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "longName": "9954497 - Disclosure - Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "shortName": "Intangible Assets, Net - Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.supernus.com/role/IntangibleAssetsNetNarrativeDetails", "longName": "9954498 - Disclosure - Intangible Assets, Net - Narrative (Details)", "shortName": "Intangible Assets, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.supernus.com/role/DebtDetails", "longName": "9954499 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R55": { "role": "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails", "longName": "9954500 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details)", "shortName": "Share-Based Payments - Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "longName": "9954501 - Disclosure - Share-Based Payments - SAR Activity (Details)", "shortName": "Share-Based Payments - SAR Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-142", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R57": { "role": "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "longName": "9954502 - Disclosure - Share-Based Payments - Restricted Stock Units (Details)", "shortName": "Share-Based Payments - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "longName": "9954503 - Disclosure - Share-Based Payments - Performance Stock Units (Details)", "shortName": "Share-Based Payments - Performance Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-151", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails", "longName": "9954504 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details)", "shortName": "Earnings per Share - Schedule of Computation of Basic and Diluted Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R60": { "role": "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails", "longName": "9954505 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details)", "shortName": "Earnings per Share - Schedule of Common Stock Equivalents Excluded in the Calculation of Diluted Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-158", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.supernus.com/role/IncomeTaxExpenseBenefitDetails", "longName": "9954506 - Disclosure - Income Tax Expense (Benefit) (Details)", "shortName": "Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R62": { "role": "http://www.supernus.com/role/LeasesDetails", "longName": "9954507 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails", "longName": "9954508 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details)", "shortName": "Composition of Other Balance Sheet Items - Accounts Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "supn:AllowanceForExpectedSalesDeductions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "supn:AllowanceForExpectedSalesDeductions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails", "longName": "9954509 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details)", "shortName": "Composition of Other Balance Sheet Items - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails", "longName": "9954510 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details)", "shortName": "Composition of Other Balance Sheet Items - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails", "longName": "9954511 - Disclosure - Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details)", "shortName": "Composition of Other Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "longName": "9954512 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "shortName": "Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "supn:AccruedRebates", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "supn:AccruedRebates", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.supernus.com/role/InterestExpenseDetails", "longName": "9954513 - Disclosure - Interest Expense (Details)", "shortName": "Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "unique": true } }, "R69": { "role": "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "longName": "9954514 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-169", "name": "us-gaap:LossContingencyDamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:LossContingencyDamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240331.htm", "first": true, "unique": true } } }, "tag": { "supn_APOKYNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "APOKYNMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APOKYN", "label": "APOKYN [Member]", "documentation": "APOKYN" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r625" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "supn_AccruedManufacturingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AccruedManufacturingExpenses", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued manufacturing expenses", "label": "Accrued manufacturing expenses", "documentation": "Accrued manufacturing expenses" } } }, "auth_ref": [] }, "supn_AccruedProductReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AccruedProductReturns", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product returns", "label": "Accrued Product Returns", "documentation": "Represents the amount of accrued product returns." } } }, "auth_ref": [] }, "supn_AccruedProductReturnsAndRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AccruedProductReturnsAndRebates", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product returns and rebates", "totalLabel": "Total", "label": "Accrued Product Returns and Rebates.", "documentation": "Carrying value as of the balance sheet date of accrued product returns and rebates." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued sales & marketing", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "supn_AccruedRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AccruedRebates", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product rebates", "label": "Accrued Rebates", "documentation": "Represents the amount of accrued rebates." } } }, "auth_ref": [] }, "supn_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued R&D expenses", "label": "Accrued Research and Development Expenses, Current", "documentation": "Represents the amount of clinical trial and clinical supply costs accrued." } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r597" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r57", "r155", "r512" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss, net of tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r93", "r160", "r509", "r530", "r531" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated\u00a0Other Comprehensive Earnings\u00a0(Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r11", "r33", "r427", "r430", "r463", "r526", "r527", "r729", "r730", "r731", "r738", "r739", "r740" ] }, "supn_AdamasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AdamasMember", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adamas Acquisition", "label": "Adamas [Member]", "documentation": "Adamas" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r675" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r85", "r625", "r778" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional\u00a0 Paid-in\u00a0Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r396", "r397", "r398", "r537", "r738", "r739", "r740", "r766", "r780" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r681" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r681" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r681" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r681" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense related to employee stock purchase plan and share-based awards", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r64", "r65", "r362" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising Expense", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r138" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising costs", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r400" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r646", "r657", "r667", "r692" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r649", "r660", "r670", "r695" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r681" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r688" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r653", "r661", "r671", "r688", "r696", "r700", "r708" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r706" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r392", "r399" ] }, "supn_AllowanceForExpectedSalesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AllowanceForExpectedSalesDeductions", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for expected sales discounts and allowances", "label": "Allowance for Expected Sales deductions", "documentation": "Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "supn_AmerisourceBergenDrugCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "AmerisourceBergenDrugCorporationMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AmerisourceBergen Drug Corporation", "label": "AmerisourceBergen Drug Corporation [Member]", "documentation": "AmerisourceBergen Drug Corporation" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.supernus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/InterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs and debt discount", "negatedTerseLabel": "Noncash interest expense on debt", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r332", "r454", "r609", "r610", "r733" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/IntangibleAssetsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r50", "r55" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock equivalents excluded in the calculation of diluted income per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r218" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r40" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r40" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r128", "r159", "r186", "r223", "r231", "r235", "r277", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r422", "r424", "r446", "r505", "r560", "r625", "r637", "r761", "r762", "r768" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r150", "r162", "r186", "r277", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r422", "r424", "r446", "r625", "r761", "r762", "r768" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r71" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r250" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 1 year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r254", "r503" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, U.S. government agency and municipal debt securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r244", "r285" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and municipal debt securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r153", "r244", "r285" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r703" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r704" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r699" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r699" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r699" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r699" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r699" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r699" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r702" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r701" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r700" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r700" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r419", "r621", "r622" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r66", "r67", "r419", "r621", "r622" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r419" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "supn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration arrangements, excess acquisition date fair value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value", "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value" } } }, "auth_ref": [] }, "supn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValueTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValueTerm", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration arrangements, excess acquisition date fair value, term", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value, Term", "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value, Term" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration gain", "terseLabel": "Change in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r421", "r732" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional cash payments upon milestone achievements maximum", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional cash payments upon milestone achievements minimum", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r69" ] }, "supn_BusinessCombinationContingentConsiderationArrangementsValuePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "BusinessCombinationContingentConsiderationArrangementsValuePricePerShare", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration arrangements, value (in dollars per share)", "label": "Business Combination, Contingent Consideration Arrangements, Value, Price Per Share", "documentation": "Business Combination, Contingent Consideration Arrangements, Value, Price Per Share" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "totalLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r68", "r420" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, current portion", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r68" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationCurrentandLongTermContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, long-term", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r68" ] }, "supn_BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare": { "xbrltype": "integerItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingents value rights", "label": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share", "documentation": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "supn_CardinalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "CardinalHealthMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardinal Health", "label": "Cardinal Health [Member]", "documentation": "Cardinal Health" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r152", "r595" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r152" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Restricted Cash and Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents, and restricted cash per statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r103", "r183" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r103" ] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r152" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r679" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r680" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r680" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r79", "r507", "r546" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r299", "r300", "r592", "r755" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common\u00a0Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r627", "r628", "r629", "r631", "r632", "r633", "r634", "r738", "r739", "r766", "r777", "r780" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r547" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares outstanding (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r84", "r547", "r566", "r780", "r781" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.001 par value; 130,000,000 shares authorized; 54,965,316 and 54,723,356 shares issued and outstanding as of March 31, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r508", "r625" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r685" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r684" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r686" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r683" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive earnings", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r167", "r169", "r174", "r500", "r517" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r594", "r753", "r754" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r41", "r44", "r73", "r74", "r239", "r591" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r41", "r44", "r73", "r74", "r239", "r532", "r591" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r41", "r44", "r73", "r74", "r239", "r591", "r715" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r41", "r44", "r73", "r74", "r239" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r41", "r44", "r73", "r74", "r239", "r591" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r70", "r600" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "supn_ContingentConsiderationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "ContingentConsiderationDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/ContingentConsideration" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration Disclosure [Text Block]", "documentation": "Contingent Consideration Disclosure" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r115", "r311", "r312", "r322", "r323", "r324", "r328", "r329", "r330", "r331", "r332", "r606", "r607", "r608", "r609", "r610" ] }, "supn_CorporateAndMunicipalDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "CorporateAndMunicipalDebtSecuritiesMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and municipal debt securities", "label": "Corporate And Municipal Debt Securities [Member]", "documentation": "Corporate And Municipal Debt Securities" } } }, "auth_ref": [] }, "supn_CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, U.S. government agency and municipal debt securities", "label": "Corporate And U.S. Government Agency And Municipal Debt Securities [Member]", "documentation": "Corporate And U.S. Government Agency And Municipal Debt Securities" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r97", "r496" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r96" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r42", "r239" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r114", "r185", "r310", "r316", "r317", "r318", "r319", "r320", "r321", "r326", "r333", "r334", "r336" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r76", "r78", "r311", "r455", "r607", "r608" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r312" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.supernus.com/role/DebtDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r188", "r311", "r312", "r313", "r314", "r315", "r317", "r322", "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r455", "r606", "r607", "r608", "r609", "r610", "r735" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.supernus.com/role/DebtDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r59", "r60", "r75", "r76", "r78", "r80", "r116", "r117", "r188", "r311", "r312", "r313", "r314", "r315", "r317", "r322", "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r455", "r606", "r607", "r608", "r609", "r610", "r735" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r750" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0, "order": 3.0 }, "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r750" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment due to credit losses", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded", "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded." } } }, "auth_ref": [ "r289" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r750" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r750" ] }, "supn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1 year to 2 years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two", "documentation": "Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesCurrentAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Debt Securities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesNoncurrentAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Debt Securities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r121", "r143", "r414", "r415", "r737" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities, net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r403", "r404", "r506" ] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities - restricted (SERP)", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r127", "r351", "r352", "r353", "r559", "r620", "r772" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r56" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r227" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired developed technology and product rights", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r122" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r611", "r612", "r613", "r614", "r615", "r616", "r617" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r349", "r611", "r612", "r613", "r614", "r615", "r616", "r617" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of disaggregation of revenues by nature", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r763" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.supernus.com/role/ShareBasedPayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r360", "r365", "r393", "r394", "r395", "r623" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r641" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r674" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "supn_EPSBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "EPSBasicAndDilutedAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per share", "label": "EPS Basic And Diluted [Abstract]", "documentation": "EPS Basic And Diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r194", "r195", "r196", "r197", "r198", "r203", "r206", "r215", "r216", "r217", "r221", "r434", "r435", "r501", "r518", "r601" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r194", "r195", "r196", "r197", "r198", "r206", "r215", "r216", "r217", "r221", "r434", "r435", "r501", "r518", "r601" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.supernus.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r202", "r218", "r219", "r220" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.supernus.com/role/IncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r406" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation, benefits, & related accruals", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r639" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r639" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r639" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r713" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r639" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r639" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r639" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r639" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r148", "r170", "r171", "r172", "r189", "r190", "r191", "r193", "r199", "r201", "r222", "r278", "r279", "r339", "r396", "r397", "r398", "r410", "r411", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r447", "r448", "r449", "r450", "r451", "r452", "r463", "r526", "r527", "r528", "r537", "r587" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r682" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r646", "r657", "r667", "r692" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r643", "r654", "r664", "r689" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r688" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r437", "r438", "r442" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r437", "r438", "r442" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value of the financial assets and liabilities", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r71", "r124" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r324", "r354", "r355", "r356", "r357", "r358", "r359", "r438", "r469", "r470", "r471", "r607", "r608", "r618", "r619", "r620" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r443" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r436" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r324", "r354", "r359", "r438", "r469", "r618", "r619", "r620" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r324", "r354", "r359", "r438", "r470", "r607", "r608", "r618", "r619", "r620" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r324", "r354", "r355", "r356", "r357", "r358", "r359", "r438", "r471", "r607", "r608", "r618", "r619", "r620" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the beginning and ending balances related to the contingent consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r13", "r72" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value gain (loss) recognized in earnings", "negatedLabel": "Change in fair value recognized in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r441" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r13" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r324", "r354", "r355", "r356", "r357", "r358", "r359", "r469", "r470", "r471", "r607", "r608", "r618", "r619", "r620" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r436", "r443" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r335", "r338", "r432", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r516", "r604", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r745", "r746", "r747", "r748" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r157", "r294" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r291", "r293", "r294", "r296", "r497", "r498" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount, Gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r110", "r498" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r497" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r51", "r54" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying Amount, Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r110", "r497" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Weighted Average\u00a0Life (Years)", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r497" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r650", "r661", "r671", "r696" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r650", "r661", "r671", "r696" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r650", "r661", "r671", "r696" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r650", "r661", "r671", "r696" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r650", "r661", "r671", "r696" ] }, "supn_GOCOVRIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "GOCOVRIMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GOCOVRI", "label": "GOCOVRI [Member]", "documentation": "GOCOVRI" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r156", "r290", "r499", "r605", "r625", "r751", "r752" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r109" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r94", "r131", "r223", "r230", "r234", "r236", "r502", "r514", "r603" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r297", "r298", "r571" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r298", "r571" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/IncomeTaxExpenseBenefit" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Expense (Benefit)", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r187", "r402", "r407", "r408", "r409", "r412", "r416", "r417", "r418", "r536" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/IncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "verboseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r136", "r144", "r200", "r201", "r228", "r405", "r413", "r519" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "supn_IncreaseDecreaseInAccruedProductReturnsAndRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "IncreaseDecreaseInAccruedProductReturnsAndRebates", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product returns and rebates", "label": "Increase (Decrease) In Accrued Product Returns And Rebates", "documentation": "Amount of increase (decrease) in product returns and rebates." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r211", "r212", "r217" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, RSUs and SARs (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r207", "r208", "r209", "r217", "r364" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r292", "r295" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r111" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r52", "r111" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r653", "r661", "r671", "r688", "r696", "r700", "r708" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r706" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r642", "r712" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r642", "r712" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r642", "r712" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets, carrying amount, gross", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r156" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r49", "r53" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r77", "r133", "r173", "r226", "r453", "r572", "r635", "r779" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/DebtDetails", "http://www.supernus.com/role/InterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r100", "r330", "r337", "r609", "r610" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense on nonrecourse liability related to sale of future royalties", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.supernus.com/role/InterestExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of interest expense", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After-tax interest expense for 2023 Notes", "label": "Interest on Convertible Debt, Net of Tax", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash." } } }, "auth_ref": [ "r205", "r210", "r217" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r108", "r598" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r161", "r596", "r625" ] }, "us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessAndRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Work in Process and Raw Materials, Net of Reserves", "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount." } } }, "auth_ref": [ "r108", "r727" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r108", "r599" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premium/discount on marketable securities", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r100" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.supernus.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r125", "r134", "r135", "r147", "r242", "r245", "r444", "r445" ] }, "supn_LabEquipmentAndFurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "LabEquipmentAndFurnitureMember", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab equipment and furniture", "label": "Lab Equipment And Furniture [Member]", "documentation": "Represents information pertaining to lab equipment and furniture." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r112" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "supn_LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "presentation": [ "http://www.supernus.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of balance sheet information related to leases", "label": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block]", "documentation": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.supernus.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r456" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r186", "r277", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r423", "r424", "r425", "r446", "r545", "r602", "r637", "r761", "r768", "r769" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r89", "r130", "r511", "r625", "r736", "r749", "r767" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r151", "r186", "r277", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r423", "r424", "r425", "r446", "r625", "r761", "r768", "r769" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r71" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Line Items]", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r58" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, damages sought, value", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r756", "r757", "r758" ] }, "supn_MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "USWM Acquisition", "label": "MDD US Enterprises LLC (Formerly USWM Enterprises) [Member]", "documentation": "MDD US Enterprises LLC (Formerly USWM Enterprises)" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r239", "r613", "r763", "r775", "r776" ] }, "us-gaap_ManufacturedProductOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManufacturedProductOtherMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Manufactured Product, Other [Member]", "documentation": "Article or substance produced by labor or machinery, classified as other." } } }, "auth_ref": [ "r764" ] }, "supn_MarketBasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "MarketBasedUnitsMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Market-Based Units", "label": "Market Based Units [Member]", "documentation": "Market Based Units" } } }, "auth_ref": [] }, "supn_McKessonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "McKessonMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McKesson", "label": "McKesson [Member]", "documentation": "McKesson" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r680" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r680" ] }, "supn_Milestone2024AndMilestone2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "Milestone2024AndMilestone2025Member", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Milestones", "label": "Milestone 2024 and Milestone 2025 [Member]", "documentation": "Milestone 2024 and Milestone 2025" } } }, "auth_ref": [] }, "supn_Milestone2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "Milestone2024Member", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone 2024", "label": "Milestone 2024 [Member]", "documentation": "Milestone 2024" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r699" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r765" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r707" ] }, "supn_NAMENDAXRNamzaricQuiTamLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "NAMENDAXRNamzaricQuiTamLitigationMember", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NAMENDA XR/Namzaric Qui Tam Litigation", "label": "NAMENDA XR/Namzaric Qui Tam Litigation [Member]", "documentation": "NAMENDA XR/Namzaric Qui Tam Litigation" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r239", "r613", "r763", "r775", "r776" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r681" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.supernus.com/role/BusinessOrganization" ], "lang": { "en-us": { "role": { "terseLabel": "Business Organization", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r137", "r145" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r182" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r182" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings", "terseLabel": "Net earnings", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r95", "r105", "r132", "r149", "r165", "r168", "r172", "r186", "r192", "r194", "r195", "r196", "r197", "r200", "r201", "r213", "r223", "r230", "r234", "r236", "r277", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r435", "r446", "r515", "r568", "r585", "r586", "r603", "r635", "r761" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Numerator for dilutive earnings per share", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r178", "r194", "r195", "r196", "r197", "r203", "r204", "r214", "r217", "r223", "r230", "r234", "r236", "r603" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements and Disclosure Rules", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r680" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r650", "r661", "r671", "r688", "r696" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r678" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r677" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r688" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r707" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r707" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash operating and investing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r99" ] }, "supn_NumberOfCommercialProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "NumberOfCommercialProducts", "presentation": [ "http://www.supernus.com/role/BusinessOrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of commercial products", "label": "Number Of Commercial Products", "documentation": "Number Of Commercial Products" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r743" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Operating earnings (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r223", "r230", "r234", "r236", "r603" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.supernus.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails", "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r459" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, long-term", "terseLabel": "Operating lease liabilities, long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r459" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r457" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.supernus.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r459" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r158" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive gain", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r6", "r10", "r123", "r166", "r169" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on marketable securities, net of tax", "verboseLabel": "Unrealized gain on marketable securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r163", "r164", "r276" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25", "r625" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncash adjustments, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://www.supernus.com/role/InterestExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r176", "r177" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r680" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r648", "r659", "r669", "r694" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r651", "r662", "r672", "r697" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r651", "r662", "r672", "r697" ] }, "supn_OxtellarXRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "OxtellarXRMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oxtellar XR", "label": "Oxtellar X R [Member]", "documentation": "Represents information pertaining to Oxtellar XR product." } } }, "auth_ref": [] }, "supn_PatentDefenseCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "PatentDefenseCostsMember", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized patent defense costs", "label": "Patent Defense Costs [Member]", "documentation": "Represents information concerning the capitalized patent defense costs related to the Watson litigation." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r676" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Employee taxes paid related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r181" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r35", "r179", "r243" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r102" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r679" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r679" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r678" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r688" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r681" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r677" ] }, "supn_PerformanceBasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "PerformanceBasedUnitsMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-Based Units", "label": "Performance Based Units [Member]", "documentation": "Performance Based Units" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Total PSUs", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r728" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r724" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r179", "r180", "r744" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Credit Line", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r611" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r237", "r496", "r520", "r521", "r522", "r523", "r524", "r525", "r593", "r611", "r626", "r716", "r759", "r760", "r763", "r775" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r237", "r496", "r520", "r521", "r522", "r523", "r524", "r525", "r593", "r611", "r626", "r716", "r759", "r760", "r763", "r775" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r112", "r154", "r513" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r504", "r513", "r625" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of property and equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r112" ] }, "supn_PurchaseCommitmentAnnualMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "PurchaseCommitmentAnnualMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual minimum purchase quantity requirement amount", "label": "Purchase Commitment, Annual Minimum Amount Committed", "documentation": "Purchase Commitment, Annual Minimum Amount Committed" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r676" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r676" ] }, "supn_QelbreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "QelbreeMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qelbree", "label": "Qelbree [Member]", "documentation": "Qelbree" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r643", "r654", "r664", "r689" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on Credit Line", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r81", "r401", "r770" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r645", "r656", "r666", "r691" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r652", "r663", "r673", "r698" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r726", "r734", "r771", "r774" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r152" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r86", "r118", "r510", "r529", "r531", "r535", "r548", "r625" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r148", "r189", "r190", "r191", "r193", "r199", "r201", "r278", "r279", "r396", "r397", "r398", "r410", "r411", "r426", "r428", "r429", "r431", "r433", "r526", "r528", "r537", "r780" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r224", "r225", "r229", "r232", "r233", "r237", "r238", "r239", "r348", "r349", "r496" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r239", "r714" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenues" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregated Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r146", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350" ] }, "supn_RevenueFromRoyaltyAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "RevenueFromRoyaltyAgreement", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash royalty revenue", "label": "Revenue From Royalty Agreement", "documentation": "Represents revenue from the sale of certain royalty and milestone rights." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Lease assets obtained for new operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r462", "r624" ] }, "supn_RoyaltyAndLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "RoyaltyAndLicenseMember", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty and licensing revenues", "label": "Royalty And License [Member]", "documentation": "Royalty And License" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r707" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r707" ] }, "supn_SPN830NDAApprovalMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "SPN830NDAApprovalMilestoneMember", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPN-830 NDA Approval Milestone", "label": "SPN-830 NDA Approval Milestone [Member]", "documentation": "SPN-830 NDA Approval Milestone" } } }, "auth_ref": [] }, "supn_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accrued expenses and other current liabilities", "label": "Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities." } } }, "auth_ref": [] }, "supn_ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accrued product returns and rebates", "label": "Schedule of Accrued Product Returns and Rebates [Table Text Block]", "documentation": "Tabular disclosure of the accrued product returns and rebates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of common stock equivalents excluded in the calculation of diluted earnings per share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of unrestricted available-for-sale marketable securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of business acquisitions by acquisition, contingent consideration", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r66", "r67", "r419" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of cash and cash equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of computation of basic and diluted earnings per share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r741" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.supernus.com/role/IncomeTaxExpenseBenefitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of effective income tax rate reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of share-based compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r51", "r54", "r497" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r16", "r111" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.supernus.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r90", "r91", "r92" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restrictions on cash and cash equivalents", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r17", "r126", "r774" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r361", "r363", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of stock options and SAR activities", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r14", "r15", "r62" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of restricted stock units", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r638" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r640" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r98" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning balance (in shares)", "periodEndLabel": "Nonvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r377", "r378" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of RSUs", "verboseLabel": "Number of PSUs", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning balance (in dollars per share)", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r377", "r378" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r361", "r363", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "periodEndLabel": "Outstanding at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r369", "r370" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number\u00a0of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r369", "r370" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise\u00a0Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r385" ] }, "supn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term\u00a0(in\u00a0years)", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of performance stock unit", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r61" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r119" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r82", "r129", "r625", "r773" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r20" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r106", "r184" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r31", "r148", "r170", "r171", "r172", "r189", "r190", "r191", "r193", "r199", "r201", "r222", "r278", "r279", "r339", "r396", "r397", "r398", "r410", "r411", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r447", "r448", "r449", "r450", "r451", "r452", "r463", "r526", "r527", "r528", "r537", "r587" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement [Line Items]", "terseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r189", "r190", "r191", "r222", "r496", "r533", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r547", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r565", "r567", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r630" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r189", "r190", "r191", "r222", "r496", "r533", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r547", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r565", "r567", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r630" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r647", "r658", "r668", "r693" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofCommonStockEquivalentsExcludedintheCalculationofDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, RSUs, PSUs", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r742" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r534", "r587", "r590" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r374" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r537", "r587", "r590", "r636" ] }, "supn_StockOptionStockAppreciationRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "StockOptionStockAppreciationRightsMember", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option and Stock Appreciation Rights", "label": "Stock Option Stock Appreciation Rights [Member]", "documentation": "Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r87", "r88", "r107", "r549", "r566", "r588", "r589", "r625", "r637", "r736", "r749", "r767", "r780" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "supn_SubsequentCommercialProductLaunchMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "SubsequentCommercialProductLaunchMember", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Commercial Product Launch", "label": "Subsequent Commercial Product Launch [Member]", "documentation": "Subsequent Commercial Product Launch" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.supernus.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItems" ], "lang": { "en-us": { "role": { "terseLabel": "Composition of Other Balance Sheet Items", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r725" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r687" ] }, "supn_ThreeMajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "ThreeMajorCustomersMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Major Customers", "label": "Three Major Customers [Member]", "documentation": "Three Major Customers" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r679" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r686" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r706" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r708" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.supernus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r335", "r338", "r432", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r516", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r745", "r746", "r747", "r748" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r709" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r710" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r708" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r708" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r711" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r709" ] }, "supn_TrokendiXrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "TrokendiXrMember", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trokendi XR", "label": "Trokendi Xr [Member]", "documentation": "Represents information pertaining to Trokendi XR patent litigation." } } }, "auth_ref": [] }, "supn_UncommittedSecuredCreditLineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.supernus.com/20240331", "localname": "UncommittedSecuredCreditLineMember", "presentation": [ "http://www.supernus.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted Secured Credit Line", "label": "Uncommitted Secured Credit Line [Member]", "documentation": "Uncommitted Secured Credit Line" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r705" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r45", "r46", "r47", "r139", "r140", "r141", "r142" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r205", "r217" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r203", "r217" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.supernus.com/role/EarningsperShareScheduleofComputationofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 89 0001356576-24-000028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-24-000028-xbrl.zip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end XML 91 supn-20240331_htm.xml IDEA: XBRL DOCUMENT 0001356576 2024-01-01 2024-03-31 0001356576 2024-05-01 0001356576 2024-03-31 0001356576 2023-12-31 0001356576 us-gaap:ProductMember 2024-01-01 2024-03-31 0001356576 us-gaap:ProductMember 2023-01-01 2023-03-31 0001356576 supn:RoyaltyAndLicenseMember 2024-01-01 2024-03-31 0001356576 supn:RoyaltyAndLicenseMember 2023-01-01 2023-03-31 0001356576 2023-01-01 2023-03-31 0001356576 us-gaap:CommonStockMember 2023-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001356576 us-gaap:RetainedEarningsMember 2023-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001356576 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001356576 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001356576 us-gaap:CommonStockMember 2024-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001356576 us-gaap:RetainedEarningsMember 2024-03-31 0001356576 us-gaap:CommonStockMember 2022-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001356576 us-gaap:RetainedEarningsMember 2022-12-31 0001356576 2022-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001356576 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001356576 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001356576 us-gaap:CommonStockMember 2023-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001356576 us-gaap:RetainedEarningsMember 2023-03-31 0001356576 2023-03-31 0001356576 us-gaap:ConvertibleDebtMember 2018-03-31 0001356576 supn:QelbreeMember 2024-01-01 2024-03-31 0001356576 supn:QelbreeMember 2023-01-01 2023-03-31 0001356576 supn:OxtellarXRMember 2024-01-01 2024-03-31 0001356576 supn:OxtellarXRMember 2023-01-01 2023-03-31 0001356576 supn:GOCOVRIMember 2024-01-01 2024-03-31 0001356576 supn:GOCOVRIMember 2023-01-01 2023-03-31 0001356576 supn:APOKYNMember 2024-01-01 2024-03-31 0001356576 supn:APOKYNMember 2023-01-01 2023-03-31 0001356576 supn:TrokendiXrMember 2024-01-01 2024-03-31 0001356576 supn:TrokendiXrMember 2023-01-01 2023-03-31 0001356576 us-gaap:ManufacturedProductOtherMember 2024-01-01 2024-03-31 0001356576 us-gaap:ManufacturedProductOtherMember 2023-01-01 2023-03-31 0001356576 supn:QelbreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:QelbreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:OxtellarXRMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:OxtellarXRMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:GOCOVRIMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:GOCOVRIMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:APOKYNMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:APOKYNMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 us-gaap:ManufacturedProductOtherMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 us-gaap:ManufacturedProductOtherMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:CardinalHealthMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:McKessonMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:CardinalHealthMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:McKessonMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 supn:ThreeMajorCustomersMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001356576 supn:ThreeMajorCustomersMember us-gaap:ProductMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2024-03-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndUSGovernmentAgencyAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2023-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2024-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:SPN830NDAApprovalMilestoneMember 2024-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:SubsequentCommercialProductLaunchMember 2024-03-31 0001356576 supn:AdamasMember 2021-11-24 0001356576 supn:AdamasMember supn:Milestone2024Member 2021-11-24 2021-11-24 0001356576 supn:AdamasMember supn:Milestone2024AndMilestone2025Member 2021-11-24 2021-11-24 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2023-12-31 0001356576 supn:AdamasMember 2023-12-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2024-01-01 2024-03-31 0001356576 supn:AdamasMember 2024-01-01 2024-03-31 0001356576 supn:AdamasMember 2024-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-12-31 0001356576 supn:AdamasMember 2022-12-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2023-01-01 2023-03-31 0001356576 supn:AdamasMember 2023-01-01 2023-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2023-03-31 0001356576 supn:AdamasMember 2023-03-31 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-31 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2024-03-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001356576 supn:PatentDefenseCostsMember 2024-03-31 0001356576 supn:PatentDefenseCostsMember 2023-12-31 0001356576 supn:UncommittedSecuredCreditLineMember us-gaap:LineOfCreditMember 2023-02-08 0001356576 supn:UncommittedSecuredCreditLineMember us-gaap:LineOfCreditMember 2023-03-30 0001356576 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-04-01 2023-06-30 0001356576 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-03-31 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2023-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2023-01-01 2023-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2024-01-01 2024-03-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2024-03-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001356576 supn:PerformanceBasedUnitsMember 2023-12-31 0001356576 supn:MarketBasedUnitsMember 2023-12-31 0001356576 us-gaap:PerformanceSharesMember 2023-12-31 0001356576 supn:PerformanceBasedUnitsMember 2024-01-01 2024-03-31 0001356576 supn:MarketBasedUnitsMember 2024-01-01 2024-03-31 0001356576 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001356576 supn:PerformanceBasedUnitsMember 2024-03-31 0001356576 supn:MarketBasedUnitsMember 2024-03-31 0001356576 us-gaap:PerformanceSharesMember 2024-03-31 0001356576 us-gaap:StockCompensationPlanMember 2024-01-01 2024-03-31 0001356576 us-gaap:StockCompensationPlanMember 2023-01-01 2023-03-31 0001356576 supn:LabEquipmentAndFurnitureMember 2024-03-31 0001356576 supn:LabEquipmentAndFurnitureMember 2023-12-31 0001356576 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001356576 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001356576 us-gaap:ComputerEquipmentMember 2024-03-31 0001356576 us-gaap:ComputerEquipmentMember 2023-12-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2019-04-01 2019-04-01 0001356576 supn:NAMENDAXRNamzaricQuiTamLitigationMember 2019-04-01 2019-04-01 shares iso4217:USD iso4217:USD shares supn:product supn:segment pure supn:right iso4217:EUR 0001356576 false --12-31 2024 Q1 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent 10-Q true 2024-03-31 false 001-35518 SUPERNUS PHARMACEUTICALS, INC. DE 20-2590184 9715 Key West Avenue Rockville MD 20850 301 838-2500 Yes Yes Large Accelerated Filer false false false Common Stock, $0.001 par value per share 54974254 SUPN NASDAQ 63401000 75054000 234335000 179820000 147734000 144155000 75079000 77408000 23772000 16676000 544321000 493113000 11662000 16617000 12969000 13530000 579752000 599889000 117019000 117019000 38367000 37505000 1304090000 1277673000 86402000 79569000 167226000 154274000 51379000 52070000 9547000 4283000 314554000 290196000 976000 1380000 32994000 33196000 19501000 24963000 6899000 6422000 374924000 356157000 0.001 0.001 130000000 130000000 54965316 54965316 54723356 54723356 55000 55000 446960000 439493000 -534000 -593000 482685000 482561000 929166000 921516000 1304090000 1277673000 138461000 140575000 5183000 13189000 143644000 153764000 16309000 23460000 24930000 21212000 86516000 85597000 20137000 19966000 -1095000 -1647000 146797000 148588000 -3153000 5176000 3396000 5346000 0 1505000 3396000 3841000 243000 9017000 119000 -7931000 124000 16948000 0.00 0.31 0.00 0.29 54801748 54380947 55626663 62454204 124000 16948000 59000 881000 59000 881000 183000 17829000 54723356 55000 439493000 -593000 482561000 921516000 5897000 5897000 241960 1570000 1570000 124000 124000 59000 59000 54965316 55000 446960000 -534000 482685000 929166000 54253796 54000 408115000 -3210000 481245000 886204000 6306000 6306000 216826 1811000 1811000 16948000 16948000 881000 881000 54470622 54000 416232000 -2329000 498193000 912150000 124000 16948000 20749000 20601000 0 532000 -1894000 1056000 -1095000 -1647000 -2449000 -2459000 5897000 6306000 -5482000 -435000 3579000 -21971000 -1990000 1851000 7517000 341000 12952000 -3813000 10019000 -10548000 38401000 49126000 193700000 0 142324000 240058000 248000 278000 -51624000 239780000 0 93000000 0 14637000 2910000 2256000 1340000 445000 1570000 80174000 -11653000 369080000 75054000 93120000 63401000 462200000 336000 203000 4002000 3457000 2604000 2601000 Business Organization<div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the "Company", see Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has eight commercial products that it markets: Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Osmolex ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("OFF" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company submitted to the U.S. Food and Drug Administration (FDA) a notification of discontinuance to withdraw Osmolex ER from distribution, stating that manufacturing has been discontinued and distribution of the product will cease by April 1, 2024.</span></div> 8 Summary of Significant Accounting Policies<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, which is primarily located in the U.S., operates in one operating segment.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year amount related to the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee taxes paid related to net share settlement of equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's unaudited condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $24.3 million and $25.9 million in advertising expense for the three months ended March 31, 2024 and 2023, respectively. These expenses are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the unaudited condensed consolidated statements of earnings.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a restricted cash balance of $403.8 million as of March 31, 2023 which was held in an escrow account with Wilmington Trust, Trustee, in connection with the payoff of the 0.625% Convertible Senior Notes Due 2023 (2023 Notes) which occurred on April 1, 2023.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,758</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash per statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements and Disclosure Rules</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2023, improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also clarifies that entities with a single reportable segment are subject to both new and existing reporting requirements under Topic 280. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2024. We expect ASU 2023-07 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) - The new standard, issued in December 2023, requires entities to disclose additional information with respect to the effective tax rate reconciliation and to disclose the disaggregation by jurisdiction of income tax expense and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Final Climate Rule</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span> (Final Rule). This rule will require registrants to disclose certain climate-related information in registration statements and annual reports with staggered compliance dates for large accelerated filers for the fiscal year beginning 2025 through 2033 for the various aspects of the Final Rule. On April 4, 2024, the SEC issued an order staying the Final Rule. The SEC’s administrative stay is expected to remain in place until the completion of litigation filed in various federal courts challenging, among other things, the agency’s authority to adopt the Final Rule. The Company is currently evaluating the final rule to determine its impact on the Company's disclosures. <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, which is primarily located in the U.S., operates in one operating segment.</span></div> 1 <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year amount related to the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee taxes paid related to net share settlement of equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.</span></div> <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's unaudited condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div> <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div> <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred.</span></div> 24300000 25900000 403800000 0.00625 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,758</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash per statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,758</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash per statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 58442000 93120000 403758000 0 462200000 93120000 <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements and Disclosure Rules</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2023, improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also clarifies that entities with a single reportable segment are subject to both new and existing reporting requirements under Topic 280. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2024. We expect ASU 2023-07 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) - The new standard, issued in December 2023, requires entities to disclose additional information with respect to the effective tax rate reconciliation and to disclose the disaggregation by jurisdiction of income tax expense and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregated Revenues </span><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and licensing revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,644 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,764 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized noncash royalty revenue of $2.3 million for the three months ended March 31, 2023. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023.</span></div><div style="padding-left:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table shows the percentage of net product sales to total net product sales:</span></div><div style="padding-left:9pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Net Product Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our three major customers, Cencora, Inc., Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total gross product sales and collectively accounted for more than 70% of our total gross product sales for the three months ended March 31, 2024 and 2023.</span></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and licensing revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,644 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,764 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.</span></div><div style="padding-left:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table shows the percentage of net product sales to total net product sales:</span></div><div style="padding-left:9pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Net Product Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.</span></div> 45104000 25782000 26943000 28915000 26562000 26010000 16649000 17209000 15989000 34790000 7214000 7869000 138461000 140575000 5183000 13189000 143644000 153764000 2300000 0.33 0.18 0.19 0.21 0.19 0.18 0.12 0.12 0.12 0.25 0.05 0.06 1 1 0.20 0.20 0.20 0.20 0.20 0.20 0.70 0.70 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments </span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>As of March 31, 2024, there was no impairment due to credit loss on any available-for-sale marketable securities. <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 246635000 197153000 1000 5000 639000 721000 245997000 196437000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 234335000 11662000 245997000 0 Fair Value of Financial Measurements<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels: </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Recorded at Fair Value</span></div><div style="margin-top:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2024 (unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted marketable securities is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div>The carrying amounts of other financial instruments, including accounts receivable, accounts payable, accrued expenses, and line of credit approximate fair value due to their short-term maturities. <div style="margin-top:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2024 (unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate, U.S. government agency and municipal debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14272000 14272000 0 0 49129000 49129000 0 0 234335000 3950000 230385000 0 11662000 0 11662000 0 612000 17000 595000 0 310010000 67368000 242642000 0 52355000 0 0 52355000 52355000 0 0 52355000 35957000 35957000 0 0 39097000 39097000 0 0 179820000 0 179820000 0 16617000 0 16617000 0 568000 16000 552000 0 272059000 75070000 196989000 0 53450000 0 0 53450000 53450000 0 0 53450000 Contingent Consideration<div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020 and the Adamas Acquisition in 2021. The contingent consideration liabilities are measured at fair value using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. The change in fair value is reported on the condensed consolidated statement of earnings in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration (gain) expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments for regulatory and development milestones and sales-based milestones. As of March 31, 2024, the remaining potential contingent consideration payments are up to $55 million in regulatory and development milestones comprised of (1) $25 million related to the FDA's approval of the SPN-830 NDA and (2) $30 million related to the subsequent commercial product launch. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, timing of projected revenues, and the discount rate.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Contingent Consideration</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 24, 2021 (the Adamas Closing Date), the Company completed its acquisition of all the outstanding equity of Adamas (Adamas Acquisition). The Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer &amp; Trust Company, LLC, as rights agent, as further defined in the CVR agreement. One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated revenue projections, volatility, estimated discount rates and risk-free interest rate.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in the Fair Value of Contingent Consideration</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024 (unaudited)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023 (unaudited)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,320 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company recorded a $0.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2024. The change in fair value of contingent consideration for the USWM milestones was primarily due to passage of time.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company recorded a $1.7 million gain due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2023. The change in the fair value of contingent consideration for the USWM milestones was primarily due to the change in timing of the regulatory and developmental milestone achievement and estimated discount rates.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company recorded a $1.8 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2024. The change in fair value of contingent consideration was primarily due to passage of time.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company recorded a $0.1 million expense due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2023. The change in fair value was primarily due to the passage of time and estimated discount rates.</span></div> <div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 51379000 52070000 976000 1380000 52355000 53450000 55000000 25000000 30000000 2 0.50 150000000 P12M 225000000 P12M 0 50900000 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024 (unaudited)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,697 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023 (unaudited)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,320 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 46400000 7050000 53450000 -680000 1775000 1095000 47080000 5275000 52355000 46270000 8697000 54967000 1710000 -63000 1647000 44560000 8760000 53320000 -700000 1700000 1800000 -100000 Intangibles Assets, Net<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,379)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,242)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $20.1 million and $20.0 million, for the three month periods ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. patents covering Trokendi XR and Oxtellar XR will expire no earlier than 2027. The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market on January 1, 2023. The Company entered into settlement and license agreements that allows a third party to enter the Oxtellar XR market in September 2024, or sooner under certain conditions.</span></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,379)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,242)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 124000000 124000000 124000000 124000000 P6Y7M9D 661311000 208667000 452644000 661311000 190395000 470916000 P0Y5M1D 43820000 40712000 3108000 43820000 38847000 4973000 P6Y6M25D 829131000 249379000 579752000 829131000 229242000 599889000 20100000 20000000 Debt<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncommitted Demand Secured Line of Credit </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, the Company entered into a credit line agreement with UBS (the "Credit Line"). The Credit Line provides for a revolving line of credit of up to $150 million, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of (i) the UBS Fixed Funding Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of (i) the UBS Variable Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Line is secured by a first priority lien and security interest in certain of the Company’s assets, including each account of the Company at UBS Financial Services Inc. (the “Collateral Account”), and other such collateral (collectively, the Collateral), as further defined in the Credit Line. The Company may be required to post additional collateral if the value of the Collateral declines below the required collateral maintenance requirements. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon certain customary events of default, all amounts due under the Credit Line will become immediately due and payable without demand, and UBS has the right, in its discretion, to liquidate, transfer, withdraw or sell all or any part of the Collateral and apply the proceeds to repay any borrowings pursuant to the Credit Line.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.</span></div>On March 30, 2023, the Company borrowed $93.0 million under the Credit Line, which bore a variable interest rate. The funds from this borrowing were used to repay outstanding indebtedness under the 2023 Notes. In the second quarter of 2023, the Company repaid the total principal balance of $93.0 million under the Credit Line and the interest incurred on the Credit Line of $0.7 million. As of March 31, 2024, there was no outstanding debt under the Credit Line. 150000000 93000000 93000000 700000 0 Share-Based Payments<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option and Stock Appreciation Rights </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2024 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2024 (unaudited):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,715,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,110,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.43</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:24.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1365000 958000 4532000 5348000 5897000 6306000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2024 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2024 (unaudited):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,715,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,110,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.43</span></td></tr></table></div> 6583822 29.20 P5Y10M24D 1107662 27.94 154567 18.83 71499 25.31 7465418 29.26 P6Y4M13D 7465418 29.26 P6Y4M13D 4715920 27.82 P4Y10M2D 6583822 29.20 P5Y10M24D 4110537 26.58 P4Y5M4D <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 300141 36.90 193914 27.94 95397 36.87 1750 35.86 396908 32.54 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:24.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 251630 32.22 20000 28.63 271630 31.96 39080 33.47 0 0 39080 33.47 52000 28.93 0 0 52000 28.93 160550 32.98 20000 28.63 180550 32.51 Earnings per Share<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2024 and 2023 (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,801,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,380,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,626,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,454,204 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted EPS because their inclusion would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2024 and 2023 (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,801,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,380,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,626,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,454,204 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 124000 16948000 0 892000 124000 17840000 54801748 54380947 824915 1289321 0 6783936 55626663 62454204 0.00 0.31 0.00 0.29 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted EPS because their inclusion would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 520152 240398 Income Tax Expense (Benefit)<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax expense (benefit) for the three months ended March 31, 2024 and 2023 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $0.1 million for the three months ended March 31, 2024, as compared to an income tax benefit of $7.9 million for the three months ended March 31, 2023. The change was primarily due to almost break-even pre-tax income for the three months ended March 31, 2024 and greater full year 2024 forecasted losses as compared to the same period in 2023. The effective tax rate for the three months ended March 31, 2024 was higher compared to the same period in 2023 primarily due to near break-even pre-tax losses forecasted for the full year 2023. The annual forecasted earnings represent the Company's best estimate as of March 31, 2024 and 2023, are subject to change and could have a material impact on the effective tax rate in subsequent periods. Accounting Standard Codification (ASC) 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span>(ASC 740), requires the Company to estimate the annual effective income tax rate for the full year and apply it to pre-tax income (loss) for each interim period, taking into account year-to-date amounts and projected results for the full year. <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax expense (benefit) for the three months ended March 31, 2024 and 2023 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 119000 -7931000 0.490 -0.880 100000 -7900000 Leases<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-569"><span style="-sec-ix-hidden:f-570">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,994 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-575"><span style="-sec-ix-hidden:f-576">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-579"><span style="-sec-ix-hidden:f-580">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,527 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-569"><span style="-sec-ix-hidden:f-570">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,994 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-575"><span style="-sec-ix-hidden:f-576">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-579"><span style="-sec-ix-hidden:f-580">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,527 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29748000 28994000 29748000 28994000 9133000 8331000 32994000 33196000 42127000 41527000 Composition of Other Balance Sheet Items<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivables, Net </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company has reduced accounts receivable by approximately $12.0 million and $10.7 million, respectively for prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues and represent estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,079 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense on property and equipment was approximately $0.6 million and $0.6 million for the three months ended March 31, 2024, and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation, benefits, &amp; related accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales &amp; marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,402 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,274 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12000000 10700000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,079 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18803000 16274000 23246000 31212000 33030000 29922000 75079000 77408000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13120000 13069000 14023000 14023000 883000 883000 960000 960000 28986000 28935000 16017000 15405000 12969000 13530000 600000 600000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation, benefits, &amp; related accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales &amp; marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,402 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> 14397000 1964000 16444000 20722000 13263000 11666000 9118000 11652000 9092000 10530000 9133000 8331000 6963000 7918000 7992000 6786000 86402000 79569000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,274 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 107681000 96984000 59545000 57290000 167226000 154274000 Interest Expense <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,505)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Noncash interest expense on debt is related to amortization of deferred financing costs on the 2023 Notes. The Company fully amortized the deferred financing costs on the 2023 Notes in the first quarter of 2023.</span></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,505)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 656000 0 317000 0 532000 0 1505000 Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Licenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the condensed consolidated statements of earnings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Enterprise Commitments Assumed</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services which was effective in April 2019. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Claims and Litigation</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NAMENDA XR/Namzaric Qui Tam Litigation </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit which was denied on November 3, 2022. On December 23, 2022, the defendants filed renewed motions to dismiss directed to the remaining unresolved issue. On March 20, 2023, the District Court entered an order and final judgement dismissing with prejudice the FCA claim while declining to exercise supplemental jurisdiction over the state false claims act claims which were dismissed without prejudice. On April 19, 2023, the plaintiff appealed the District Court's dismissal of the Federal False Claims Act claim. </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2024, the plaintiff filed a motion for an indicative ruling and to set aside the judgment in the District Court, based on the same arguments raised in his appeal. That motion was fully briefed and the District Court determined that the motion for an indicative ruling was suitable for determination without a hearing. On May 7, 2024, the District Court denied the plaintiff’s motion for an indicative ruling. The plaintiff’s appeal remains pending in the United States Court of Appeals for the Ninth Circuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APOKYN Litigation</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No.22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. On January 10, 2023, the Company filed motions to dismiss all claims and the lawsuit in its entirety. As of April 12, 2023, briefing on those motions is now complete. Those motions remain pending. On April 10, 2023, the Court issued a scheduling order that provides for a Pretrial Conference on March 7, 2025, and a jury trial beginning on March 24, 2025. Pretrial discovery is ongoing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.</span></div> 3900000 17500000 2500000000 Subsequent Events <div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPN-830 Regulatory Development</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for SPN-830. The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA. The first area relates to product quality. Prior to the issuance of the CRL, the Company submitted additional product quality data to the FDA, which it had not yet reviewed at the time of the CRL's issuance. The second relates to the master file for the infusion device, which is proprietary to the device manufacturer. No clinical safety or efficacy issues were identified as a requirement for approval. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we may identify indicators of impairment for the related IPR&amp;D asset, which represents an estimate of the fair value of SPN-830, resulting from the receipt of the CRL. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration liabilities related to the milestone payments due upon the achievement of certain FDA regulatory approvals and the commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, any potential adjustments would be recognized and reported within the second quarter of 2024. Any material adjustments to the fair value of the IPR&amp;D asset or the fair value of contingent consideration liabilities could impact the Company’s results of operations and financial condition.</span></div> false false false false Excludes amortization of acquired intangible assets